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Abstract
Chemokines were initially defined as host defence proteins involved in cellular 
migration. They are now known to play a central role in the temporal and spatial 
positioning of leukocytes required for the successful induction of inflammation and 
the establishment of immunity. Moreover, chemokines exert many biological 
responses on other cell types and have been implicated in haemopoiesis, 
angiogenesis, oncogenesis and development.
In order to carry out their functions, chemokines must bind to and activate seven 
transmembrane (TM) domain G protein coupled receptors usually expressed on the 
surface of target cells. The chemokine system is implicated in many diseases such as 
chronic inflammation, autoimmunity, allergy, AIDS and cancer. This has lead to 
considerable efforts aimed towards understanding chemokine/receptor interactions 
with a view to preventing pathological consequences and this interaction.
Human D6  (hD6 ) is an unusual p chemokine receptor that binds with high affinity to 
many pro-inflammatory p chemokines, yet is not able to couple to signalling 
pathways activated by other related chemokine receptors. Moreover, 
immunocytochemistry has revealed that hD6  is absent from peripheral blood 
leukocytes and rather is expressed by endothelial cells in a subset of lymphatic 
vessels in the skin, lung, gut and secondary lymphoid tissue. The function of this 
receptor on these cells is currently uncertain, but its properties are provocative of a 
role in leukocyte migration, lymphangiogenesis and possibly metastasis.
XXII
In this thesis, chimaeric receptors have been used to understand the atypical 
biochemistry of hD6 . The ultimate aim was to identify domain(s)/residue(s) 
responsible for the broad ligand binding promiscuity and the high affinity ligand 
interactions apparent for this receptor and probe the signalling properties of hD6 . 
This work revealed the many problems associated with this approach to biochemical 
analysis. Chimaeric constructs bearing domains of CC and CXC receptors and large 
domain swaps between CC chemokine receptors, were shown to be poorly expressed 
on the surface of transfected cells. Additionally, these studies highlight the 
importance of the epitope tag, cell lines and the transfection systems used, thus 
indicating that the design and interpretation of receptor chimaera studies should be 
carefully considered.
Using small extracellular domain swaps between hD6  and hCCR5 it has been shown 
that: 1/ the first extracellular, and most highly conserved, loop of hD6  is required for 
high affinity binding to chemokine; 2 / the second and third extracellular loops appear 
to weakly influence ligand interaction, although antibody binding studies suggest that 
this result may be due to the gross structure of the chimaeric receptor being subtly 
altered; 3/ the N-terminus of hD6  can be replaced with that of hCCR5 with little 
effect on the binding of most chemokines, although the binding site for 
RANTES/CCL5 appears to have been altered compared to wild type hD6 .
Signalling studies on mutant or chimaeric receptors have revealed that a single amino 
acid change in hD6  is sufficient to introduce ligand-induced signalling via pertussis 
toxin sensitive G-proteins into this receptor. Specifically, a single point mutation (E
XXIII
to A) to convert the DKYLE motif in the second intracellular loop closer to the 
conserved DRYLA sequence can allow this receptor to induce weak calcium ion 
fluxes. A reciprocal mutation in hCCR5 blocked signalling through this receptor. 
Surprisingly, no other chimaeras of hD6  carrying the intracellular domains of hCCR5 
were able to induce calcium ion fluxes or enhance the response seen with the E to A 
mutant. However, these mutants were, unlike the wild type, hD6 , able to internalise 
upon ligand binding. Taken together these data suggest that coupling to calcium ion 
flux and internalisation are independently regulated events.
The results in this thesis have highlighted the technical difficulties associated with 
chimaeric receptor work, and the interpretation of these studies. Nonetheless, this 
work has identified the first extracellular loop as crucial for interaction of hD6  with 
ligand, derived signalling active mutants of hD6  by a single amino acid change, and 
generated new ideas on GPCR signalling and receptor internalisation. This work 
should act as a platform for the more detailed analysis of the biochemistry of hD6 .
1Chapter 1- Introduction
To guarantee survival, animals must defend themselves against invading pathogens. 
The immune system has evolved to defend vertebrates against infection. This system 
is composed of single cells, primarily haemopoeitic, whose function depends on their 
capacity to traffic, localize within tissues and interact with each other in a precisely 
coordinated manner. The ultimate aim of these cells is to detect and destroy 
pathogens and protect against subsequent infection. The body has evolved two 
different types of immune responses in order to guarantee lifelong immunity against 
many possible pathogens (immunological memory). When the body is first exposed 
to the antigen it develops a primary immune (innate) response that appears after a lag 
period of several days, rises rapidly and exponentially and then more gradually falls 
again. In the event of the body encountering this antigen again, whether it is within a 
period of weeks, months or even years, the immune system is capable of eliciting a 
secondary immune response (adaptive response), based on its immunological 
memory. This secondary immune response is characterised by a much greater 
response with a much shorter lag period and a longer duration in comparison to that 
of a primary response (for review see (Alberts et al., 1989)).
Lymphocytes are cells responsible for immune specificity. They are found in large 
numbers in the blood, the lymph and in specialized lymphoid organs. Once 
lymphocytes mature, they migrate from the primary lymphoid organs, the thymus and 
bone marrow, through the blood stream to the peripheral lymphoid tissues, the lymph 
nodes, the spleen, and the lymphoid organs associated with mucosa (appendix, 
Peyer’s patches and tonsils). It is in these secondary lymphoid organs that
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lymphocyte activation by a foreign antigen first occurs. The lymphatic vessels drain 
extracellular fluid from the tissues as lymph which passes through the lymph nodes 
and into the thoracic duct. The thoracic duct subsequently returns the lymph to the 
blood stream by emptying the lymph into the left subclavian vein. Lymphocytes that 
circulate in the bloodstream enter the peripheral lymphoid organs, and are eventually 
carried by lymph to the thoracic duct where they re-enter the bloodstream. Antigens 
and lymphocytes will eventually encounter each other in the secondary lymphoid 
organs. Naive lymphocytes are continually recirculating through these tissues, to 
which antigen is also carried from all sites of infection and where it is trapped and 
presented by specialized antigen presenting cells (Alberts et al., 1989; Playfair, 
1987). This continuous recirculation of naive lymphocytes is important during 
primary/innate responses where the antigen-specific T and B lymphocytes need to 
increase their possibility of encountering the antigen and each other (Sallusto et al., 
2000).
Upon infection/injury, inflammatory mediators such as TNF-a and IL-1 are released 
and leukocytes adhere to endothelial cells. This L-selectin mediated adhesion of 
leukocytes to endothelial cells is a loose reversible interaction that allows rolling of 
leukocytes along the affected segments of the endothelium. Once activated, 
leukocytes are then capable of adhering strongly to the vascular endothelium and 
migrating through it into the tissues (Melchers et al., 1999; Rossi & Zlotnik, 2000). 
The passage of lymphocytes across the endothelium into lymph nodes and Peyer’s 
patches is a multi-step process that involves selectin-mediated rolling, followed by a 
triggering event and finally firm adhesion (Cyster, 1999). This multi-step process 
depends on adhesion molecules and chemotactic factors (Melchers et al., 1999; Rossi
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& Zlotnik, 2000) and it is driven by chemoattractants. Chemoattractants can not only 
induce directional migration of leukocytes (Foxman et al., 1997), but also activate 
leukocytes to release enzymes that can facilitate migration through the extravascular 
tissue. Chemoattractants identified to this date include C5a, the proteolytic fragment 
of complement (Didsbury et al., 1992; Gerard & Gerard, 1994) and the bacterial- 
derived formyl-methionyl-leucyl-phenylalanine (fMLP) (Boulay et al., 1997), shown 
to attract both neutrophils and mononuclear cells, the lipid mediator platelet- 
activating factor (PAF) (Wardlaw et al., 1986) and leukotriene B4 (LT B4) (Ng et al., 
1991), potent chemoattractants for eosinophils and numerous chemokines (Melchers 
et al., 1999; Schall, 1994a; Rossi & Zlotnik, 2000).
It would be impossible to summarise everything published so far in the chemokine 
field. In this introduction chapter I intend to introduce the chemokine superfamily, 
their receptors and illustrate the importance of these molecules in leukocyte 
trafficking, development, angiogenesis, haemopoiesis, as well as in inflammation and 
disease by giving examples of chemokine/chemokine receptor pairings shown to be 
involved in these processes. I will also describe how chemokines interact with their 
receptors and the outcomes of this interaction. Finally I will concentrate on hD6 , a |3- 
chemokine receptor that constitutes the centre of my studies.
1.1. The Chemokine superfamily
In the last decade, chemokines (chemotactic cytokines), previously known as 
intercrines, Scy (small cytokine) family or SIS (small inducible, secreted) cytokines 
were identified as heparin binding molecules with chemotactic activity for specific
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types of leukocytes (for reviews refer to (Baggiolini, 1998; Baggiolini et al., 1997; 
Lindhout et al., 1999; Rollins, 1997; Schall, 1994; Wuyts et al., 1999)). Initially, 
researchers were trying to identify novel genes that were typically expressed in a cell- 
type-specific (e.g. by T cells or monocytes) or activation-state specific (e.g. after 
antigen exposure) fashion. The first chemokine to be identified was PF-4/CXCL4 
(Walz et al., 1977), because of its presence in blood platelets and because of PF4’s 
ability to bind strongly to heparin. Subsequently other structurally related proteins 
(e.g. IP-10/CXCL10, mMCP-l/CCL2, Mig/CXCL9, RANTES/CCL5, I-309/CCL1, 
and MIP-la/CCL3) were identified on the bases of their cell differentiation and 
activation properties. IL-8 /CXCL8  was the first chemokine to be identified to which 
a chemoattractant property was demonstrated (Walz et al., 1987; Yoshimura et al., 
1987). Chemokines discovered subsequently were purified as chemoattractant 
activators and then identified through cDNA cloning by signal sequence trapping or 
by homologous hybridisation. More recently, chemokines have been identified by 
bioinformatics using expressed sequence tag (EST) databases. Chemokines are 
particularly easy to find in EST databases because they have relatively small coding 
sequences that can be captured by a single EST and also because they have conserved 
sequence motifs (see below) that are easy to recognize (Wells & Peitsch, 1997). Due 
to the recent ‘boom’ in the chemokine family, in part facilitated by the use of 
bioinformatics, many chemokines were codiscovered by different groups of 
scientists. This has caused some confusion in the chemokine field since the same 
protein has been give different names for example chemokine ESkine is also known 
as CTACK, ILC, ALP or skinkine (Murphy et al., 2000). A new systematic 
nomenclature has been introduced to avoid confusion. In the new nomenclature, the 
number in the systematic name for each chemokine matches that of the
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corresponding human gene name. For example, IL8  which gene alias is SCYB8  is 
now called CXCL8  where CXC reflects the chemokine family, 8  the number of the 
gene and L indicates ligand. Throughout this work the most common name of a given 
chemokine will be used followed by the new systematic name, e.g. ESkine/CCL27.
Chemokines are a growing superfamily of small, inducible, predominantly secreted 
pro-inflammatory cytokines. The members of this family are structurally related and 
exhibit from 20% to over 90% identity in their amino acid sequences (Zlotnik & 
Yoshie, 2000). Structurally, the members of this family share similarities in that they 
have at least three p- pleated sheets and a C-terminal a-helix (Rollins, 1997). This 
superfamily is subdivided into four smaller subfamilies (Fig. 1.1), which are defined 
by the position of conserved Cys residues involved in forming disulfide bonds in the 
tertiary structure of the proteins (Baggiolini et al., 1994; Miller & Krangel, 1992; 
Schall, 1994). The CC (or p) chemokine subfamily has the first two Cys residues 
adjacent to each other, whilst C X C  (or a) chemokines have one intervening 
nonconserved amino acid between these two residues. More recently, two other 
subfamilies have been identified: the C (or y) subfamily that lacks two (the first and 
the third) of the Cys residues and the C X 3 C  (or 6 ) subfamily, which has three amino 
acids between the first two Cys residues (Fig. 1.1). To date, many members of the CC 
(Table 1.1) and C X C  (Table 1.2) chemokine subfamilies have been identified, 
whereas for the C (Table 1.3) and C X 3 C  (Table 1.4) subfamilies there is only one 
chemokine identified as yet, namely, lymphotactin and fractalkine, respectively 
(Bazan et al., 1997; Kelner et al., 1994).
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The genes encoding for CXC chemokines are predominantly localized in 
chromosome 14 although some members of this family have been found to be 
localized in other chromosomes e.g. SDF-1/CXCL12 in chromosome 10 (Shirozu et 
al., 1995), and bolekine/CXCL14 found in chromosome 5. These findings suggest 
that these genes probably arose through gene duplication followed by divergence. 
Initially, the CXC chemokines were thought to act primarily on neutrophils. 
However, the recently identified CXC receptors, CXCR3 and CXCR4, were shown 
to mediate lymphocyte chemotaxis (Bleul et al., 1996; Loetscher et al., 1996; Oberlin 
et al., 1996). The CXC chemokine subfamily can be further subdivided depending on 
the presence of a Glu-Leu-Arg (ELR) motif immediately after the first Cys residue 
localized on the N-terminus of the mature protein (Wuyts et al., 1999) (see more 
details later).
The CC chemokines, which constitute the largest chemokine family, are known to be 
attractants and activators of monocytes, lymphocytes, basophils, eosinophils, NK 
cells and DCs but not generally neutrophils. All CC chemokine genes were thought 
to be mapped to chromosome 17 but genes encoding for recently identified CC 
chemokines have been shown to be localized in chromosome 9, for ELC/CCL19 and 
SLC/CCL21, chromosome 16, for TARC/CCL17 and MDC/CCL22 and 
chromosome 2, for LARC (reviewed in (Wuyts et al., 1999)).
Lymphotactin/XCLl-2, the only member of the C family, is a chemokine-like 
molecule specific for lymphocytes chemoattraction (Kelner et al, 1994 ). Cerdan and 
colleagues, have shown that lymphotactin is capable of inhibiting CD4+, but co- 
stimulating CD8 +, T cell activation (Cerdan et al., 2000). More recently,
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Lymphotactin/XCLl-2 has been reported to enhance TCR-induced apoptosis of 
CD4+ T cells (Cerdan et al., 2001). In humans, there is evidence for two closely 
related genes that encode for two isoforms of lymphotactin: ATAC/XCL1 and SCM- 
1P/XCL2. These two isoforms are thought to have arisen as a result of a very recent 
gene duplication event and they differ from each other by two amino acids only 
(Yoshida et al., 1996).
Fractalkine/ C X 3 C L I ,  the sole member of the C X 3 C  family, is a membrane-anchored 
chemokine that shares high homology with CC chemokines (Pan et al., 1997). This 
chemokine, expressed on activated endothelium, can be cleaved to release a soluble 
form that functions as a chemoattractant for monocytes, NK cell and T lymphocytes 
(Bazan et al, 1997). Fractalkine/ C X 3 C L I  has been shown to be capable of mediating 
capture, firm adhesion and activation of circulating leukocytes without the 
involvement of integrins or other adhesion molecules (Fong et al., 1998).
Functionally, chemokines can be broadly divided into two subgroups: homeostatic 
and inflammatory. The homeostatic chemokines (e.g.: SDF-1/CXCL12, BCA- 
1/CXC13, LARC/CCL20, ELC/CCL19, SLC/CCL21, TARC/CCL17, TECK/CCL25 
and DCCK1/CCL18) are constitutively expressed within lymphoid organs and have a 
key function in homeostatic leukocyte traffic and cell compartmentalisation within 
these organs (more details later). On the other hand, inflammatory chemokines (e.g. 
MCP-1/CCL2, IL-8 /CXCL8 , GRO-a/CXCLl, GRO-P/CXCL2, GRO-y/CXCL3, 
Mig/CXCL9,1-TAC/CXC11, RANTES/CCL5, MIP-la/CCL3, MIP-ip/CCL4, MIP- 
ly/CCL15, Eotaxin 1/CCL11 and 2/CCL24, MCP-2/CCL8, MCP-3/CCL7, MCP- 
4/CCL13 and MCP-5/CCL12) are produced by many different types of cells (such as
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leukocytes, endothelial, epithelial and stromal cells) in response to inflammatory 
stimuli such as LPS, IL-1 and TNF-a, regulate recruitment of leukocytes to 
inflammatory sites and are mostly expressed during inflammation (Lindhout et al.,
1999). Some chemokines such as MDC/CCL22 can have an inflammatory role 
(Godiska et al., 1997), as well as homeostatic properties (Schaniel et al., 1998; Tang 
& Cyster, 1999) depending on when and where they are expressed (see more details 
later).
1.2. Chemokine receptors
Chemokines mediate their activities by binding to cell surface receptors that belong 
to the 7 transmembrane domain G protein-coupled receptors. In general, chemokine 
receptors are characterized by having an acidic N-terminal domain, the sequence 
DRYLAIVHA, or a variation of it, in the second intracellular loop, and a Cys in each 
of the four extracellular domains. These four conserved Cys residues are thought to 
be involved in maintaining the tertiary structure of the mature protein, holding the 
receptors in a cylindrical shape (Fig. 1.2) (Murphy et al., 2000).
Chemokine receptors can be classified into four different classes based on the 
chemokine member(s) they bind. Therefore, they are known as |3- or CC-chemokine 
receptors (CCRs), a- or CXC- chemokine receptors (CXCRs), y- or C-chemokine 
receptors (XCRs), 8 - or CXsC-chemokine receptors (CX3CRS). According to 
Premack and Schall, (Premack & Schall, 1996), chemokine receptors can also be 
classified as: specific, shared, promiscuous and viral (Table 1.5).
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Specific receptors are defined as those receptors that bind to one ligand only such as 
CXCR5 and CXCR4 that only bind to BLC/CXCL13 and SDF-1/CXCL12, 
respectively. Shared receptors bind to more than one receptor within the same family. 
Examples of shared receptors are CXCR2 that binds to all ELR+ chemokines (Ahuja 
et al., 1996; Lee et al., 1992), CXCR3 that binds to the ELR‘ chemokines, IP- 
10/CXCL10, Mig/CXCL9 and I-TAC/CXCL11 (Bao et al., 1999) and CCR5 shown 
to bind to MIP-lcx/CCL3, MIP-lp/CCL4, RANTES/CCL5 and MCP-2/CCL8. A 
promiscuous receptor is a receptor that binds to many chemokine ligands of either 
CXC or CC branches. For example, the Duffy blood group antigen (DARC) which 
was originally identified as Duffy glycoprotein D (Chauduri et al., 1993) and later as 
the human erythrocyte chemokine receptor (Horuk et al., 1993, Chaudhuri et al, 
1994), binds to many CC and CXC chemokines such as RANTES/CCL5, MCP- 
1/CCL2, IL-8 /CXCL8  and GROa/CXCLl. Moreover, these chemokines have been 
shown to displace heterologous chemokine binding, suggesting that chemokines of 
either family compete for a single binding site in DARC (Horuk et al., 1993). Lastly, 
viral chemokine receptors are shared receptors that have been transduced into the 
viral genome during evolution (more details later).
Different chemokine receptors have been shown to be expressed on different types of 
immune cells (Table 1.6), however, in some cases expression of these receptors 
seems to be restricted to a certain leukocyte subset (Sallusto et al., 1998). For 
example, Thl cells, which trigger a cell mediated immunological response, 
preferentially express CXCR3, and CCR5, whereas Th2 cells (responsible for 
humoral immunity) express CCR3, CCR4 and CCR8  (Sallusto et al., 1998, 
Baggiolini, 1998). The ability of leukocytes to express different types of chemokine
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receptors allows these cells to respond to many chemoattractant signals presented to 
leukocytes in a certain spatial/temporal context.
It is worth emphasizing the fact that most chemokines can bind to more than one 
receptor, that most receptors bind more than one ligand and that under appropriate 
conditions most cell types can produce chemokines (Tables 1.5 and 1.6). However, 
this apparent redundancy seems to be important for the robust role of the chemokine 
system. Knock out mice that lack either a given chemokine or receptor -exception 
made for SDF-1 or CXCR4 knock out mice that are lethal (more details later)- were 
shown not to have gross deficiencies in development or survival but rather are found 
to be different in specialized reactions. For example, natural deletions of CCR5 are 
known to occur in a certain population of humans that have no obvious phenotype 
rather than HIV resistance (Samson et al., 1996). In general, blocking of certain 
chemokines or receptors affects specialized outputs but does not compromise the role 
of the chemokine system (for review see (Mantovani, 1999)).
1.3. Functions of chemokines and chemokine 
receptors
1.3.1. Chemokines and leukocyte trafficking
The chemokine-induced migration of cells has been shown to be important not only 
for immune surveillance, innate and adaptive immune responses, but also of 
fundamental importance in haemopoiesis, angiogenesis, development and varied 
forms of pathological inflammation (Foxman et al., 1997; Springer, 1994). Several 
chemokines and their receptors have been shown to be good candidates for inducing
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directional migration of lymphocytes within primary lymphoid organs, from primary 
to secondary lymphoyd organs, as well as within and between secondary lymphoid 
organs during humoral immune response (for review see (Campbell et al., 1998b)). 
Much molecular information has now been gathered on the pathways, the role of 
adhesion molecules in identification of homing sites and on the chemokines involved 
in leukocyte trafficking, although it is still not fully clear how this whole system is 
regulated. A three-step model of leukocyte migration (Fig. 1.3) has been suggested 
whereby upon activation, leukocytes become firmly adhered and will finally migrate 
into the tissue space (for review see (Schall, 1994)). Upon infection or injury, 
chemokines are secreted by resident tissue cells, resident and recruited leukocytes 
and by cytokine-activated endothelial cells. These secreted chemokines are locally 
retained on matrix and cell-surface heparan sulphate proteoglycans and therefore 
establish a chemokine gradient around the inflammatory stimulus as well as on the 
surface of the overlying endothelium. Leukocytes rolling on the endothelium in a 
selectin-mediated process are brought into contact with chemokines retained on cell- 
surface heparan sulfate proteoglycans. Chemokine-induced signalling activates 
leukocyte integrins leading to firm adherence and finally extravasation (for reviews 
see (Butcher, 1991; Springer, 1994)).
How the chemotactic gradients are established in vivo is not clear. It is known that 
chemokines are found preferentially immobilized through low affinity binding to 
proteoglycans on the vascular endothelium and to the extracellular matrix proteins in 
the tissues where they are presented to leukocytes. The positive charge of 
chemokines allows these molecules to bind to sulphated proteoglycans found on the 
cell surface or in the extracellular matrix (Webb et al., 1993). This property intrinsic
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to chemokines is of special importance in maintaining chemotactic gradients on the 
surface of endothelial cells that are constantly exposed to blood flow. The CC 
chemokine SLC/CCL21, thought to be involved in T cell migration, is expressed by 
HEVs and is involved in inducing integrin-mediated adhesion of naive lymphocytes 
(Gunn et al., 1998b; Tanabe et al, 1997;; Hedrick & Zlotnik, 1997; Hromas et al., 
1997; Nagira et al., 1997; Nagira et al., 1998). Treatment of rolling peripheral blood 
lymphocytes (PBLs) with ELC/CCL19, SLC/CCL21 or SDF-1/CXCL12 in the 
presence of PNAd (peripheral node addressin- a mixture of glycoproteins expressed 
on HEV (Berg et al., 1991)) and ICAM-1 (intracellular adhesion molecule-1), 
induces arrest of PBLs (Campbell et al., 1998b). SLC/CCL21 stimulates a rapid 
a4p7-integrin-mediated adhesion of lymphocytes to MadCAM-1 (mucosal addressin 
cellular adhesion molecule-1) expressed on PP and HEV (Pachynski et al., 1998).
In order to attract circulating lymphocytes chemokines must cross the endothelial 
cells. It was initially thought that chemokines could cross the endothelium by 
diffusing through intracellular gaps. Work by Middleton et al (Middleton et al., 
1997) has demonstrated by immuno-electron microscopy that abluminal IL-8 /CXCL8  
is internalised by venular endothelial cells and subsequently transcytosed to the 
luminal endothelial cell membrane where it is presented to adherent leukocytes. 
Binding assays in situ have also shown that RANTES/CCL5, MCP-1/CCL2, MCP- 
3/CCL7 bind to the endothelial cells of venules and small veins but not arteries or 
capillaries (Hub & Rot, 1998). Additionally, it has been demonstrated by 
immunocytochemistry that DARC, a promiscuous receptor for a  and p chemokines, 
is expressed on HEV (Hadley et al., 1994). More recently, immunocytochemistry has 
revealed that D6 , a promiscuous p chemokine receptor, is expressed on the lymphatic
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endothelium but not on endothelial cells lining blood vessels (Nibbs et al., 2001). 
Taken together these observations suggest that expression of these receptors on the 
surface of endothelial cells or lymphatic endothelium might play a role in chemokine 
transcytosis from the tissue space to the luminal surface of endothelial cells where it 
is available to attract, interact and activate leukocytes.
The aim of this section is to give examples of chemokine/chemokine receptor 
pairings shown to be involved in leukocyte trafficking. Firstly, lymphocyte 
maturation within the primary lymphoid organs, bone marrow and thymus, and the 
role of chemokines and their receptors for lymphocyte homing to secondary 
lymphoid organs will be described. Secondly, lymphocyte migration during primary 
and secondary immune responses will be addressed. Thirdly, the role of chemokines 
during effector and immune responses will be outlined.
a). Bone marrow
In order to proliferate and differentiate, T and B lymphocytes have to move through 
different tissue compartments. During maturation, immature lymphocytic precursors 
either remain in the bone marrow and proceed along the B-lymphoid differentiation 
pathway or leave the bone marrow and seed into the thymus where they differentiate 
into mature naive T cells (see below). While in the bone marrow, immature B cells 
with high avidity for autoantigens are arrested in their development and die (a 
process known as negative selection) while the other immature B cells are allowed to 
leave the bone marrow via the venous sinuses (Melchers et al., 1999).
Bone marrow (BM) stromal cells have been shown to produce the chemokine SDF- 
1/CXCL12 that is capable of attracting B cell progenitors and to place these
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progenitors in contact with the stromal cells (D'Apuzzo et al., 1997). The stromal 
cells, in turn, release growth and differentiation factors required for B cell 
maturation. Moreover, SDF-1/CXCL12 has also been shown to induce BM 
colonization by haemopoietic precursors (CD34+) during embryogenesis via its 
receptor CXCR4 (Aiuti et al., 1997; Ma et al., 1999). Knock out mice studies have 
shown that mice lacking CXCR4 or its ligand SDF-1/CXCL12 die perinatally and 
that mutant embryos have very low numbers of B cell progenitors in both the fetal 
liver and the bone marrow (Tachibana et al., 1998). These mice were also shown to 
have other developmental abnormalities that suggest that SDF-1/CXCL12 and 
CXCR4 are not only important for the haemopoietic system but are also involved in 
organ development (Ma et al., 1998; Tachibana et al., 1998; Zou et al., 1998).
MIP-3a/CCL23 has also been shown to be expressed by BM stromal cells (Godfrey 
& Zlotnik, 1993). Unlike SDF-1/CXCL12, MIP-3a/CCL23, is only expressed in the 
BM after lipopolysaccharide (LPS) stimulation. MIP-3a/CCL23 is thought to be 
specifically involved in attracting macrophage precursors into the BM during 
inflammation (Godfrey & Zlotnik, 1993).
Other chemokines, such as HCC-1/CCL14, MCP-2/CCL8 and MIP-la/CCL3, have 
also been shown to be expressed in the bone marrow however their role in the BM 
environment is still unclear (for review see (Rossi & Zlotnik, 2000)).
b). Thymus
Thymocytes mature in the thymus as they migrate from the cortex to the medulla. In 
the thymus, thymocytes expressing both CD4 and CD8 , encounter processed antigen
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on the major histocompatibility complex (MHC) class I or II molecules on 
specialized antigen presenting cells (APC). As described above for the development 
of B cells, thymocytes expressing receptors with high avidity for MHC class I or 
II/autoantigen peptide complexes undergo negative selection. Those thymocytes that 
survive negative selection will then become either CD8  or CD4 single positive cells, 
migrate to the medulla and leave the thymus via venous blood to move to arterial 
blood in the heart.
The role of chemokines present in the thymus is dependent on the maturation status 
of T cells (Campbell et al., 1999; Kim et al., 1998). T cells found in the cortex and in 
the medulla of the thymus can respond to TECK/CCL25 (CCR9 ligand), however T 
cells lose their ability to respond to this chemokine when they reach their late stages 
of maturation just before they are ready to leave the thymus (Vicari et al., 1997; 
Zaballos et al., 1999). At the same time, L-selectin expression is upregulated. During 
the late stages of thymocyte maturation, T cells start to respond to ELC/CCL19 and 
SLC/CCL21, both ligands for CCR7. Additionally, thymocytes in the process of 
migrating from the cortex to the medulla, can transiently respond to MDC/CCL22, 
the CCR4 ligand (Campbell et al., 1999; Imai et al., 1998; Yoshida et al., 1997; 
Yoshida et al., 1998). These observations point towards a model that supports a role 
for CCR9 in maintaining cells in the thymus until they are matured, a role for CCR4 
in driving the migration of developing cells from the cortex to the medulla and 
finally, a role for CCR7 and CXCR4 (known to be expressed at all developmental 
stages (Zou et al., 1998) in migration of mature T cells.
Surprisingly, published work describing knock out studies of CCR4 (Chvatchko et 
al., 2000) (MDC/CCL22 receptor), SDF-1/CXCL12, CXCR4 (Ma et al., 1998) and or
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CCR7 (Forster et al., 1999) (SLC/CCL21 receptor) did not report any abnormal 
phenotype suggesting that these chemokines might have a redundant effect in 
thymocyte development.
The observation that different chemokines are expressed at different stages of 
thymocyte maturation suggests that these molecules may have a role in 
compartmentalization within lymphoid organs and hence are involved, along with 
other molecules, in T cell development. Moreover, it is also possible that the absence 
of phenotype of these knock out mice could reflect functional redundancy.
c). Primary Immune Responses
During a primary immune response T and B lymphocytes need to interact with the 
antigen presenting cells (APC) and subsequently with each other. These interactions 
take place within the secondary lymphoid organs: lymph nodes, Peyer’s patches (PP) 
and the spleen. Naive T and B cells enter the lymph nodes and PP through the high 
endothelial venules (HEVs) whereas the antigen (Ag) is carried to these secondary 
lymphoid organs via the afferent lymphatics together with APC or is transcytosed by 
intestinal M cells into the dome region. In the spleen, the route of entry is the 
marginal zone sinuses for both lymphocytes and Ag (for review see (Moser & 
Loetscher, 2001; Sallusto et al., 2000)). Here, the traffic of dendritic cells (DCs) will 
be described followed by that of T and B cells. Finally, the interactions between these 
three types of cells will be discussed.
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DC traffic
In order to encounter the Ag, DCs and their precursors have to migrate from the 
blood into the tissue. Once in the tissue these cells are activated, redirected to the 
lymphatics and then to T cell areas of the secondary lymphoid organs where DCs 
present the Ag to T cells. Receptors for inflammatory chemokines (e.g. CXCR1, 
CCR1, CCR2, CCR5 (Godiska et al., 1997; Moser & Loetscher, 2001; Sallusto et al., 
2000) and D6  (J. Townson, pers. comm.)) that are known to be expressed by DCs are 
thought to play a role in extravasation of these cells into the site of infection/injury as 
well as in the local recruitment of resident tissue DCs. On exposure to immune or 
inflammatory signals DCs undergo maturation which includes downregulation of 
their endocytic activity, upregulation of MHC, adhesion and costimulatory molecules 
along with a switch in the chemokine receptor they use (Moser & Loetscher, 2001; 
Sallusto et al., 2000). Antigen uptake, together with LPS stimulation and/or TNF-a, 
induces expression of CXCR4 and CCR4 and increases CCR7 expression levels. 
Simultaneously, the levels of CXCR1, CCR1 and CCR5 are downregulated 
(Lindhout et al., 1999). These changes in receptor profile enable DCs to migrate from 
inflammatory sites towards secondary lymphoid organs where they subsequently 
migrate towards the T cell areas of these organs. DCs’ expression of high levels of 
CCR7 after activation by the Ag regulates migration of these cells towards 
SLC/CCL21 and ELC/CCL19 (Ngo et al., 1998; Sozzani et al., 1998a; Yoshida et al.,
1997), which are produced by lymphatic endothelial cells and interdigitating DCs, 
respectively. Evidence for the role of CCR7 in regulating DC migration is supported 
by knock out mice that are deficient in CCR7 (Forster et al., 1999) and by pit mice
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(Gunn et al., 1999) where maturing DCs cannot migrate from the skin to lymph 
nodes.
Migration of DCs from the site of Ag capture to the site of Ag presentation can vary 
depending on anatomical sites (Dieu et al., 1998). For example, in the spleen, 
immature DCs are found in the marginal zone where blood-borne Ags enter and 
migrate to the T cell areas after being exposed to maturating stimuli such as LPS. In 
the tonsils, DCs are found at the site of entry for Ag, the epithelial crypts. These 
epithelial crypts have been shown to selectively produce LARC/CCL20 (Dieu et al.,
1998), a ligand for CCR6  that is expressed (along with other chemokine receptors) by 
immature DCs present in the skin, Langerhans cells (Yang et al., 1999). Generation 
of CCR6  7' mice by Cook and et al has demonstrated the importance of this receptor 
in DC migration into the PP (Cook et al., 2000). Once in the PP, the Ag is then 
transcytosed by the M cells into the dome region where immature DCs are found 
before they migrate to the T cell areas (for review see (Sallusto et al., 2000)).
A few hours after the DCs stimulation by LPS, MIP-la/CCL3, MIP-1|3/CCL4 and 
LL-8 /CXCL8  are produced. This initial early burst of inflammatory chemokine 
production by DCs while at the same time downregulating the expression of the 
cognate receptors is thought to allow DCs to follow different chemokine gradients 
and at the same time sustain the recruitment of immature DCs as well as other 
inflammatory cells. At the same time, the late production of lymphoid chemokines 
(Foti et al., 1999; Sallusto et al., 1999c) such as TARC/CCL17, MDC/CCL22 and 
DCCK1/CCL18 ensures the correct cell positioning and appropriate cell-cell 
interaction within the lymph node (for review see (Moser & Loetscher, 2001)).
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T and B cell homing to secondary lymphoid organs
In order to enter lymph nodes and PP, T and B lymphocytes need to cross the HEVs. 
CCR7 is thought to be responsible for lymphocyte arrest on these components of the 
vasculature. This receptor is widely expressed on naive T and B lymphocytes 
(Burgstahler et al., 1995; Campbell et al., 1998a; Sallusto et al., 1998) and one of its 
ligands, SLC/CCL21, has been shown to be produced by the endothelial cells of the 
HEV (Gunn et al., 1998b), retained on the surface of these cells and displayed to 
rolling lymphocytes. Recognition of SLC/CCL21, arrests the lymphocytes on the 
surface of HEVs under blood flow conditions (Yoshie et al., 1997). Studies with pit 
mice and CCR7'/_ support the idea that this chemokine-chemokine receptor paring is 
important for lymphocyte arrest in the HEVs. Mice lacking SLC/CCL21 (pit mice) 
have been shown to have defective T cell trafficking into lymphoid organs (Gunn et 
al., 1999; Tangemann et al., 1998) and injection of SLC has been shown to be 
sufficient to restore T cell trafficking in these mice (Stein et al., 2000). Mice lacking 
CCR7 have T cells with reduced ability to enter lymph nodes and PP, whereas B cell 
trafficking is less affected (Forster et al., 1999). These CCR77 mice have an 
abnormal distribution of T and B cells in the secondary lymphoid organs and in fact 
T and B cells appear in higher numbers in the blood (Forster et al., 1999). Moreover, 
CCR7 expression is thought to be necessary not only to recognize SLC/CCL21 
produced by HEVs to allow lymphocyte entry from blood into secondary lymphoid 
organs, but also to be required for recognition of SLC/CCL21 produced by stromal 
cells to allow proper positioning of resting T and B cells into their appropriate areas 
within the lymphoid organs (Forster et al., 1999).
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After crossing the HEV, the T and B lymphocytes follow different routes guided by 
specific chemokines. The T cell lymphocytes localize to the T cell area where they 
can scan the surface of DCs in order to detect the specific Ag. Production of 
DCCK1/CCL18, MDC/CCL22, TARC/CCL17 and ELC/CCL19 by mature DCs 
probably encourages the interaction of these cells with T cells (Adema et al., 1997). 
The B cell lymphocytes enter the T cell area and then migrate into the B cell follicle 
where the Ag is displayed by FDC. These migrating B lymphocytes have been shown 
to be capable of responding to BCA-1/CXCL13, a CXCR5 ligand shown to be 
produced by stromal cells (probably FDC) found within the B cell follicles (Gunn et 
al., 1998a; Legler et al., 1998). Mice lacking CXCR5 have no inguinal lymph nodes 
and have little or no normal PP. In these CXCR5 null mice, B lymphocytes are not 
organized into discrete follicles in the remaining lymph nodes but B cell homing into 
these tissues is not impaired which suggests that CXCR5 is not the only receptor 
involved in lymphocyte homing (Forster et al., 1996).
Activation of T lymphocytes and T cell-B cell interactions
Segregation of T and B lymphocytes into separate areas within the lymphoid organ 
allows for separate stimulation by Ag that is displayed to each one of these different 
types of lymphocytes by the appropriate type of APC. Once B and T cells encounter 
the Ag they become activated and move towards each other in response to a switch in 
chemokine receptor usage (for review see (Melchers et al., 1999; Moser & Loetscher, 
2001; Sallusto et al., 2000)). Ag stimulated T cells downregulate expression of CCR7 
and upregulate expression of CXCR5 and CCR4, by doing so these activated T 
lymphocytes become sensitive to BLC/CXCL13 and MDC/CCL22 that are produced 
in the B cell areas (Schaniel et al., 1998; Tang & Cyster, 1999). Simultaneously, Ag
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stimulated B cells become responsive to ELC/CCL19, by upregulating expression of 
CCR7 and therefore are able to migrate towards the T cell area (Ngo et al., 1998).
After B cells interact with specific T cells, some B cells proliferate and differentiate 
outside the follicle, while others are attracted to the follicular dendritic cells (FDC). 
The FDC will form a mesh of structures where the B cells will proliferate to form 
germinal centres (GC) where memory B cells and plasma cells are generated. 
Memory and plasma B cells migrate into the sites of infection/injury or into the bone 
marrow through the lymph and blood (for review see (Melchers et al., 1999; Moser & 
Loetscher, 2001; Sallusto et al., 2000)).
d). Effector and memory responses
After being primed by the Ag, effector T cells acquire new migratory properties that 
allow them to leave the secondary lymphoid organs and enter the peripheral inflamed 
tissues. Different types of protective or pathogenic responses are mediated by type 1 
(Thl) and type 2 (Th2) polarized T cells that secrete different cytokines, and for this 
reason interact with and stimulate different types of leukocytic effector cells. Type 1 
cells produce IFN-y and are associated with macrophages and neutrophils in delayed 
type hypersensitivity (DTH) lesions whereas type 2 cells produce IL-4, IL-5 and IL- 
13 and are found at sites of allergic inflammation together with eosinophils and 
basophils (for review see (Sallusto et al., 2000)). Although not only CCR3 (Sallusto 
et al., 1998), but also CCR4 (Imai et al., 1999) and CCR8  (DAmbrosio et al., 1998) 
have been shown to be expressed on Th2 cells it is for CCR3 and its ligand 
(Eotaxin/CCLll) that the most striking evidence for the role of chemokines and their 
receptors in polarized T cell response has been gathered. Eotaxin has been shown to 
be highly produced in mucosal tissues where allergic inflammation is taking place
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and CCR3 is found on the surface of eosinophils, basophils and in vivo and in vitro 
polarized Th2 cells. It is thought that the sharing of CCR3 by these cells allows for 
colocalization of these three cell types at the site of inflammation (Gerber et al.,
1997).
Unlike Th2 polarized cells, Thl cells express CCR5, CXCR3 and CCR1 (Sallusto et 
al., 1998). However, studies have shown that 6  hours after stimulation of the T cell 
receptor (TCR), the receptors for inflammatory chemokines are transiently 
downregulated at both the mRNA and the protein level whereas the expression of 
CCR7, CCR4, CCR8  and CXCR5 is increased (Sallusto et al., 1999a). This change 
in expression of the chemokine receptors is known to last for a few days and is 
thought to be involved in relocalizing activated T cells within the tissues where the 
ligands ELC/CCL19, SLC/CCL21, BCA-1/CXCL13,1-309/CCL1 and TARC/CCL17 
are being produced (for review see (Melchers et al., 1999; Moser & Loetscher, 2001; 
Sallusto et al., 2000)).
From the activated T cell pool generated during a primary immune response, some 
differentiate to become circulating memory cells. These memory T cells are involved 
in a much more efficient response upon a secondary challenge.
Interestingly, Sallusto et a l have identified two different subsets of memory T cells 
that are functionally distinct. CCR7' memory cells express receptors for migration to 
inflamed tissues and display immediate effector functions. These cells do not migrate 
through the secondary lymphoid organs but instead are involved in immune 
surveillance in the peripheral tissues. The CCR7+ memory cells, or central memory 
cells, expresses lymph-node homing receptors and have no effector function.
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However, when these central memory cells come in contact with an Ag they lose 
their CCR7 expression presumably allowing them to migrate into the site of infection 
(Sallusto et al., 1999b).
e). Selective homing to skin and gut
Skin homing T cells are identified by their expression of cutaneous lymphocyte 
associated antigen (CLA) and the chemokine receptor CCR4. TARC/CCL17, the 
ligand for CCR4, has been shown to be expressed on endothelial cells of inflamed 
skin (but not gut) and is capable of inducing integrin-dependent adhesion of CLA+ T 
cells (Campbell, 1999). Along with its role in extravasation, CCR4 is also involved 
in directing cell migration within inflamed tissues in response to MDC/CCL22 and 
TARC/CCL17 that are produced by resident cells in places such as the lung and the 
liver (Sallusto et al., 2000). More recently, CCR10 has also been shown to be 
expressed on CLA+ memory T cells that migrate in response to 
ESkine/CTACK/CCL27 and MEC/CCL28 (Morales, 1999; Tang & Cyster, 1999).
In contrast, gut homing memory T cells do not express CLA but express the integrin 
heterodimer a4|37. a4|37 is a ligand for the mucosal-addressin-cell adhesion 
molecule-1 (MAdCAM-1) found on intestinal blood vessels (Melchers et al., 1999; 
Moser & Loetscher, 2001; Sallusto et al., 2000). The receptor hypothesized to be 
involved in homing to the gut is CCR9, which binds to TECK/CCL25 a chemokine 
expressed in the endothelial cells of gut-associated tissues and the thymus (Zabel et 
al., 1999).
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1.3.2. Chemokines and haemopoiesis
Along with the well described effects on mature leukocyte trafficking, chemokines 
also exert effects on other haemopoietic cell types. MIP-la/CCL3 (for review refer to 
(Cook, 1996)), MIP-1J3/CCL4, GRO-p/CXCL2 and GRO-y/CXCL3 have been 
shown to enhance the formation of CFU-GM (colony -forming unit granulocyte- 
macrophage) in the presence of M- or GM-CSF (colony stimulating factor) 
(Broxmeyer et al., 1993). However, chemokines, such as MIP-la/CCL3, GRO- 
P/CXCL2, PF-4/CXCL4, IL-8/CXCL8 , MCP-1/CCL2, IP-10/CXCL10 and mMIP- 
ly/CCL9, have also been shown to be able to act as inhibitors of more immature 
progenitors (Broxmeyer et al., 1993; Graham et al., 1990; Youn et al., 1995). In vivo 
administration of MIP-la/CCL3, and pre-treatment of animals with MIP-la/CCL3 
enhances myeloid recovery after treatment with S-phase-active chemotherapeutic 
agents (Quesniaux et al., 1993). Work by Graham and colleagues reports that MIP- 
la/CCL3 does in fact directly inhibit the proliferation of haemopoietic stem cells 
(Graham et al., 1990). The requirement for MIP-la/CCL3 for haemopoiesis was 
investigated using MIP-1CI/CCL37' mice (Cook et al., 1995). The studies with MIP- 
la/CCL3"/' mice did not show an increase in progenitor pool, in fact these knock out 
mice were shown to have normal numbers of both total nucleated cells and early 
progenitor cells. From this data, it seems as if MIP-la/CCL3 is not required to 
maintain the quiescent state of haemopoietic cells in normal physiology, but one 
cannot disregard the fact that maybe other factors may compensate for the lack of 
MIP-la/CCL3. Indeed, Jacobsen and co-workers demonstrated by analysing the 
effect of multiple inhibitory chemokines in vitro that various inhibitors can synergize 
with one another to reach levels of inhibition impossible to achieve by a singular
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inhibitor (Jacobsen et al., 1994). The generation of mice lacking more than one 
inhibitor would most certainly provide a means of identifying the role of stem cell 
inhibitors in vivo. Furthermore, the role of MIP-la/CCL3 in haemopoeisis is thought 
to be not only restricted to inhibition of early haemopoietic progenitors but has also 
been shown to be capable of enhancing maturation of mature haemopoietic 
progenitors (Broxmeyer & Kim, 1999).
To date, studies using the SDF-1/CXCL12 (Nagasawa et al., 1996) or the CXCR4 
(Tachibana et al., 1998; Zou et al., 1998) knock out mice provide the strongest 
evidence supporting the role of chemokines in haemopoiesis. As mentioned before, 
apart from their developmental defects, these null mice exhibit profound 
haemopoietic defects such as absence of B lymphopoiesis and of bone marrow 
myelopoiesis. Chemokines such as ELC/CCL19 and SLC/CCL21 have also been 
shown to induce chemotaxis in haemopoietic stem and progenitor cells. Broxmeyer 
and colleagues demonstrated that these two chemokines chemoattract CFU-GM cells 
through their shared receptor CCR7 (Broxmeyer & Kim, 1999). More recently, IP- 
10/CXCL10 and Mig/CXCL9 have also shown to be capable of inducing chemotaxis 
in GM-CSF-stimulated CD34+ cells via their shared receptor CXCR3 (Jinquan et al.,
2000). The in vivo importance of these observations awaits clarification.
1.3.3. Chemokines and disease
Despite being capable of supporting host defence, chemokines and their receptors can 
act as amplifiers of inappropriate inflammation in non-infectious inflammatory 
disorders and therefore cause organ disfunction and increased mortality (Strieter et 
al., 1996). Chemokines and their receptors have been shown to be involved in many
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diseases such as asthma, gastrointestinal allergy, multiple sclerosis, pneumonia, 
arthritis, atherosclorosis, some types of cancer and allograft rejection (Rollins, 1997). 
The role of proinflammatory chemokines in these diseases has been demonstrated by 
detecting chemokine production in the inflamed site as well by the presence of cells 
known to respond to the chemokine. Most of the studies that generated information 
on the role of chemokines in disease processes were based on antibody blocking 
experiments to a given chemokine or chemokine receptor as well as by knock out 
mice that lack a certain chemokine or chemokine receptor that have subsequently 
been challenged with an Ag. The following examples demonstrate the wide variety of 
disease states in which the chemokine system is implicated.
Asthma. Asthma is a chronic inflammatory disease characterized by an exaggerated 
airway responsiveness that leads to airway inflammation and obstruction (Bertrand, 
2000; Gerard & Rollins, 2001; Lukacs et al., 1999; Strieter et al., 1996; Teran, 2000). 
The recruitment and activation of many cell types such as eosinophils, mast cells, 
Th2 lymphocytes and neutrophils contribute to the pathogenesis of asthma (Foresi & 
al, 1997; Kon & Kay, 1999, Lamblin, 1998; Rossi & Oliveira, 1997). IL-8 /CXCL8 , 
MDC/CCL22, RANTES/CCL5, MIP-la/CCL3, MCP-3/CCL7, Eotaxin/CCLll, 
MCP-5/CCL12, MCP-4/CCL13, HCC-1/CCL14 and Eotaxin-2/CCL24 are examples 
of chemoattractants and activators of eosinophils (for review see (Teran, 2000; 
Zlotnik et al., 1999)) that have been isolated from nasal secretions and 
bronchoalveolar lavage fluid of patients with active asthma (Alam et al., 1996). It 
seems likely that these chemokines play a role in the pathology of the disease, but the 
large number of chemokines found is testimony to the complexity and apparent 
redundancy in the system.
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Lukacs and colleagues (Lukacs et al., 1999; Lukacs et al., 1996; Lukacs et al., 1997) 
have used a murine model of allergic airway inflammation in vivo to demonstrate the 
role of MIP-la/CCL3 and RANTES/CCL5 in eosinophil chemoattraction. Upon 
intra tracheal challenge of presensitized mice with parasite egg antigen, an increase in 
MIP-la/CCL3, RANTES/CCL5, IL-4 and TNF production was registered (Lukacs et 
al., 1996). In vitro neutralization of MIP-la/CCL3 or RANTES/CCL5 reduced 
eosinophils recruitment to the lung tissue and airways during the allergic response, 
whereas neutralization of MCP-1/CCL2 significantly diminished leukocyte migration 
in total (Lukacs et al., 1997). Airway hyper-reactivity was seen to diminish when 
MCP-1/CCL2 is depleted but depletion of RANTES/CCL5 and MIP-la/CCL3 had 
no affect on airway hyper-reactivity (Lukacs et al., 1997).
Although many cell types have been demonstrated to be involved in asthma, I will 
here concentrate on eosinophils to illustrate how complex the interactions within the 
system can be. Three chemokine receptors were initially isolated from eosinophils: 
CCR1, CCR3 and CXCR2 (Sabroe et al., 1999). From these, CCR3 was thought to 
be the major eosinophils chemokine receptor (Heath et al., 1997). Eotaxin/CCLll, 
the ligand for CCR3, is reported to be released in vitro by epithelial cells after 
stimulation with the cytokines TNF-a, IL-lj3 and IFN-y (Lilly et al., 1997). High 
levels of Eotaxin/CCLll are produced in the airway epithelium in human asthma; 
this localized production attracts eosinophils to the epithelium where the release of 
epithelium-damaging proteins occurs (Lukacs et al., 1999). Eotaxin/CCLll can also 
induce basophil degranulation, causing tissue damage characteristic of asthma 
(Teran, 2000). Moreover, Eotaxin/CCLll attracts Th2 lymphocytes that promote and 
maintain the allergic response by ensuring the presence of antigen-specific Th2 cells
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(Gutierrez-Ramos et al., 1999). Targeted disruption of the Eotaxin/CCLll gene in 
mice demonstrated that this CC chemokine is involved in regulating the constitutive 
number of eosinophils in the peripheral blood and that it is also involved in 
enhancing the early recruitment of eosinophils in models of asthma and stromal 
keratitits (Rothenberg et al., 1997). A recent study has demonstrated that CCR4, and 
to a lesser extent, CCR8  are also expressed in the majority of T cells infiltrating the 
bronchial biopsies of allergen-challenged asthmatics (Panina-Bordignon et al., 2001). 
More recently, Luckacs and co-workers have demonstrated the importance of CCR6  
and MIP-3a/CCL20 in allergic pulmonary responses (Luckacs et al., 2001). In this 
study, the authors challenged CCR6  deficient mice with cockroach antigen and they 
noticed that these mice had reduced airway resistance, fewer eosinophils around the 
airway, decreased levels of IL-5 in the lung and low serum levels of IgE.
Rheumatoid arthritis. Infiltration of monocytes and neutrophils into the synovial 
tissues and synovial fluid of the joints is characteristic of rheumatoid arthrititis (RA) 
(Strieter et al., 1996). MCP-1/CCL2 and MIP-la/CCL3 were found to be elevated in 
synovial fluid from patients suffering from RA (Kunkel et al., 1996). Experiments 
with CIA (collagen-induced arthritis) mice injected with antibodies against MIP- 
la/CCL3 and GROa/CXCLl demonstrated a delay in the onset, and a reduction on 
the severity, of arthritis (Kasama et al., 1995). In situ hybridisation has detected 
RANTES/CCL5 mRNA on synovial lining cells of patients with rheumatoid arthritits 
and MIP-lp/CCL4 has been found in association with synovial fibroblasts and 
macrophages (Kasama et al., 1995). Additionally, CXC chemokines have also been 
shown to be involved in the pathogenicity of human rheumatoid arthritis (Kunkel et 
al., 1996). For example, IL-8 /CXCL8  and ENA-78/CXCL5 were shown to be
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expressed by both synovial fibroblasts and macrophages (Kunkel et al., 1996). Taken 
together these studies demonstrate that both CC and CXC chemokines are present in 
RA, however their involvement in the pathogenesis of arthritis is still unclear. 
Nevertheless, it is hypothesized that these chemokines are overexpressed at 
inflammatory focci and are therefore thought to be responsible inducing strong 
adhesive interactions between rolling leukocytes and the endothelium.
Atherosclerosis. Atherosclerosis, is thought to result from an inflammatory response 
to arterial damage caused by hypertension, shear stress or disordered blood flow 
(Ross, 1999). Animal models demonstrated a role for IL-8 /CXCL8 , SDF-1/CXCL12, 
Mig/CXCL9, I-TAC/CXCL11, IP-10/CXCL10, I-309/CCL1 and CXCR2 in 
atherosclerosis (Abi-Younes et al., 2000; Boisvert et al., 2000; Haque et al., 2000; 
Mach et al., 1999). CXCR2 is expressed on macrophages in atherosclerotic lesions, 
and CXCR2 deficiency strongly reduces the progression of advanced atherosclerosis 
in mice (Boisvert et al., 2000). SDF-1/CXCL12 induces platelet aggregation and is 
expressed in smooth muscle cells, endothelial cells and macrophages in 
atherosclerotic plaques but not in normal vessels (Abi-Younes et al., 2000). 
Immunofluorescence staining demonstrated differential expression of IP- 
10/CXCL10, I-TAC/CXCL11, Mig/CXCL9 and INF-y in cells composing 
artherosclerotic plaques (Mach et al., 1999). CX3CRI heterozygosity has been shown 
to be related with a reduced risk of coronary atherosclerosis (Moatti et al., 2001). 
RANTES/CCL5, Eotaxin/CCLll and MIP-la/CCL3 have also been isolated from 
plaques in atherosclerotic patients (Gerard & Rollins, 2001). Knockout mice of 
CCR2, the receptor for MCP-1/CCL2, crossed with apoliprotein (apo) E-null mice, 
which develop severe atherosclerosis, show decreased lesion formation (Boring et al.,
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1998). All together these studies indicate that certain chemokines and their receptors 
paly an important role in modulating the functions of leukocytes and smooth muscle 
cells involved in the development and progression of atherosclerosis.
Multiple sclerosis. Multiple sclerosis (MS) is an inflammatory, demyelinating 
disorder of the human central nervous system (Trapp, 1998). Sorensen et al found 
elevated levels of IP-10/CXCL10, Mig/CXCL9 and RANTES/CCL5 in cerebrospinal 
fluid during MS attacks (Sorensen et al., 1999). CXCR3 was shown to be expressed 
on lymphocytic cells in virtually every active MS lesion and CCR5 was detected on 
lymphocytic cells, macrophages, microglia in actively demyelinating MS brain 
lesions (Sorensen et al., 1999; Balashov, 1999). Several studies have reported that 
RANTES/CCL5, MIP-la/CCL3, MIP-1|3/CCL4, IP-10/CXCL10 and MCP-1/CCL2 
mRNA and protein are associated with inflammatory lesions (Gerard & Rollins,
2001). However, MIP-la/CCL3 and CCR5 deficient mice were shown to contract 
experimental allergic encephalitis (EAE), the best animal model for MS, whereas 
CCR1'7' mice has a decreased incidence and less severe clinical score (Rottman et al., 
2000; Tran et al., 2000). Mice deficient in MCP-1/CCL2 were shown to be resistant 
to EAE (Gu et al., 2000), and CCR27" mice are completely resistant to the disease 
(Izikson et al., 2000). It is thought that MCP-1/CCL2 is important in triggering cells 
expressing CCR2, for example macrophages, involved in producing the characteristic 
manifestation of this disease (Gerard & Rollins, 2001).
Allograft rejection. Animal models have shown that chemokines also play a role in 
allograft rejection (Gerard & Rollins, 2001). It is thought that after transplantation of 
the allograft, the early release of chemokines, triggered by damage to the organs,
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attracts leukocytes expressing CCR2, CXCR3 and CCR5. Host natural killer (NK) 
cells after surveying MHC mismatches at the vascular endothelium respond by 
producing IFN-y. IP-10/CXCL10, Mig/CXCL9 and I-TAC/CXCL11 are produced 
locally and attract CXCR3 expressing T cells as well as DCs. The host cells invade 
the graft and cause acute and chronic rejection probably independently driven by 
CXCR3 and MCP-1/CCL2 (Gerard & Rollins, 2001). CCRl7' (Gao et al., 2000), 
CCR2'\ CCR4 '-, CCR5‘\  IP-IO/CXCLIO7' (Hancock et al., 2000a), and CXCR37' 
(Hancock et al., 2000b) mice have a much higher allograft survival than the wild-type 
mice when treated with subtherapeutic doses of immunosuppressants.
It is clear that chemokines play a fundamental role in the development of 
pathological inflammation and disadvantageous immune responses. Recent research 
is beginning, particularly through the use of neutralising antibodies and receptor 
knock-out mice, to elude the function of individual receptor-ligand pairs. Such 
research is likely to be of considerable use in defining new targets on the treatment of 
these pathologies. Indeed, small molecule antagonists of several chemokine receptors 
have been reported to prevent or amelliorate some of these problems in animal 
disease models.
1.3.4.Chemokines and cancer:
The overall role of chemokines in tumour biology is not clear. The aim of this section 
is to give examples of studies that have demonstrated a role for chemokines and their 
receptors regarding metastasis and angiogenesis.
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Work by Muller et al (Muller et al., 2001) strongly suggests that chemokines and 
their receptors have a critical role in determining the metastatic destination of tumour 
cells. In this study, expression of CXCR4 and CCR7 was reported to be elevated in 
human breast cancer cells, malignant breast tumours and metastases. Additionally, 
expression of SDF-1/CXCL12, ELC/CCL19 and SLC/CCL21 was found in the most 
common metastatic sites for breast cancer (Muller et al., 2001). This study also 
reported that, SDF-1/CXCL12 and SLC/CCL21 stimulated tumour cells were capable 
of inducing actin polymerisation, a process necessary for cell motility and migration. 
Moreover, treatment in vivo with anti-human CXCR4 monoclonal antibody leads to a 
significant decrease in lung metastasis (Muller et al., 2001).
Introducing chemokines into tumour cells in animal models has also been shown to 
modulate tumourgenicity. For example, Botazzi and colleagues showed that 
transduction of the MCP-1/CCL2 gene in melanoma cells caused growth retardation 
when injected in mice, but an increase in tumorigenicity and lung metastases is 
reported when lower numbers of tumour cells are injected into the same animal 
model (Bottazi et al., 1992). MCP-1/CCL2 was also shown to increase lung 
metastasis by increasing neovascularization in melanoma cells transfected with this 
chemokine (Nakashima et al., 1995). Except for one report by Manome et al 
(Manome et al., 1995), MCP-1/CCL2 gene transfer does not seem to confer 
immunity against parental tumour cells. In fact, Salcedo and co-workers have indeed 
demonstrated by means of neutralizing antibodies to MCP-1/CCL2, that this 
chemokine is indeed a direct mediator of angiogenesis (Salcedo et al., 2000). It is 
therefore thought that MCP-1 can have direct effects in promoting angiogenesis and 
for this reason therapy employing antagonists of MCP-1 together with other
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inhibitors of angiogenesis might prove effective in achieving tumour growth 
inhibition.
Transduction of IP-10/CXCL10, RANTES/CCL5, I-309/CCL1 and MIP-la/CCL3 
into tumour cells, consistently reduces tumorigenicity and also stimulate hosts 
immune response (Laning et al., 1994; Luster & Leder, 1993; Mule et al., 1996; 
Nakashima et al., 1996). Injection of Lymphotactin/XCLl-2 together with the T-cell 
expanding and activating cytokine IL-2 increased T lymphocyte infiltration in 
myeloma and gave rise to a synergistic anti-tumour response (Dilloo et al., 1996). 
More recently, transduction of a colon carcinoma cell line with mouse SLC/CCL21 
cDNA was shown to have reduced tumourigenicity (Vicari et al., 2000). In this study 
the tumours were heavily inlfitrated with leukocytes, including granulocytes, 
dendritic cells and CD8 + T cells which suggests that the antitumour effects caused by 
SLC/CCL21 are due to induction of both angiostatic, CD8 + T cell-mediated and 
possibly NK-mediated tumour resistance mechanisms.
As mentioned before, the CXC chemokines can be subdivided into ELR+ or ELR' 
depending on the presence or absence of the ELR motif. The ELR+ CXC chemokines 
(Table 1.2.), functioning through two shared receptors CXCR1 and CXCR2, have 
been shown not only to be potent neutrophil attractants but also to be powerful 
promoters of angiogenesis (Belperio et al., 2000), whereas some of the ELR' 
chemokines have angiostatic properties (see below). For example, the ELR+ CXC 
chemokine IL-8 /CXCL8 , has been found to be an essential autocrine growth factor 
for some melanoma cell lines and experiments with neutralized antibodies as well as 
with IL-8 /CXCL8  antisense oligonucleotides has been shown to inhibit growth of
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two human malignant cell lines in vitro (Schadendorf et al., 1993). Additionally, this 
chemokine has been reported to be involved in mediating human ovarian carcinoma 
angiogenesis and tumourigenesis (Yoneda et al., 1998), and to contribute to the 
overall angiogenic activity of non-small cell lung cancer (Smith et al., 1994). 
Generation of a mutant of IL-8 /CXCL8  lacking the ELR motif showed that this 
mutant no longer exhibited its normal angiogenic effects and in fact had acquired 
angiostatic properties (Strieter et al., 1995). Furthermore, when a mutant of 
Mig/CXCL9 was made where the ELR motif was cloned in after the first Cys residue 
this new protein was shown to be now capable of angiogenesis (Strieter et al., 1995). 
These observations suggest that regulation of CXC chemokines expression is 
important for angiogenesis control.
In contrast to the ELR+ angiogenic properties the expression of ELR' CXC 
chemokines, IP-10/CXCL10 and Mig/CXCL9 were found to be elevated in tumours 
that regress spontaneously (Sgadari et al., 1996). Intra-tumour injection of IP- 
10/CXCL10 or Mig/CXCL9 in nude mice previously injected with a lymphoma cell 
line leads to reduction of tumour-associated angiogenesis (Sgadari et al., 1997; 
Teruya-Feldstein etjal., 1997).
In summary, the chemokine system is capable of regulating tumour growth by 
exercising their angiostatic and/or angiogenic properties, by initiating tumour 
immunity or by regulating the tumour metastatic potential. Although it was initially 
thought that inoculation of tumour cells transfected with various chemokines would 
result in tumour infiltration by host immune cells that would migrate in vitro in 
response to the transfected chemokine it is now evident that divergent data can be
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obtained depending on the animal model and on the chemokine species used. Overall 
it is believed that, many factors can regulate angiogenesis but the balance between 
ELR+ and ELR' chemokines produced by a given tumour is thought to determine the 
degree of angiogenesis and invasiveness of the tumour (Strieter et al., 1995; Wang,
1998).
1.4. Host-virus interactions within the chemokine 
system
Viruses depend on living cells for replication, so in order to escape detection by the 
immune system, viruses have developed many ways of circumventing the host’s 
immune defences. For example, some viruses have evolved to encode versions of 
chemokines (viral chemokine homologs) that act as chemokine antagonists and 
agonists, or chemokine binding proteins or viral chemokine receptor homologs that 
have been proposed to function as extracellular chemokine scavengers (Alcami & 
Koszinowski, 2000). The study of viruses that are known to encode genes which are 
involved in blocking an immune response attracted many researchers to this area as 
these studies will not only prove helpful in finding how to prevent these viruses from 
invading the immune system but also provides researchers with a unique model 
system to study the immune system.
a). Viral chemokines:
Viral chemokines can bind to many chemokine receptors and work as antagonists and 
thereby block leukocyte migration (Lalani & McFadden, 1999). Alternatively, viral 
chemokines can act as leukocyte attractants in order to favour viral tropism and
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propagation of the virus. Below are some examples of viruses capable of producing 
viral chemokines that illustrate the widely divergent roles of these molecules in the 
viral life cycle.
KSHV. The Kaposi’s Sarcoma-associated Herpes virus (KSHV)/ Human 
Herpesvirus 8  (HHV-8 ), has been shown to encode a number of molecules that 
mimic cytokine genes, including three proteins homologous to chemokines, named 
vMIP-I, vMIP-H and vMIP-in (Dittmer & Kedes, 1998). These virally encoded 
chemokines have 25-40% amino acid similarity to MIP-la/CCL3 (Lalani & 
McFadden, 1999) and were initially thought to be involved in dampening the 
immune response to KSHV infection by inhibiting chemokine signalling by 
antagonistic binding to receptors (Kledal et al., 1997). vMIP-H has been shown to 
function as a broad spectrum competitive antagonist since it can bind to CCR1, 
CCR2, CCR3, CCR5, and CXCR4 but is unable to elicit cellular signalling 
transduction (Kledal et al., 1997). Moreover, this protein has been shown to block 
chemoattraction by CC and CX3C chemokines in vitro (Boshoff et al., 1997). In 
contrast, vMIP-I and vMIP-IH are chemokine agonists. vMIP-I binds to and induce 
calcium mediated signalling through CCR8  selectively expressed in human T cells 
(Dairaghi et al., 1999), whereas vMIP-IH acts selectively on CCR4. It is now known 
that Thl polarized cells, which preferentially express CCR5 and CXCR3, usually 
mediate a host response to a viral infection (Spprigs, 1996). By attracting Th2 cells, 
which preferentially express CCR3, CCR4 and CCR8  (D'Ambrosio et al., 1998; 
Sozzani et al., 1998b), these proteins produced by the virus skew the immune 
response from a Thl to a Th2 microenvironment within the KS lesion (Stine et al., 
2000). In addition to deviating the immune response, these viral peptides have been
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reported to be involved in angiogenesis (Boshoff et al., 1997; Stine, 2000). Given 
that KS lesions are characterized by extensive neovascularization (Hayward, 1999) of 
the affected tissue it is possible that the angiogenic properties of these viral gene 
products may contribute to the generation of new blood vessels in KS which in turn 
may support tumour development.
HCMV. The Human Cytomegalovirus (HCMV) is responsible for severe 
opportunistic infections and encodes two chemokine antagonists, vCXC-1 and 
vCXC-2 (MacDonald et al., 1999), and a viral chemokine receptor (see below). 
Although the biological properties of vCXC-2 are still to be characterized, vCXC-1 is 
known be biologically similar to IL-8 /CXCL8  and GROa/CXCLl despite the fact 
that these peptides share very little sequence similarity. Penfold and colleagues 
showed that vCXC-1 is capable of inducing calcium mobilization, chemotaxis and 
neutrophil degranulation via high affinity binding to CXCR2, just like IL-8 /CXCL8  
(Penfold et al., 1999). vCXC-1 has been proposed to be important for disease 
dissemination by recruiting neutrophils during cytomegalovirus infection, although a 
definitive role requires further experimentation.
MCV. The human poxvirus, Molluscum contagiosum virus (MCV) causes 
proliferative lesions on the skin of immunocompromised patients and is characterized 
by poor infiltration of leukocytes and low inflammation markers. Senkevich and 
colleagues isolated several genes thought to be potentially involved in preventing an 
inflammatory response. Amongst these genes, they identified a chemokine 
homologue, vMCC-1, a gene product of ORF MC148R (Senkevich et al., 1996). 
vMCC-1 inhibits chemotaxis of multiple leukocytes subsets induced by CC and CXC
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chemokines (Damon et al., 1998). Chemotaxis assays, indicated that vMCC-1 is 
likely to bind to CCR1 and/or CCR5, CCR2, CCR8 , CXCR1 and/or CXCR2 and 
CXCR4 (Damon et al., 1998). For vMCC-1, its antagonistic properties are thought to 
be attributed to the fact that vMCC-1 lacks a receptor activation domain which is 
usually found in the N-terminus of cellular chemokines (Damon et al., 1998; Lalani, 
1999).
HIV. The HIV transcription factor Tat is a potent chemoattractant for monocytes that 
can function as a chemokine mimic (Murphy, 2001). Tat is capable of sharing 
receptors with MCP-1/CCL2, MCP-3/CCL7 and Eotaxin/CCLll. Receptor binding 
studies demonstrated that Tat can bind to CCR2 and CCR3 but not CCR1, CCR4 and 
CCR5 (Albini et al., 1998). Moreover, Tat can induce expression of CXCR4 in 
monocytes/macrophages and lymphocytes, of CCR5 and CCR3 in 
monocytes/macrophages but not in lymphocytes (de Paulis et al., 2000; Huang et al.,
1998). By triggering cell surface receptors, Tat induces leukocyte chemotaxis and 
possibly allows more efficient virus spread by attracting monocytes towards HIV- 
infected cells.
b). Chemokine-binding proteins
Viruses can also secrete chemokine-binding proteins (vCKBPs) proposed to protect 
viruses from host immune and inflammatory responses (reviewed in (Lalani et al., 
2000; Lalani & McFadden, 1999; Murphy, 2001; Zlotnik et al., 1999)) e.g. the 
myxoma virus M-T7 gene product, vCkBP-I, and the poxvirus M-Tl gene product, 
vCkBP-II (Lalani & McFadden, 1997). vCkBP-I can promiscuously bind to CXC, C 
and CC chemokines (Lalani et al., 1997) and function as an inhibitor of IFN-y (Upton
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et al., 1992). Studies have shown that vCkBP-I inhibits the formation of a chemokine 
solid phase gradient on endothelial surfaces by interacting with the C-terminal GAG 
domain of chemokines known to be involved in binding to glycosaminoglycans 
(Clark-Lewis et al., 1995; Witt & Lander, 1994). vCkBP-II binds with high affinity to 
multiple CC chemokines and with low affinity to the CXC chemokine, IL-8  (Smith et 
al., 1997a). By blocking chemokine interaction with cellular receptors and potentially 
inhibiting Ca2+ mobilization as well as chemokine-mediated chemotaxis, vCkBP-H is 
believed to inhibit recruitment of inflammatory cells into viral infected tissues 
(Alcami et al., 1998; Lalani et al., 1998; Smith et al., 1997a)
c). Virally encoded chemokine receptors
The viral receptor US28, is the most characterized of the four human 
cytomegalovirus (HCMV) GPCR homologs identified to this date. This molecule 
shares 30% identity with CCR1, and binds to MIP-la/CCL3, MIP-lp/CCL4, 
RANTES/CCL5, MCP-1/CCL2, MCP-3/CCL7 and fractalkine/CX3CLl (Kledal et 
al., 1998; Gao, 1994; Bodaghi, 1998; Neote, 1993 ; Vieira, 1998). The exact role of 
US28 is not known but work by Bodaghi and colleagues has suggested that US28 
might a play a role in chemokine sequestration and thereby block inflammatory 
events during HCMV infection (Bodaghi et al., 1998). However, a report by Streblow 
et al demonstrates that deletion of US28 decreases smooth muscle cell (SMC) 
migration in comparison to wild type HCMV (Streblow et al., 1999). This study 
provides evidence that migration of SMCs upon infection with HCMV depends on 
the expression of US28 and therefore points towards a disease model whereby 
HCMV mediates vascular SMC migration through US28.
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The murine cytomegalovirus (CMV) M78 GPCR-like protein (Rawlison et al., 1996) 
appears to be quite different. Interestingly, Oliveira et al have shown that M78 is 
delivered to cells as a constituent of the virion and that this molecule is involved in 
facilitating the accumulation of immediate-early mRNA (Oliveira & Shenk, 2001). It 
is thought that M78 is involved in either transcription stimulation or acts 
posttranscriptionally to influence mRNA stability; it is also possible that M78 
initiates a signal that modulates transcriptional regulatory systems whereby it 
represses some genes and activates others, in order to guarantee survival of the virus.
The KSHV G protein-coupled receptor is a product of KS-associated herpesvirus or 
HHV8  that is thought to be responsible in part for KS pathogenesis (Bais et al.,
1998). Ligands for this viral receptor include both CC and CXC chemokines 
(Arvanitakis et al., 1997). The G protein coupled receptor encoded by KSHV is 
constitutively active and is thought to be a viral oncogene since it is capable of 
driving proliferation of cells transfected with this receptor (Arvanitakis et al., 1997) 
by activating the protein kinases, JNK/SAPK and p38/MAPK, which activate 
angiogenesis and are mitogenic for Kaposi’s sarcoma and B cells (Bais et al., 1998). 
Moreover, it has been demonstrated that signalling through this receptor is pertussis 
toxin resistant and can be altered either negatively or positively by chemokine 
ligands. In fact, some chemokines such as Mig/CXCL9, bind but do not appear to 
modulate signalling (Arvanitakis et al., 1997). How these complex interactions 
conspire to favour the virus survival and replication is by no means clear.
U12 and U51 are also examples of virally encoded GPCRs homologs. These 
receptors encoded by HHV-6  are capable of eliciting calcium mobilization upon 
binding to RANTES/CCL5, MIP-la/CCL3, MIP-ip/CCL4 and MCP-1/CCL2
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(Isegawa et al., 1998). The equine herpesvirus 2 can only encode for a viral 
chemokine receptor, E l, which shares sequence similarities with CC chemokine 
receptors (Telford et al., 1995) and was shown to mediate signalling transduction in 
the presence of eotaxin (Camarda et al., 1999). Examples of virally encoded 
chemokine receptors are the herpes saimiri virus that encodes a receptor-like 
molecule (ECRF3/ORF74) similar to CXCR1 and CXCR2. This receptor binds to 
GROa/CXCLl, IL-8 /CXCL8  and NAP-2/CXCL7 (Ahuja & Murphy, 1993) and is 
capable of calcium mobilization.
It is not clearly known why viruses encode chemokine receptors. What it is known is 
that they are encoded and that bearing in mind the limitations of viral genome size 
they must be important. Moreover, the fact that these virally-encoded chemokine 
receptors are signalling competent suggests that this signalling function must be of 
importance for the virus. At a first glance it is hard to envisage a situation where 
chemotaxis would benefit the survival of the virus. Alternatively, it is possible that 
viruses might possibly use these receptors to control cell cycle progression or even by 
inhibiting apoptosis of the host cell. On the other hand, it is also possible that if the 
chemokine receptor is present in the virion it may play a role in directing the virus to 
specific cells with specific chemokines tethered to their surfaces.
1.4.1. Chemokine receptors and pathogen entry
Recently, attention has been paid to the role of chemokine receptors in infectious 
dieseases. It is now known that chemokine receptors participate in several disease 
states, either by overexpressing receptors or by facilitating viral entry into host cells. 
Examples of agents that can invade host cells by manipulating the chemokine
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receptor system (for reviews refer to (Murdoch & Finn, 2000; Murphy, 1996; 
Premack & Schall, 1996)) are described below.
HIV. HIV-1 has been shown to use chemokine receptors together with CD4 to gain 
access to cells (for review refer to (Murdoch & Finn, 2000; Murphy, 1996; Premack 
& Schall, 1996)). Feng and colleagues have identified CXCR4 as an entry co-factor 
for T-cell-tropic HIV isolates (Feng et al., 1996). The CC chemokine receptors, 
CCR2, CCR3 and CCR5 have also been shown to serve as co-factors along with 
CD4 to allow entry of macrophage-tropic and dual-tropic strains of HIV-1 (Alkhatib 
et al., 1996; Deng et al., 1996; Dragic et al., 1996). More recently, CCR8  has also 
been identified as an entry co-factor for T-cell tropic or for macrophage-tropic HIV-1 
strains (Horuk et al., 1998). Although many chemokine receptors have been shown to 
act as co-factors for HIV entry into the host cells, their role in vivo has only been 
well documented for CXCR4 and CCR5 (for review see (Murphy et al., 2000)).
It is thought that the gpl20 subunit of HIV recognizes the host-encoded CD4 receptor 
and undergoes a conformational change that allows this subunit to bind to chemokine 
receptors (Trkola et al., 1996; Wu et al., 1996). The binding of gpl20 to the 
chemokine receptor induces another conformation change in the Env that leads to 
activation of the other subunit, gp41. Activation of gp41 allows penetration of the 
host cell membrane and fusion of the viral and host cell membranes (Berger et al., 
1999). The discovery of a group of individuals resistant to HIV-1 infection lead to the 
identification of a 32bp deletion in the CCR5 gene (CCR5 A32). This deletion in the 
CCR5 gene results in a truncated protein that is not expressed on the cell surface 
(Samson et al., 1996) and this lack of surface expression is thought to be the reason
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why these individuals (with no other apparent phenotype) are more resistant to HIV-1 
than others that have a normal CCR5. More recently, a polymorphism in CCR2 has 
also been identified which is thought to be related to delayed progression to AIDS 
(Smith et al., 1997b).
Plasmodium. Plasmodium knowlesi and P. vivax, the parasites responsible for 
malaria, also uses a chemokine receptor to gain entry into host cells (Chauduri et al., 
1989; Hadley & Peiper, 1997; Horuk et al., 1993). Malarial blood infections occur 
when the parasite invade red blood cells (RBCs) which express the Duffy 
antigen/receptor for chemokines (DARC). Studies have shown that although malaria 
is endemic in Africa, 95% of the African population is resistant to the parasites 
P.vivax and P. knowlesi. Work by Miller and colleagues showed that the erythrocytes 
of individuals that are resistant to P.vivax do not express the DARC chemokine 
receptor on their surface and that an anti-DARC antibody could block parasite 
invasion into normal erythrocytes (DARC-positive erythrocytes) (Miller et al., 1975).
Poxvirus. During evolution, poxviruses have acquired many genes encoding proteins 
whose function is to counteract the host response to infection (for review see (Alcami 
& Smith, 1995)). Poxviruses have evolved to modulate the host immune response by 
producing viral chemokines and chemokine homologs as well as secreting virus- 
encoded chemokine-binding proteins. Like in the case of HIV (see above), 
poxviruses can use chemokine receptors, such as CCR5 and CXCR4, to infect cell 
subtypes (Lalani et al., 1999). Experiments using 3T3 cells have demonstrated that 
Myxoma virus infection requires the presence of either CCR1, CCR5 or CXCR4 
(Lalani et al., 1999). In this study it was also demonstrated that infection of 3T3 cells
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transfected with CCR5 by Myxoma virus can be blocked by RANTES/CCL5 or by 
an anti-hCCR5 polyclonal antibody.
In conclusion, the role of the chemokine system goes beyond simple immune 
modulators. In order to exploit the therapeutic potential of the chemokine system it is 
essential to identify specific ligands and receptors that are important in a given 
disease setting. In the last couple of years, attention has been turned to chemokine 
receptors that compose attractive targets because they are GPCRs, a class of proteins 
for which there is a well documented history of developing small, non-peptidyl 
antagonists. It is therefore of extreme importance to understand the nature of 
chemokine/ chemokine receptor interactions in order to develop therapeutic targets as 
well as in developing inhibitors of chemokine/ chemokine receptor interactions.
1.5. Chemokine and chemokine receptor interactions
Many studies have attempted to dissect the molecular requirements for 
chemokine/chemokine receptor interactions. Initially, in order to determine 
functionally relevant domains, researchers directly compared primary sequences of 
chemokines and used mutagenesis to investigate its role in receptor interactions. This 
approach was soon abandoned not only because it was rather inefficient but also 
because it was impossible to distinguish between residues that made direct contact 
with the receptor and residues that are structurally important. Nowadays, structure- 
function analyses usually include the construction of chimaeric and mutant molecules 
the biochemical properties of which are then assessed by radioligand binding assays 
and signalling studies. Although this most recent approach has been successfully
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used to study chemokines as well as their receptors, it is possible that the chimaeric 
protein might have its overall structure disturbed and therefore will not be 
particularly informative. In order to minimise disturbances of the overall structure, 
researchers have tried to make chimaeric proteins between more related proteins. 
Although this approach is thought to generate potentially stable proteins, it might 
overlook functional contributions attributed to shared determinants. So, together with 
the generation of chimaeric constructs, Alanine scanning mutagenesis, to target 
individual residues, and NMR, to detect any structural disturbances, approaches have 
been used.
Many studies have shown that the N-terminal domain of a  and p chemokines is 
important for chemokine function. Early studies centred on CXCR1 and CXCR2 and 
their ligands, on MCP-1/CCL2 and its receptor, CCR2. Studies by Clark-Lewis and 
colleagues demonstrated that the ELR domain found in N-terminal domain of IL- 
8 /CXCL8  is essential for binding to its receptors (Clark-Lewis et al., 1991). 
Specifically, Alanine scanning mutagenesis of IL-8 /CXCL8  identified the Arg 
residue at position 6 , i.e. within the ELR motif, as being critical for ligand binding 
(Williams et al., 1996) and work carried out by Clark-Lewis reports that deletion the 
first part of the N-terminus including the ELR motif generates a mutant that retains 
binding but is no longer biologically active (Clark-Lewis et al., 1991). Although 
cloning of the ELR domain into PF-4/CXCL4, a non-ELR chemokine that does not 
bind to CXCR1 or CXCR2 allows binding of the mutant to the IL-8 /CXCL8  receptor 
(Clark-Lewis et al., 1993), the cloning of the same motif into IP-10/CXCL10 
generates a mutant that does not bind to the IL-8 /CXCL8  receptors (Wuyts et al., 
1999). These studies suggest that other parts of the molecules, other than just the
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ELR motif are also involved in receptor binding. In fact, the C-terminal a-helix of 
IL-8 /CXCL8  has been reported to be required for binding to CXCR2 but it is not 
necessary for high affinity binding to CXCR1. Moreover, residues Tyr 13 and Lysl5 
have been shown to be important for interaction with CXCR1. Similarly, 
experiments carried out with IL-8 /GROa (CXCL8/CXCL1) chimaeric chemokines 
have also shown that it is not just the ELR motif but also other regions that are 
necessary and indispensable for high affinity binding (for review see (Wuyts et al.,
1999)). Thus, it is quite apparent that multiple domains are required for interaction 
with receptors and that these domains are different when different receptors are 
studied. Additional studies have shown that an antibody against CXCR1 can block 
IL-8 /CXCL8 -induced activity without affecting binding (Wuyts et al., 1999), 
suggesting that there must be two distinct sites in the chemokine: one important for 
binding and another important for receptor activation.
The idea that the initial receptor contact is provided by the main body of the 
chemokine and activation of the receptor is provided by the N-terminus (two-site 
model) has been demonstrated for several chemokines such as SDF-1/CXCL12 and 
MCP-1/CCL2. Alanine scanning of MCP-1/CCL2 allowed identification of residues 
in this protein involved in signalling transduction and binding (Hemmerich et al.,
1999). It is thought that in the case of MCP-1/CCL2, its receptor lies along the 
hydrophobic groove and that the N-terminus, especially residue Y13, interacts with 
the receptor with high affinity (Hemmerich et al., 1999). In contrast with the data 
collected for IL-8 /CXCL8 , when as little as two amino acid deletions are made in the 
N-terminus of MCP-1/CCL2 this chemokine lowers its activity and becomes an 
antagonist (Zhang et al., 1994). Crump and colleagues demonstrated that the N loop
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region (region after the CXC motif) of SDF-1/CXCL12 is important for initial 
docking of the chemokine with CXCR4 and that the N-terminus is also an important 
binding site where mutations in residues 1 and 2  cause loss of receptor activity 
(Crump et al., 1997). Alanine-scanning mutagenesis on the N-terminal and the N- 
loop regions (region after the CC motif) of eotaxin showed that in contrast with 
MCP-1/CCL2, SDF-1/CXCL12 and IL-8 /CXCL8 , the residues involved in receptor 
binding affinity and triggering are scattered throughout the N-terminal and N-loop 
regions (Mayer & Stone, 2001).
Extensions of the N-terminus have also been shown to affect the function of CC 
(Proudfoot et al., 1996) and CXC chemokines (Malkowski et al., 1995). Production 
of RANTES in E. coli produced a functionally inactive protein (Met-RANTES) 
where the initiating methionine was not removed from RANTES/CCL5 endogenous 
amino peptidases (Proudfoot et al., 1996). This variant of RANTES/CCL5, Met- 
RANTES was found to be fully folded but was completely inactive in assays 
measuring calcium mobilization and chemotaxis despite maintaining its ability to 
bind its receptors (Proudfoot et al., 1996). The finding that N-terminus extensions of 
RANTES/CCL5 could serve as receptor antagonists lead to the generation of a 
RANTES/CCL5 analogue, AOP-RANTES where the first eight amino acids of 
RANTES/CCL5 have been replaced by an aminooxypentane (AOP) group (Simmons 
et al., 1997). This modified version of RANTES/CCL5 proved to be capable of 
inducing hCCR5 internalization and therefore acts as a very potent inhibitor of HIV 
infection (Simmons et al., 1997; Townson, 2000) with slightly altered receptor 
specificities (Proudfoot et al., 1999). More recently, another antagonist (Met-Ck|37) 
has been described that is reported to have a much potent antagonist effect in CCR3
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and therefore of potential importance for the treatment of asthma (Nibbs et al., 2000). 
Met-Ckj37 is a modified form of MIP-4/CCL18, where the extreme N-terminal 
residue has been replaced by a methionine (Nibbs et al., 2000). This modified version 
of MIP-4/CCL18 is reported to be a potent and specific antagonist CCR3 that 
prevents signalling through this receptor and that at very low concentrations can 
block eosinophil chemotaxis induced by CCR3 ligands.
Interestingly, naturally truncated forms of chemokines have been identified in vivo. It 
seems as if the immune system exploits the fact that the activity of chemokines can 
be affected by slight alteration on their N-terminal domain in order to regulate 
immune responses. It is now known that chemokines can serve as substrates for a 
number of peptidases. For example, CD26, a dipeptidyl peptidase, has been shown to 
have a substrate specificity of NPU-X-Pro that cleaves chemokines such as MCP- 
1/CCL2, Eotaxin/CCLll, IP-10/CXCL10 and RANTES/CCL5 (Oravecz et al.,
1997). Work by Oravecz et al demonstrates that the truncated version of 
RANTES/CCL5 lacking the first two N-terminal residues was incapable of eliciting 
calcium mobilization in human monocytes but retained this activity in human 
macrophages stimulated with colony stimulating factor. In this study the authors 
report that this observation is due to the fact that the truncated version of 
RANTES/CCL5 has reduced activity, relative to that of RANTES/CCL5, in cells 
expressing CCR1 but retained the capacity of stimulating CCR5 and inhibiting HIV 
entry (Oravecz et al., 1997). Another example of proteins that can cleave chemokine 
is the family of matrix metalloproteinases (MMP). MMP-2, which is naturally 
secreted by stromal cells, can cleave the first four N-terminal extreme amino acids of 
MCP-3/CCL7 (McQuibban et al., 2000). This cleaved MCP-3/CCL7 binds to CCR1,
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CCR2 and CCR3 but is not capable of inducing calcium mobilization or chemotaxis 
and therefore acts as an antagonist potentially involved in dampening the immune 
response (McQuibban et al., 2000). However, these MMP can also serve as positive 
regulators of inflammation. MMP9 can cleave the first 6  N-terminal amino acid 
residues of IL-8 /CXCL8  and generate an even more potent form of IL-8 /CXCL8  
thought to be involved in enhancing the inflammation process perhaps by increasing 
signalling through CXCR1 (Van Den Steen et al., 2000). Proteolytic cleavage is also 
associated with the generation of a PF-4/CXCL4 variant whose first four amino acids 
have been cleaved to generate an inhibitor of endothelial cells (Gupta et al., 1995) 
and with the generation of thrombocidins, microbicidal proteins form human blood 
platelets have been reported to be C-terminal deletion products of CXC chemokines 
such as NAP-2/CXCL7 (Krijgsveld et al., 2000).
The ligand binding site on chemokine receptors is also highly complex. It is thought 
to be composed of multiple non-contiguous domains and at least two distinct sub­
sites: one for docking and another for triggering (Ahuja et al., 1996; Murphy et al.,
2000). The first evidence for this model regarding chemokine receptors came from 
studies with CCR1/CCR2 chimaeric receptors (Monteclaro & Charo, 1996). In this 
study the authors mapped the MCP-1/CCL2 binding site to the N-terminal domain of 
CCR2 and that other regions were necessary for efficient signal transduction 
(Monteclaro & Charo, 1996). More evidence supporting this model came from 
studies with CCR2/CD8 fusion proteins and a truncated form of CCR2 reported by 
the same authors (Monteclaro & Charo, 1997). This construct was obtained by fusing 
the N-terminal residues of CCR2 to the transmembrane domain and cytoplasmic tail 
of CD8  and was shown to bind MCP-1/CCL2 with an affinity similar to that of the
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wild type CCR2 (Monteclaro & Charo, 1997). Furthermore, this study also shows 
that when the truncated mutant of CCR2 that lacks the high affinity binding sites to 
MCP-1/CCL2 is co-transfected with the CCR2/CD8 fusion protein, calcium 
mobilization is reported demonstrating that two distinct domains of MCP-1/CCL2 
interact with CCR2: one for high affinity ligand binding, the N-terminus, and one for 
interacting with the distal regions of the receptor to induce activation (Monteclaro & 
Charo, 1997).
In contrast with the CCR2 data, chimaeric constructs of CCR5 and CCR2b initially 
reported that the N-terminus of CCR5 is not involved in ligand selectivity, but rather, 
that the second extracellular loop of CCR5 is the main determinant of ligand 
specificity (Blanpain et al., 1999). However, N-terminal truncations of CCR5 
abrogated high affinity chemokine binding and functional response to MIP-lp/CCL4 
and RANTES/CCL5 (Blanpain et al., 1999; Samson, 1997) suggesting that indeed 
the N-terminal domain of CCR5 was important for ligand binding. Alanine-scanning 
mutagenesis generated a panel of CCR5 mutants that were used by Blanplain et al to 
investigate the role of specific residues in the N-terminus of CCR5 which are 
involved in binding to, and signalling in response to, chemokines (Blanpain et al.,
1999). In agreement with data published before, this study showed that mutations in 
the N-terminal domain of CCR5 lead to the generation of mutants with less binding 
affinity and responsiveness to the ligands (Blanpain et al., 1999). This work shows 
that not only the first 13 N-terminal amino acids of CCR5 are important for 
chemokine binding and receptor triggering, but also that other receptors must share 
structural determinants with CCR5 since swapping the N-terminus of CCR5 with the 
corresponding domain of other receptors (e.g. CCR2b, CXCR2, CXCR4 and CCR1)
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was shown to have little or no effect on chemokine binding and receptor activation. 
Studies with monoclonal antibodies raised against CCR5, have further confirmed that 
in fact the domain involved in ligand specificity is localized in the second 
extracellular loop of this receptor (Wu et al., 1997). Nevertheless, the negatively 
charged and aromatic residues in N-terminal region of hCCR5 are also reported to be 
important in binding to the positively charged chemokines (Bannert et al., 2001).
Studies with CXCR4, the SDF-1/CXCL12 receptor, have also shown that this 
receptor binds to SDF-1/CXCL12 in a way consistent with the two-site model of 
chemokine-receptor interaction (Brelot et al., 2000). In this study, the authors 
identified the N-terminus as the site involved in chemokine binding but not signalling 
and the second extracellular loop as being the site involved in chemokine binding and 
receptor activation. Moreover, deletions in the N-terminus domain of CXCR4 were 
shown to abolish signalling but not binding, suggesting that the N-terminus 
comprises different functional regions (Brelot et al., 2000). Replacement of the 
extracellular N-terminus of CXCR2 with the corresponding region of DARC showed 
that the N-terminal domain of DARC is important for the promiscuous binding 
profile of DARC (Hadley & Peiper, 1997).
In the case of CXCR1, the Cys residues in the extracellular regions of this protein 
have been shown to be important for binding and mediated signalling in response to 
IL-8 /CXCL8  (Wuyts et al., 1999). Replacement of the N-terminal part of CXCR1 by 
the corresponding domain of CXCR2 and vice-versa has shown that the N-terminal 
region of these receptors is responsible for the differences in binding specificity 
between CXCR1 and CXCR2 (Gayle et al, 1993). Again, as demonstrated for other
Filipa L. de Mendonga, 2002 Chapter 1
chemokine receptors, binding to and signalling through CXCR1 takes place in two 
distinct steps involving specific regions of the receptor (Clark-Lewis et al., 1995).
The overall conclusion that emerges from these studies is that the interaction between 
chemokines and their receptors is a two-step process where binding and activation is 
processed via two domains that operate independently from each other. It is this 
property of separate domains for activation and binding that allows the 
generation/design of potent antagonist with potential therapeutic properties.
1.6. Signal transduction
The binding of a chemokine to its receptor results in the activation of G proteins. 
Activated G proteins are then capable of mobilizing intracellular secondary 
messengers, which are ultimately involved in coordinating cytoskeleton 
reorganization and in focal adhesion formation that in turn will be responsible for 
appropriate cell migration in response to the chemoattractant molecule (for reviews 
refer to (Bokoch, 1995; Murdoch & Finn, 2000; Murphy, 1996; Premack & Schall, 
1996). The complex pathways involved in regulating chemotaxis and other 
chemokine effects are outwith the scope of this introduction. Instead, I will focus 
primarily on early receptor-mediated events and on the fate and regulation of the 
receptor.
G proteins are inactive when GDP is bound to the G-protein subunit and active when 
GDP is exchanged for GTP. Binding of the ligand to the receptor selects for a 
receptor conformation state that facilitates the exchange of GDP to GTP on the G 
protein a-subunit. Once in the active state, G-proteins dissociate into G a and Gj3y
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subunits. The Gpy subunit is capable of activating phospsholipase C (PLC) that 
cleaves phosphatidylinositol 4,5-biphosphate (PIP2) to give rise to the secondary 
messengers, phosphatidylinositol 1,4,5-triphosphate (IP3) and diacyl-glycerol (DAG). 
IP3 has been shown to be involved in calcium mobilization from intracellular stores 
and DAG, together with calcium ions, activates various forms of protein kinase C, 
PKC (reviewed in (Bokoch, 1995; Murdoch & Finn, 2000; Murphy, 1996; Premack 
& Schall, 1996)). Additionally to PKC and calcium-dependent mechanisms, other 
signalling mechanisms have been found to be involved in leukocyte activation such 
as activation of phospholipase D (PLD), mitogen activated protein kinase (MAPK), 
Janus kinase (JAK), phosphatidylinositol 3 kinase (PI3K), tyrosine kinases and 
phosphatases as well as serine/threonine kinases and phosphatases. Ultimately, these 
signalling mechanisms lead to cell motility, degranulation, release of superoxide 
anions and modification of integrins with the response being dictated by the cellular 
background (reviewed in (Bokoch, 1995; Murdoch & Finn, 2000; Murphy, 1996; 
Premack & Schall, 1996) (see Fig. 1.3). Additionally, it has also been proposed that 
chemokines through the appropriate GPCR can activate the expression of genes by 
the phosphorylation and nuclear translocation of signal transducer and activator of 
transcription (STAT) (Wong et al., 1997; Mellado, 2001). It is now thought that 
binding of the ligand to the receptor causes a conformation change that results in 
exposure of the DRY motif to the cell cytoplasm that allows the binding of members 
of the JANUS family of kinases to bind to the activated receptor (Mellado et al., 
1998).
It is not clear how a single receptor can sort different signalling transduction 
pathways in response to the ligand. Functional evidence has been accumulated that
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shows that chemokine signals can be sorted depending on the cell type, concentration 
and type of ligand (Murphy, 1996). For example, RANTES/CCL5 has been shown to 
elicit chemotaxis and degranulation in eosinophils whereas in basophils this 
chemokine induces chemotaxis but not degranulation (Baggiolini & Dahinden, 
1994). MCP-1/CCL2, on the other hand, is capable of inducing basophil 
degranulation without chemotaxis but is capable of inducing chemotaxis of 
monocytes and lymphocytes (Baggiolini & Dahinden, 1994). Moreover, different 
concentrations of RANTES/CCL5 have been shown to elicit biochemically distinct 
signalling pathways in T cells (Murphy, 1996). Distinct cell type specific signalling 
pathways have also been demonstrated for IL-8 /CXCL8 , GROa/CXCLl and NAP- 
2/CXCL7. Although these CXC chemokines are all chemoattractants for neutrophils, 
only IL-8 /CXCL8  is capable of inducing PLD activation in these cells (L'Heureux et 
al., 1995).
The idea of ‘one chemokine-one receptor’ has been recently challenged by the 
demonstration of receptor dimerization. Receptor dimerization has been shown to be 
important for transphosphorylation and activation of JAKs for a variety of GPCRs. 
By using tagged receptors, monoclonal antibodies and mutant receptors, CCR2 
dimerization has been demonstrated (Rodriguez-Frade et al., 1999). Moreover, 
evidence has now been collected that demonstrates that receptors can not only 
dimerize with themselves (homodimerization), but also with others 
(heterodimerization). This ability to dimerize is believed to generate considerable 
functional interactions. For example, studies with HEK-293 cells co-expressing 
CCR2 and CCR5 have revealed that calcium mobilization, upon a simultaneous 
stimulus with MCP-1/CCL2 and RANTES/CCL5, was triggered at a much lower
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concentration than that required by other chemokines alone (Mellado et al., 2001). It 
is now accepted that these two receptors form heterodimers that are more efficient at 
inducing biological responses due to synergistic interaction of several signalling 
complexes recruited by each individual receptor. Moreover, the authors report that an 
additional signalling pathway is triggered and that activation of PI3K is delayed 
(Mellado et al., 2001). As a consequence, a PTX-resistant calcium flux is elicited and 
cell adhesion rather than chemotaxis is triggered (Mellado et al., 2001; Rodriguez- 
Frade, 2001).
As mentioned above, signalling transduction via chemokine receptors has been 
shown to be dependent on coupling to pertussis toxin-sensitive G-proteins usually 
those of the Gj-type (Bokoch, 1995; Murphy, 2001). Although most of the chemokine 
receptors can couple to Gi proteins to activate PLC, Kuang and co-workers have 
demonstrated that different chemokine receptors have different specificities in 
coupling to the G a subunits of the Gq classes (Kuang et al., 1996). Additionally it 
has been reported that CC chemokine receptors can couple to Gaq proteins whereas 
CXC chemokine receptors cannot (Arai & Charo, 1996). Furthermore, Arai and 
colleagues have demonstrated that not only chemokine receptors couple to multiple 
G-proteins but also that the receptor-G protein pairing is highly cell type-specific 
(Arai & Charo, 1996).
After activation, receptors can become desensitised to repeated stimulation with the 
same or other agonists. This is thought to depend on a combination of different 
mechanisms that include, receptor phosphorylation of Ser and Thr residues by GRKs, 
internalisation of cell surface receptors, and downregulation of the receptor by
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changes in transcription, translation or degradation of pre-existing receptors 
(Ferguson, 2001; Murphy, 1996; Murdoch, 2000). Studies have shown that a receptor 
can be desensitised directly by a given ligand or indirectly when a ligand first 
encountered by the receptor desensitises a second stimulus by a different ligand. For 
example, work by Sozzani and colleagues demonstrates that MCP-1/CCL2 
desensitises monocytes to a second response with MCP-1/CCL2, RANTES/CCL5 or 
MIP-la/CCL3. However, when the same cells are treated with RANTES/CCL5 and 
MIP-la/CCL3 first, they are capable of eliciting a second calcium flux in response to 
the second challenge with MCP-1/CCL2 (Sozzani, 1991; Sozzani, 1993). These 
studies show that MCP-1/CCL2 is capable of cross-desensitising these cells to all 
other chemokines tested possibly by interfering with the receptors in such a fashion 
so that they are no longer responsive to MIP-la/CCL3 or RANTES/CCL5.
Once receptors have bound to the ligand activated G proteins, they become 
phosphorylated. Phosphorylation of the C-terminal domain or of the third 
intracellular loop by G protein-coupled receptor kinases promotes p-arrestin binding 
which in turn will not only promote uncoupling of the G proteins from the receptor 
but also mediates internalisation of the G protein-coupled receptor. Endocytosis of 
the receptor is mediated by clathrin that directly interacts with (3-arrestins. Once 
internalised the receptors can either be degraded in lysosomes or recycled back to the 
surface after they become dissociated from p-arrestins (Ferguson & Garon, 1998).
How it is decided whether to degrade an internalised receptor or to recycle it to the 
surface is not yet known. Chimaeric studies have suggested that receptors have 
specific determinants in the C-terminus that determine whether GPCRs are either
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recycled back to the surface or are retained within the intracellular compartment of 
the cell and/or targeted to lysosomes (Anborgh et al., 2000). For example, truncation 
of the CXCR4 C-terminus is reported to lead to higher receptor mediated activities in 
inositol phosphate formation and in the induction of a more sustained calcium 
elevation in the presence of the ligand, SDF-1/CXCL12 (Haribabu et al., 1997). 
Experiments performed by Cheng et al have demonstrated that p-arrestin can 
regulate internalisation and signalling of CXCR4 and that these functions are 
mediated through the C-terminus and the third intracellular loop of CXCR4 (Cheng 
et al., 2000). More recently, it was demonstrated that CCR5 can be internalised 
through pathways involving clathrin coated pits or caveolae upon stimulation with 
MIP-la/CCL3 (Mueller et al., 2002). Following internalization, CCR5 was shown to 
be transported to early endosomes where dephosphorylation and resensitization 
occurs before being recycled back to the surface (Mueller et al., 2002).
Another level of receptor trafficking is determined by palmitoylation, a post- 
translational modification of Cys residues by thioesterification. This type of 
modification is a dynamic phenomenon shown to affect a broad range of biological 
activities such as G-protein coupling efficiency and control of receptors 
phosphorylation and desensitisation (Morello & Bouvier, 1996). Recent studies have 
demonstrated that a cluster of Cys residues in the C-terminus of CCR5 can be 
palmitoylated (Blanplain et al., 2001; Percherancier et al., 2001). Moreover, these 
studies demonstrate that palmitoylation is indeed required for efficient trafficking of 
CCR5 to the cell surface and for triggering intracellular signal transduction pathways.
Mutagenesis approaches to investigating chemokine receptor signalling
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Mutagenesis studies have shown that there are some important motifs within 
chemokine receptors that are important for G protein coupling and proper signalling 
transduction (Oliveira et al., 1994; Brelot, 2000; Gosling, 1997; Schraufstatter,
1998). For example, mutation of the highly conserved aspartic acid residue found in 
the second TM domain of virtually all GPCRs, leads to loss of certain intracellular 
effects (e.g. calcium flux is no longer detectable) without affecting ligand binding 
(Farzan et al., 1997). Another important motif is the DRYLATVHA sequence found 
at the interface between the third TM and the cytoplasm of most GPCRs. 
Experiments have demonstrated that mutations in this ‘DRY’ motif can abolish G 
protein coupling (Bennet et al., 2000) and unable recruitment and triggering of JAK 
phosphorylation and association to the receptor (Mellado et al., 1998). Studies carried 
out by Burger and colleagues have shown that mutation of the ‘DRY’ motif in 
CXCR2 to ‘VRY’ causes constitutive signalling of this receptor and leads to 
transforming activity (Burger et al., 1999).
Conserved Pro residues in the 5th, 6 th, and 7th TM domains of chemokine receptors 
have been demonstrated to be important for the formation of proline kinks (PK) (Ji et 
al., 1998; Barlow, 1988; Woolfson, 1990) which are thought to be involved in 
conferring backbone flexibility required for the conformation change associated with 
ligand binding induced activation step. Mutations of the conserved Pro residue in TM 
six was shown to generate impaired surface expression of the new mutant receptor 
(Kolakowski et al., 1995), reduced functional coupling (Nakayama & Khorana, 1991) 
and in some cases constitutive signalling (Tonacchera et al., 1998) whereas mutations 
of this Pro residue in the conserved NPXXY motif in the 7th TM were shown to 
generate a mutant receptor with impaired activity (Wess et al., 1993; Vichi, 1999;
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Barak, 1995). More recently, by analysing the aligned sequences of chemokine 
receptors, Govaerts et al identified another sequence motif (TXP motif) in the 2nd 
TM helix of these receptors. This TXP motif has been shown to play a key structural 
role in chemokine receptors where the PK is the main element and the Thr residue 
works as an accessory element for PK. Mutations of the TXP motif in hCCR5 
demonstrated that this newly identified motif is mainly involved in receptor 
activation and contributes very little for ligand binding (Govaerts et al., 2001).
Additionally, the carboxy-terminus portion of chemokine receptors has been shown 
to be involved in signalling and receptor internalisation. Truncations and Ala 
scanning mutagenesis of CCR5’s C-terminus have shown that this portion of the 
receptor is important for high affinity association with p-arrestin, in controlling 
calcium responses and granular enzyme release in response to the ligand (Kraft et al.,
2001). Moreover, C-terminal Ser residues and a dileucine motif have been identified 
in CXCR4, CXCR2 and CCR5, and have been shown to be involved in differently 
regulating internalisation of these receptors (Vila-Coro et al., 1999; Aramori, 1997 ; 
Oppermann, 1999; Fan, 2001; Kraft, 2001). For example, the dileucine motif in 
CXCR2 was found to be critical for receptor-mediate chemotaxis in response to IL- 
8 /CXCL8  (Ben-Baruch et al., 1995) whereas mutation of the same motif in CCR5 
does not impair cellular migration (Kraft et al., 2001).
1.7. hD6, an atypical p-chemokine receptor
In an attempt to further understand the mode of action of MIP-la/CCL3, murine 
members of the beta-chemokine receptor family were isolated (Nibbs et al., 1997b).
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Fragments obtained by degenerative oligonucleotide-primed PCR from genomic 
DNA were used as probes to isolate full length cDNAs (Nibbs et al., 1997b). This led 
to the identification of a novel gene, murine (m) D6 , which encodes a protein capable 
of binding to MIP-la/CCL3 with high affinity when expressed in CHO cells (Nibbs 
et al., 1997b). Subsequently, fragments of human D6  used to identify the full length 
cDNA were generated by PCR using degenerative primers against mD6  from regions 
which have been shown to be conserved across species in other chemokine receptors 
(Nibbs et al., 1997a).
The human D6  (hD6 ) gene encodes a protein of 384 amino acid in length that, like 
other G protein-coupled receptors, comprises seven predicted transmembrane- 
spanning domains and four conserved Cys residues involved in maintaining receptor 
structure. Human D6  shares 71% identity and 8 6 % similarity to the murine 
counterpart, and like the murine homologue it has an alteration in the highly 
conserved DRYLAIVHA motif (Nibbs et al., 1997a; Nibbs et al., 1997b). In hD6 , a 
DKYLEIVHA motif is found in place of this highly conserved motif (Nibbs et al., 
1997a). Also, the conserved aspartic acid residue found in the second TM domain of 
other GPCRs is changed to an asparagine. The loss of this aspartic acid residue is not 
found in any other chemokine receptors apart from DARC and some virally encoded 
proteins found to be signalling competent (Nibbs et al., 1997a). In common with 
other chemokine receptors cloned, hD6  has been shown to possesses a single putative 
N-linked glycosylation site at the N-terminus, a C-terminus rich in Ser and Thr 
residues that constitute potential phosphorylation sites and a highly acidic N- 
terminus. Although the highly acidic nature of the N-terminus is characteristic of 
chemokine receptors, the first thirteen amino acids found in the N-terminus of hD6
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are predicted to form a hydrophobic domain that is not seen in other chemokine 
receptors (Nibbs et al., 1997a).
D6  has been shown to be most closely related to CCR4 and two murine IL-8 RL 
genes. D6  has a lower sequence homology (40% identity and 50% similarity) to 
CCR1, CCR2, CCR3, CCR4, CCR5, CCR6 , CCR7 and CCR8  than these receptors 
have to one another and therefore it is seen as the most divergent member of the p- 
chemokine receptor family (Nibbs et al., 1997a). See Figures 1.5 and 1.6 for 
dendogram and sequence alignment of hD6  and other p-chemokine receptors.
Receptor binding studies have demonstrated that hD6  binds with high affinity to 
MIP-laP (a hMIP-la/CCL3 isoform, see below), mMIP-la/CCL3, RANTES/CCL5, 
MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, MCP-5/CCL12, and weaker affinity 
to MCP-1/CCL2, eotaxin/CCLll and HCC-1/CCL14 (Nibbs et al., 1997a; Nibbs et 
al., 1999). hD6  and mD6  were initially reported to have different binding specificities 
to hMIP-la/CCL3. Both D6  homologues and CCR5 bind with high affinity to 
mMIP-la/CCL3 whereas binding to hMIP-la/CCL3 was always seen to be weak 
(Nibbs et al., 1997a; Boring, 1996; Nibbs et al., 1997b). The basis for this 
discrepancy was clarified when two distinct but highly related human MIP-la/CCL3 
genes, namely LD78a and LD78P, were isolated (Nibbs et al., 1999). These two 
isoforms of human MIP-la/CCL3 bear two reciprocal serine/glycine swaps in the 
region between Cys three and four and also have different amino acid residues at 
position 2. LD78a (or M IP-laS) has a serine residue at position 2 whereas LD78P 
(or MIP-laP) has a proline residue at that position. hD6  was shown to bind weakly to 
the commercially available form of hMIP-la/CCL3, LD78a or M IP-laS, but to bind
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with high affinity to MIP-laP. Similarly, CCR5 was shown to bind with high affinity 
to M IP-laP and with low affinity to mMIP-la/CCL3. It is thought that the proline 
residue at position 2 is important for high affinity binding to hD6 . Interestingly, the 
CXC chemokine, SDF-1/CXCL12 has a proline residue at position 2 yet it does not 
bind to D6 , implying that proline-2 must be presented in the context of a |3- 
chemokine to allow for high affinity binding to D6  (Nibbs et al., 1999).
Surprisingly, in the standard signalling assays for chemokine receptors, such as 
calcium flux detection, chemotaxis and microphysiometry, hD6 , like DARC (Neote 
et al., 1994) and CCR11 (R. Nibbs, pers. comm.), has not been shown to signal 
(Nibbs et al., 1997a). Bearing in mind the sequence alterations in the DRY motif and 
in the highly conserved aspartic acid residue, these findings do not necessarily imply 
that this receptor is signalling incompetent. It is possible that hD6  couples to 
alternative G proteins, or interacts with other membrane components, which could be 
expressed in a cell type specific fashion to mediate D6  functional responses. Thus, it 
was of fundamental importance to identify the cell types that express this receptor.
Northern blot analysis of hD6  expression in tissues revealed that hD6  is expressed in 
the placenta at high levels, in the liver at lower levels and weakly expressed in the 
lung and thyroid. Weak expression is detected, after longer exposure times, in a range 
of tissues including the small intestine and the colon. No hD6  expression was 
detected in PBLs (Nibbs et al., 1997a).
Binding studies in situ, where pieces of human skin were used to determine the 
binding characteristics of several p-chemokines, revealed that chemokines such as 
RANTES/CCL5, MCP-1/CCL2, MCP-3/CCL7 but not MIP-laS or IL-8 /CXCL8
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bound to lymphatic endothelial cells (Hub & Rot, 1998). However, 125I-MIP-laP did 
show binding to these cells (Nibbs et al., 2001) indicating that the receptor expressed 
in these endothelial cells displays the same binding fingerprint as hD6 . 
Immunocytochemistry in sections of human tissue with an anti-hD6  monoclonal 
antibody revealed that hD6  is in fact the receptor expressed in the lymphatic 
endothelium (Nibbs et al., 2001). These detailed studies showed that hD6  is 
expressed in the lymphatic endothelium of the mucosa and other layers of the gut, in 
afferent vessels entering lymph nodes and in lymphatic sinuses within secondary 
lymphoid tissue (Nibbs et al., 2001). hD6  expression was not found in any of the 
endothelial cells lining blood vessels or in sections of heart, kidney, liver, skeletal 
muscle, brain, cerebellum, pancreas, prostate or thyroid (Nibbs et al., 2001). 
Expression of this receptor was also found in a subset of vascular tumours (Nibbs et 
al., 2 0 0 1 ).
The functional role of D6  is not clear, however given its promiscuous binding profile 
and its expression on the lymphatic it is hypothesised that D6  might play a role in 
leukocyte trafficking. As suggested for DARC (Horuk et al., 1993), D6  might 
function as a sink whereby D6 ’s ligands bind to the receptor and are subsequently 
neutralized. By doing so hD6  would be preventing leukocyte firm adhesion to the 
lymphatic ECs thus allowing the lymph to passively transport leukocytes from the 
lymphatics into the lymph node. By doing so hD6  would help dampening leukocyte 
extravasation from blood vessels so other chemokines such as SLC/CCL21,which is 
not a ligand for hD6 , that has been reported to be expressed by lymphatic ECs and 
thought to be involved in constitutive lymphocyte and DC traffic (Gunn et al., 
1998b), would remain free to interact with their target cells.
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Another possibility is that D6  functions as a presenting molecule involved in binding 
chemokines, which remain fully functional, and then presenting them to the 
leukocytes. As proposed for DARC (Middleton et al., 1997), it is possible that hD6  
might have a role in immune and inflammatory processes by binding chemokines 
derived from the tissues and therefore inducing leukocyte migration into the lymph 
node. Conversely, it is possible that by retaining pro-inflammatory p-chemokines in 
the tissue, D6  might in fact prevent migration of its ligands into the lymphatic 
vessels, thus ensuring that cells that no longer respond to D6  ligands, for example 
mature DCs, would be capable of entering the lymph nodes.
Also, hD6  may be involved in transporting chemokines across the endothelium. Like 
DARC (Middleton et al., 1997), D6  may play a role in transcytosis of tissue derived 
chemokines across the endothelium into the luminal space.
Given the well documented functions of chemokines in chemotaxis, EC migration 
and regulation of angiogenesis it is also fair to hypothesize that D6  might also be 
involved in lymphangiogenesis during development and/or tissue regeneration. 
Further studies involving in vivo and in vitro experiments will be necessary to 
identify the function of D6  on the lymphatic endothelial cells.
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CC or p chemokines:
CC — C  C ----------------  e.g.: MIP-lcx/p, MCP 1-5, eotaxin
RANTES, ESkine
 p  r ___________ CXC or a  chemokines:
e.g.: IL-8 , PF4, IP10, SDF
C or y chemokine:
e.g.: lymphotactin
rY Y Y r n n ___________ CX3C or 5 chemokine:
e.g.: fractalkine/neurotactin
Figure 1.1. The different classes of chemokines. The chemokine superfamily can 
be divided into 4 subclasses defined by the arrangement of conserved cysteine (C) 
residues. X indicates an amino acid other than cysteine and unbroken lines other 
amino acids. Spacing between cysteines is similar in all four classes. N and C 
terminus can vary in length.
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Table 1.1 The CC chemokines
Systematic
Name Common Names Receptor(s)
CCL1 1-309, TCA-3 (mouse), SIS-f (mouse) CCR8
CCL2 MCP-1, MCAF, HC11, JE (mouse) CCR2, DARC, D6
CCL3 MIP-la, MIP-laS/P, SCI CCR1, CCR5, CCR3 (mouse), 
D6
CCL4 MIP-ip CCR5, D6
CCL5 RANTES CCR3, CCR5, DARC, D6
CCL6 CIO (mouse); no human homologue known Unknown
CCL7 MCP-3 CCR2, CCR3, DARC, D6
CCL8 MCP-2 CCR2, CCR3, CCR5, D6
CCL9 MRP-2, MlP-ly, CCF18 (no human homologue known) Unknown
CCL10 Unknown
CCL11 Eotaxin CCR3, D6
CCL12 MCP-5 (mouse); no human homologue known CCR2, D6
CCL13 MCP-4, Ck|310, NCC-1; no mouse homologue known CCR1, CCR2, CCR3, DARC, 
D6
CCL14 HCC-1, HCC-3, NCC-2, Cicpi, CCCK-l/CCCK-3, 
MCF-1 (no mouse homologue)
CCR1, D6
CCL15 HCC-2, NCC-3, MIP-5, MIP-16, Lkn-1, CC-2 CCR1, CCR3
CCL16 HCC-4, LEC, HCC-4, LCC-1, Ck|312, Mtn-1 CCR1
CCL17 TARC, ABCD-2, STCP-1 CCR4
CCL18 DCCK1, PARC, MIP-4, AMAC-1, Ck|37; (no mouse 
homologue)
CCR3
CCL19 ELC, MIP-3P, exodus-3, C xpil CCR7, CCR11
CCL20 MIP-3a, LARC, exodus-1; Cicpi (mouse) CCR6
CCL21 6Ckine, SLC, exodus-2, TCA4, ckP9 CCR7, CCR11
CCL22 MDC, dc/p- c k  (mouse), abcd-1, STCP-1 CCR4
CCL23 MPIF-1, MIP-3, CkP8-1 (no mouse homologue) CCR1
CCL24 MPIF-2, eotaxin-2, CkP6 CCR3
CCL25 TECK, Cxpl5 CCR9, CCR11
CCL26 eotaxin-3, MIP-4a (no mouse homologue) CCR3
CCL27 Eskine, CTACK, ILC (mouse) ALP, skinkine CCR10
CCL28 MEC CCR10
Table 1.1. The CC (or p) chemokine family. Adapted from (Murphy et al., 2000). 
D6 ’s ligands are shown in bold.
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Table 1.2. The CXC chemokines
Systematic
Name
Common Names Subclass Receptor(s)
CXCL1 GROa, MGSA-a, NAP-3, MIP-2 
(mouse), N(51)/KC (mouse)
ELR+ CXCR2, DARC
CXCL2 GROP, MIP-12a, MGSA-P ELR+ CXCR2
CXCL3 GROy, MGSA-y, MIP-2P ELR+ CXCR2
CXCL4 PF-4 ELR" Unknown
CXCL5 ENA-78, LEX ELR+ CXCR2
CXCL6 GCP-2, CKA-3 ELR+ CXCR1, CXCR2
CXCL7 PBP, CTAPIII, P-TG, NAP-2, 
LA-PF4 (no mouse homologue)
ELR+ CXCR2
CXCL8 IL-8 , NAP-1, GCP-1 (no mouse 
homologue)
ELR+ CXCR1, CXCR2, DARC
CXCL9 Mig ELR" CXCR3
CXCL10 IP-10, CRG-2 (mouse) ELR" CXCR3
CXCL11 I-TAC, IP9,P-R1, H174 (no 
mouse homologue)
ELR" CXCR3
CXCL12 SDF-1 (2 human isoforms, a  and 
P), PBSF
ELR" CXCR4
CXCL13 BCA-1, BLC ELR" CXCR5
CXCL14 BRAK, bolekine ELR" Unknown
CXCL15 WECHE, lungkine ELR+ Unknown
CXCL16 CXCL16 ELR" CXCR6
Table 1.2. The CXC (or a) chemokine family. Adapted from (Murphy et al., 2000).
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Table 1.3. The C chemokines
Systematic
Name
Common Names Receptor(s)
XCL1 Lymphotactin a, SCM -la, ATAC XCR1
XCL2 Lymphotactin (3, SCM-lp, ATAC XCR1
Table 1.3. The C (or y) chemokine family. Adapted from (Murphy et al., 2000)
Table 1.4. The C X 3 C  chemokines
Systematic
Name
Common Names Receptor(s)
C X 3 C L I Fractalkine, neurotactin (mouse) C X 3 C R I
Table 1.4. The C X 3 C  (or 6 ) chemokine family. Adapted from (Murphy et al., 
2000).
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N-terminus
OUT
PM
DRYLAIVHA
C-terminus
Figure 1.2. Structure of chemokine receptors. In general chemokine receptors are 
composed of an extracellular N-terminus, an intracellular N-terminus and seven 
transmembrane domains (grey cylinders numbered 1 to 7) connected by three 
extracellular loop and three extracellular loops. This structure is held together in a 
cylindrical shape by two disulphide bonds: one between cysteine residues found in 
the first and in the second extracellular loops and another between cysteine residues 
found in the N-terminus and in the third extracellular loop. The highly conserved 
DRYLAIVHA motif thought to be involved in coupling to G-proteins is shown.
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Table 1.5. Chemokine receptors
Group Receptor(s) Class Ligand(s)
Shared CXCR1 CXC IL-8, GCP-2
CXCR2 all ELR+ chemokines
CXCR3 IP-10, Mig, I-TAC
CCR1 CC M IP-la, RANTES, MCP-3, MPIF-1
CCR2 MCP-1, MCP-2, MCP-3, MCP-4
CCR3 MCP-2, MCP-3, MCP-4, eotaxin-1, eotaxin-2, RANTES
CCR4 TARC, MDC
CCR5 RANTES, M IP-la, MIP-ip, MCP-2
CCR6 MIP-3a
CCR7 SLC, ELC
CCR8 1-309
CCR9 TECK
CCR10 ESkine, MEC
CCR11 TECK, SLC, ELC
D6 MIP-la, MIP-ip, MCP-1, MCP-2, MCP-3, MCP-4,
MCP-5, HCC-1, eotaxin, RANTES
Specific CXCR4 CXC SDF-1
CXCR5 BLC
CXCR6 CXCL16
XCR1 XC Lymphotactin
CX3CR1 CX3C fractalkine/neurotactin
Viral CMV US28 MIP-la, MIP-1|3, RANTES, MCP-1, MCP-3, fractalkine
UL12 RANTES, M IP-la, MIP-ip, MCP-1
KSHV ORF74 many CC and CXC chemokines
El eotaxin
ECRF-3 GRO-a, IL-8 , NAP-2
Promiscuous DARC many CC and CXC chemokines
Table 1.5 The different groups of chemokine receptors. Adapted from (Kunkel,
1999). Chemokine receptors can be classified into four different groups according to 
their binding profiles, these receptors can also be classified into different classes 
depending to which members of a certain chemokine family they bind to.
Table 1.6. Haemopoietic cell distribution of chemokine receptors.
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Receptor(s) Haemopoietic cell distribution
CXCR1 N, M, T, NK, Bs, Ms, En
CXCR2 N, M, T, NK, MS, As, Ms, En
CXCR3 Activated T
CXCR4 Myeloid, T, B, Ep, En, DC
CXCR5 B, T
CXCR6 T, NK
CCR1 N, M, T, NK, B, Ms, As
CCR2 M, T, B, Bs
CCR3 Eo, Bs, T
CCR4 T, P
CCR5 T, M, M0, DC
CCR6 T, B, DC
CCR7 T, B, DC
CCR8 M, Thymus
CCR9 T, Thymus
CCR10 Skin homing T cells (CLA+)
CCR11
XCR1 T, B, NK
CX3CR1 NK, M, T
DARC En, RBC, T
D6 Dc (Townson,pers. comm.)
Table 1.6. Haemopoietic cell distribution of chemokine receptors. N, neutrophil; 
M, monocyte/macrophage; T, T-lymphocyte; B, B-lymphocyte; NK, natural killer 
cell; Eo, eosinophils; Bs, basophil; Ms, mast cell; As, astrocyte; P, platelet; En, 
endothelial cell; Ep, epithelial cell; Hp, hepatocyte; Dc, dendritic cell, M 0, 
macrophage; RBC, red blood cell. Adapted from (Murdoch & Finn, 2000).
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Selectin-mediated Activation by Integrin-mediated Extravasation 
rolling chemokines adhesion
Leukocyte
Vessel
Space
Chemokine
Endothelial cells G coupled 
receptorTissue
Space
Site of infection or injury/
Constitutive signal
Figure 1.3. Schematic representation of the multi step model of leukocyte 
extravasation. Production of cytokines in response to a specific stimulus induces changes 
in the endothelium which include upregulation of adhesion and production of chemokines. 
Chemokines presented on endothelial cells trigger integrin activation and arrest of those 
leukocytes that carry the corresponding chemokine receptors. Activated leukocytes become 
firmly adhered cells which migrate along the endothelial cell surface and eventually into 
the tissue space, (adapted from (Schall, 1994)).
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Figure 1.4. Chemokine receptor signal transduction mechanisms. Ligand (L) 
binding to the 7 TM domain G-protein coupled chemokine receptor causes guanosine 
triphosphate displacement (GTP) in the Gai subunit, which allows dissociation of 
G al from G(3y- Gp activates phospholipase C (PLCp), which cleaves PIP2 into the 
second messengers DAG and IP3. DAG activates PKCp and IP3 causes the release of 
calcium from the intracellular stores. The rapid rise in intracellular calcium activates 
PLD. At the same time Gai directly activates PTK (protein tyrosine kinase) which in 
turn activates MAP kinases and phosphorylate serine and threonine residues in the C- 
terminus of the receptor causing receptor inactivation. Phospholipase A (PLA) is 
activated by MAP kinases. PLA as well as DAG, intracellular calcium and PKC all 
interact with specific cell mechanisms leading to actin polymerisation, cell adhesion 
and motility, degranulation, cytoskeletal rearrengement, chemotaxis and receptor 
desensitisation. Figure adapted from (Murdoch & Finn, 2000)
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 ME-MIPloRLl
RN31-CCR1 
G17-CCR3
Figure 1.5. Phylogenic relationship of chemokine receptors. The diagram above 
was obtained by comparing the chemokine receptors’ amino acid sequences known at 
the time this project was designed. The amino acid sequences were compared using 
the GCG software Pileup and Distances (Kimura method) programs, and then 
displayed graphically with Growtree (Neighbor-joining program). The distances 
between each receptor indicate the number of amino acid changes between each 
receptor. This figure was adapted from (Nibbs et al., 1997b).
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Figure 1.8. Protein sequence of hD6, mD6 and other (3-chemokine receptors.
Dashed lines indicate putative transmembrane domains. The conserved Cys residues 
are indicated by an underlined C underneath each line up. The DKYLEIV motif 
characteristic of D6  is shown in bold. A putative N-linked glycosylation site (NSS) is 
shown in bold and underlined. The # symbol, denotes the aspartic residue conserved 
amongst G-protein coupled receptors, that is changed to an asparaginine in D6  
sequence. This line up was adapted from (Nibbs et al., 1997a).
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Chapter 2- Materials and Methods
2.1. Materials
Antibodies
Covance
FITC Labelled Mouse Monoclonal Antibody, H A .ll (clone 16B12)
Boehringer Mannheim
Anti-HA High Affinity rat monoclonal antibody (clone 3F10)
Kodak
Anti-FLAG M2, purified murine IgGl monoclonal antibody that binds to FLAG 
fusion proteins
Anti-FLAG M5, purified murine IgGl monoclonal antibody that binds to Met-FLAG 
fusion proteins
LeukoSite,Inc (Millenium Pharmaceuticals)
1D4, mouse anti-human D6  antibody. This antibody was made in collaboration with 
LeukoSite Inc. and optimised using hD6  transfected cell lines as described by Nibbs 
and colleagues. (Nibbs et al., 2001)
Pharmingen
CCR5 R-FITC- conjugated mouse anti-human monoclonal antibody (clone 
2D7/CCR5)
Santa Cruz Biotechnology, Inc
Y ll, anti-HA TAG antibody
Sigma
Alkaline Phosphatase conjugated Anti-Mouse IgG (Fc specific)
Anti-Mouse IgG (Fab specific) FITC conjugate
Anti-mouse IgG horseradish peroxidase linked whole antibody (raised in sheep) 
Anti-Rat IgG (Whole molecule) FITC conjugate
Bacteriology
Beatson Institute Central Services
LB (Luria Bertani) liquid medium 
Glycerol
Filipa L. Mendonga, 2002 Chapter 2 79
Becton Dickinson Labware
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
Falcon 2501 (miniprep tubes)
Beta Laboratories
Yeast extract
Bibby Sterilin Ltd
90mm bacteriological petri dishes
Difco Laboratories.
Bacto-Agar
Bactotryptone
Gibco BRL Europe Life Technologies Ltd
E.coli DH5a competent cells
Nunc
lml screw cap tubes
Sigma Chemical Co. Ltd
Ampicillin
Chloramphenicol
Cell lines
CHO -  Chinese Hamster Ovary cells 
COS-7 -  African green monkey kidney cells 
HEK-293 -  Human Embryonic Kidney cells 
HOS -  Human OsteoSarcoma cells
Chemicals and Reagents
BDH Analar Laboratory Supplies
D- glucose
Fisons Scientific Equipment
Ammonium acetate
Butan-2-ol
Chloroform
Dimethyl sulfoxide (DMSO)
Ethylene diamine tetra acetate (EDTA) disodium salt
Filipa L. Mendonga, 2002 Chapter 2 80
EGTA 
Methanol 
Propan-2-ol 
Sodium acetate
Sodium dodecyl sulphate (SDS)
Gibco BRL Europe Life Technologies Ltd
Agarose (ultrapure electrophoresis grade)
Tris base
Severn Biotech Ltd.
30% (w/v) acrylamide: 0.8% (w/v) bis-acrylamide 
40% (w/v) acrylamide: 2.1% (w/v) bis-acrylamide
Sigma Chemical Co. Ltd
Bovine Serum Albumen (BSA)
Bromophenol Blue 
Coomassie Brilliant Blue R 
Ethidium Bromide 
Goat Serum 
HEPES
Ponceau S solution
SIGMA FAST™ pNPP (p- Nitrophenyl Phosphate) substrate tablet set 
TEMED (N,N,N’,N’ -  tetraethylenediamine)
Tween-20 (Polyoxyethylene sorbitan nonolaureate)
Chemokines
Beatson Institute
PM2 ( non- aggregating murine M IP-la mutant); a gift from Dr. G. Graham(Graham 
et al., 1994)
Peprotech
Recombinant Human Eotaxin (carrier free)
Recombinant Human MCAF (Human MCP-1) (carrier free)
Recombinant Human MCP-2 (carrier free)
Recombinant Human RANTES (carrier free)
Filipa L. Mendonga, 2002 Chapter 2
Enzymes and Kits
ABgene
1.1 x Pre-Aliqouted ReddyMix™ PCR Master Mix in Thermo-Tubes 
Gibco BRL Europe Life Technologies Ltd
All restriciton enzymes and reaction buffers were obtained from Gibco BRL unless 
otherwise stated.
Invitrogen
TOPO TA cloning
Kramel Biotech
Alkaline Phosphatase
New England BioLabs Inc.
Xmal  
Xmn I
Roche
Rapid DNA Ligation Kit 
Promega
Set of dATP, dCTP, dGTP, dITP 
Qiagen Ltd
QLAprep Spin Miniprep Kit 
QIAGEN Plasmid Maxi Kit 
QLAquick Gel Extraction Kit 
QLAquick PCR Purification Kit
STRATAGENE
QuickChange ™ Site-Directed Mutagenesis Kit 
Cloned Pfu DNA polymerase
Miscellaneous
Amersham International pic
Hybond-Cextra
ECL Western Blotting Reagents
Alpha Laboratories Ltd
Microcentrifuge tubes
Filipa L. Mendonga, 2002 Chapter 2
Decon Laboratories Ltd
Decon 75
James Burrough Ltd
Ethanol
Kodak Scientific imaging Systems Ltd.
X-OMAT AR X-Ray film
Gelman Sciences Ltd
Sterile 0.2pm acrodisc filters
Pierce
Iodo-Gen® iodination reagent
Premier Beverages
Marvel (dried skimmed milk)
Vector Labs
VectaShield
Sigma chemical Co. Ltd
Kodak X-ray film
STRATAGENE
Pfu DNA Polymerase
Whatman international Ltd
Whatman 3MM filter paper
DNA and protein markers
Amersham International pic
Rainbow™ coloured protein molecular weight markers
Gibco BRL Europe life Technologies Ltd
1 Kb DNA Ladder 
Low DNA mass Ladder
Plasmids
pcDNA.3-mIL8RL-l: plasmid encoding mouse Interleukin 8  receptor-like 1 
(mIL8 RL-l) cloned into pcDNA.3 as a Hindlll/Notl insert. This plasmid was 
constructed by Dr. R. Nibbs (Beatson Institute).
Filipa L. Mendonga, 2002 Chapter 2
pcDNA.3-hD6: plasmid encoding human D6  cloned into pcDNA.3 as a Hindlll/Notl 
insert. This plasmid was constructed by Dr. R. Nibbs (Beatson Institute).
pcDNA.3-hCCR5: plasmid encoding human CCR5, cloned into pcDNA.3 as a 
Hindlll/Notl insert. This plasmid was constructed by Dr. R. Nibbs (Beatson 
Institute).
pKSII: plasmid commercially available from STRATAGENE
pcDNA.3: mammalian expression vector commercially available from Invitrogen
pMACS Kk: plasmid encoding for the truncated mouse MHC class I molecules of H- 
2 Kk haplotype; this plasmid is commercially available from Miltenyi Biotec
Radiochemicals
NEN™ Life Science Product, INC
Iodine-125, carrier free radionuclide (Specific activity, 643.8GBq/mg)
1[ I]- MCP-4 (human, recombinant); Specific activity 9.36 MBq/pg 
[125I]- RANTES (human recombinant); Specific activity 10.2 MBq/pg
Tissue Culture
BDH
BES ( NN-Bis (2-hydroxyethyl)-2- aminoethane sulphonic acid)
Beatson Institute Central Services
Sterile distilled water 
Sterile glycerol
Sterile phosphate buffered saline (PBS)
Sterile phosphate buffered saline + EDTA (PE)
Becton Dickinson Labware
90mm tissue culture dishes 
1 0 0 ml plastic pipettes 
50ml plastic pipettes
Bibby Sterilin Ltd
Sterile plastic bijoux and universal containers
Gibco BRL Europe Life Technologies Ltd
Special Liquid Medium (SLM)
lOx Dulbecco’s Modified Eagles Medium
2.5% Trypsin
200mM L-glutamine
7.5% sodium bicarbonate
lOOmM sodium pyruvate
Filipa L. Mendonga, 2002 Chapter 2 84
Geneticin (G418)
Globepharm
Foetal calf serum
Harlan Sera-Lab Ltd
Foetal calf serum
QIAGEN
Effectene™ Transfection Reagent 
SuperFect Transfection Reagent
Nunc
Cryotubes
T25, T75, T125 cm2 tissue culture flasks
Miltenyi Biotec
MACSelect Kk Microbeads
OctoMACS (magnetic cell separator for eight simultaneous separations) 
MACS Separation Columns type MS +
Promega
Transfectam® Reagent for the Transfection of Eukaryotic Cells
Sigma Chemical Co. Ltd
Pertussis toxin 
Saponin
Filipa L. Mendonga, 2002 Chapter 2
2.2. Methods
2.2.1. Tissue culture
All cell culture work was performed using strict aseptic techniques inside a laminar 
flow hood (Class II Microbiological Safety Cabinets, Medical Air technology Ltd., 
Manchester, UK). Cells were incubated at 37°C in a dry atmosphere containing 5% 
(v/v) CO2 (Heraeus, Essex, UK).
2.2.1.1. Chinese Hamster Ovary (CHO)-K1 Cells
CHO-Kl cells were grown in Special Liquid Medium (SLM) containing 10% (v/v) of 
FCS and 5mM L-glutamine.
2.2.1.1.1. Stable transfection of CHO cells
CHO cells were transfected using the modified calcium phosphate mediated method 
especially suitable for stable transfection of CHO cells. 5E5 cells were plated onto 
10mm diameter petri dishes containing 10ml of SLM supplemented with 10% of 
FCS and 5mM of glutamine were incubated overnight in a ‘cake box’ at 37°C, 5% 
CO2. The next day 20pg of DNA were diluted in 0.5ml of 0.25M CaCU in a bijoux 
bottle. 0.5ml of 2xBES Buffered Saline (BBS). (BBS contains 50mM BES, 280mM 
NaCl, 1.5mM Na2HP0 4 ). This mixture was incubated at room temperature for 20 
minutes and then added dropwise to the plated cells. Plates were placed back into the 
‘cake box’ and gassed with 3% CO2. The box was sealed and incubated at 35°C 
overnight. 18 hours later the medium was aspirated and plates washed twice with 
warm SLM containing 10% FCS and glutamine. Plates were re-fed with 10ml of
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medium and incubated overnight at 37°C, 5 %CC>2. 48 hours after transfection the 
cells were harvested and seeded onto 100mm ( diameter) plates at 1E3 cells and 1E4 
cells/plate. Plates were again incubated overnight at 37° C, 5% CO2. 72 hours after 
transfection 1.6mg/ml of G418 was added for selection of transfected cells. Colonies 
appeared, in general, around day 10. Once single colonies were visible, clones were 
picked and transferred into a 24 well plate.
2.2.1.1.2. Transient transfection of CHO cells
1.5E6 cells/lOOmm diameter plate were seeded the night before transfection and 
incubated at 37°C, 5% CO2. The next day 2\ig of DNA were transfected into cells 
using Effectene transfection reagent following manufacturer’s instructions. Cells 
were incubated O/N at 37°C, 5% CO2. 18 hours later cells were washed once in 
PBS, re-fed with complete medium, and incubated O/N at 37°C, 5% CO2. Cells were 
harvested 24 hours later.
2.2.1.2. Human Embryonic Kidney Cells (HEK.293)
HEK.293 cells were grown in DMEM medium supplemented with 5mM glutamine, 
lOOnM NaPyruvate, 10% FCS, 0.3% Na2H C03, 5mM HC1.
2.2.1.2.1. Stable Transfection of HEK.293
Cells were seeded at 2E6 cells/lOOmm dish and incubated at 37°C, 5 %C0 2  for 2 
days. Cells were then gently washed with serum-free DMEM and 1.25ml of serum-
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free DMEM added to each plate. 7pg of DNA were mixed with 1.25ml of serum-free 
DMEM in a bijou bottle (solution A) and 15pi TRANSFECTAM® with 1.25ml of 
serum-free DMEM in a separate bijou bottle (solution B). Solutions A and B were 
then mixed together and added dropwise to cells. Cells were incubated for 4 hours at 
37°C, 5%CC>2, in a ‘cake box’. After 4 hours, 13ml of complete medium was added 
to each plate and cells were left to incubate for another 2 days. Selection was initiated 
at day 6  by feeding the cells with complete DMEM supplemented with 800pg/ml of 
G418.
2.2.I.2.2. Pertussis toxin treatment of stably transfected HEK.293 cells
Stably transfected HEK.293 were grown to reach confluence in a 175 cm2 flask. 
Cells were incubated overnight with lOOpg/ml of Pertussis toxin. The next day cells 
were tested for their ability to flux calcium as described in Section 2.2.3.8.
2.2.1.3. COS-7 cells
COS-7 cells were grown in Special Liquid Medium (SLM) containing 10% (v/v) of 
FCS and 5mM L-glutamine.
2.2.1.3.1. Stable transfection of COS-7 cells
The day before transfection, 5E5 cells were seeded in a 100mm diameter dish in 
15ml of growth medium. Cells were incubated O/N at 37°C and 5% CO2. The next 
day lOpg of DNA was diluted in serum-free growth medium to a total volume of 
300pl. To this DNA solution 40pl of SuperFect Transfection Reagent were added. 
Mixing was ensured by pipetting up and down 5 times or by vortexing for 10
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seconds. Samples were incubated for 5-10 minutes at room temperature to allow 
complex formation. While complex formation took place, growth medium from the 
dish was aspirated and the cells washed once with 5ml of PBS. After the incubation 
period, 3ml of complete growth medium was added to the reaction tube containing 
the transfection complex. After mixing by pipetting up and down twice, the total 
volume of transfection complex was added to the cells drop wise.
Selection was started on day 6 by feeding the cells with complete DMEM 
supplemented with 200pg/ml of G418.
2.2.1.3.2. Transient transfection of COS-7 cells
Transient transfection of COS-7 cells was carried out following the same protocol 
used for stable transfection of CHO cells (see section 2.2.1.1.2.)
2.2.1.4. Human OsteoSarcoma (HOS) cells:
HOS cells were grown in DMEM medium supplemented with 5mM glutamine, 
lOOnM NaPyruvate, 10% FCS, 0.3% Na2H C03, 5mM HC1.
2.2.1.4.1. Stable transfection of HOS cells
Stable transfection of HOS cells was carried out following the same protocol used for 
transient transfection of HEK.293 cells (see Section 2.2.I.2.I.)
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2.2.2. Molecular Biology
2.2.2.1. Oligonucleotide Synthesis
Oligonucleotides were synthesized by an in-house facility on an Applied Biosystems 
Model 381A DNA synthesiser using the manufacturers protocols and Cruachem 
reagents. The oligonucleotides were synthesized without trityl group protection, 
obtained as a pellet, and resuspended in 600pl sterile distilled water. The final 
concentration of oligonucleotide was determined by absorbance measurement at 
260nm and 280nm using a Beckman DU 650 spectophotometer. An OD26o reading of 
1 corresponds approximately to 33pg/ml single stranded DNA or 50pg/ml double 
stranded DNA. The DNA sample purity was estimated from the OD26o/ OD2go ratio.
2.2.2.2. Agarose Gel Electrophoresis
Agarose gel electrophoresis was carried out using horizontal gel cast apparatus. 
Generally, 1% agarose gels were used. Ultrapure electrophoretic grade agarose was 
dissolved in lxTAE (40mM Tris-acetate, ImM EDTA) by boiling the solution. After 
the solution was cooled down, 0.5pg/ml of Ethidium Bromide were added. The gel 
was poured into the gel cast and left to set.
To each DNA sample, DNA loading buffer (6x solution: 30% glycerol and 
bromophenol blue to colour) was added and samples as well as size markers were 
loaded into the appropriate wells of the gel. The DNA was usually separated by 
running the gel in lxTAE buffer at 70-100 constant voltage. DNA bands were 
visualised using a UV transilluminator and photographed.
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2.2.2.3. Restriction Enzyme Digests
DNA was digested in a final volume of 20-50pl using the appropriate enzymes and 
reaction buffers according to the manufacturer’s instructions. In general, 5-10 units of 
restriction enzyme/pg of plasmid DNA was used. The reactions were carried out at 
the appropriate temperature (according to manufacturer’s instructions) for 60-90 
minutes. Digested vectors to be used in ligation reactions (see Section 2.2.2.6.) were 
treated with 1 unit of Alkaline Phosphatase and further incubated in a water bath at 
37°C for 30 minutes to prevent vector religation.
2.2.2.4. DNA purification (gel extraction)
DNA of interest was excised from a gel using a scalpel and purified using a QIAGEN 
QLAquick Gel Extraction Kit according to manufacturer’s instructions. The DNA 
was eluted from the columns in 30-50 pi of distilled water and the yield determined 
by running a 5 pi aliquot on an agarose gel in the presence of a 1Kb DNA ladder and 
a DNA mass ladder.
2.2.2.5. DNA Ligation
After the vector and insert were appropriately digested, purified and quantitated, they 
were ligated by using the Rapid DNA Ligation Kit, according to the manufacturer’s 
instructions. The amount of vector and insert to be used in these reactions was 
calculated using the following formula:
(50ng of vector x Kb size of insert/ Kb size of vector) x (ratio insert:vector)= ng of 
insert
Filipa L. Mendonga, 2002 Chapter 2
t hThe ratio of insert to vector used was 4:1 and 1/10 of the above reaction was used to 
transform E.coli DH5a competent cells (see below)
2.2.2.6. Transformation of Competent Bacterial Cells
E.coli DH5a competent cells were used for the propagation of plasmid DNA. A 20pl 
aliquot of the competent cells were thawed on ice and then transferred to a chilled 
polypropylene tube (Falcon 2059). The appropriate amount of DNA was added to 
each tube and left to incubate on ice for 30 minutes. Cells were then heat shocked for 
45 seconds in a water bath at 42°C. 80pl of SOC medium (2% bactotryptone, 0.55% 
yeast extract, lOmM NaCl, 2.5mM KC1, lOmM MgCl2, lOmM MgSC>4, 20mM 
glucose) was added to each sample and each tube was incubated at 37°C for 1 hour 
with vigorous shaking. The whole of the transformation reaction was then plated on 
to L-agar plates containing 50p,g/ml of ampicillin. Plates were inverted and incubated 
O/N at 37°C to allow colony formation.
2.2.2.7. Preparation of Plasmid DNA (Miniprep/ Maxiprep)
Single bacterial colonies were picked and incubated overnight in 6ml of LB-medium 
containing 50pg/ml of ampicillin with vigorous shaking at 37°C. 1.5ml of the 
overnight culture was centrifuged for 10 minutes at 14,000 r.p.m in a bench top 
centrifuge. DNA was purified using the QIAprep Spin Miniprep Kit according to 
manufacturer’s instructions. DNA from larger volumes of overnight cultures (100ml) 
was purified using the QIAGEN Maxi kit following the manufacturer’s instructions.
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2.2.2.7.1. Plasmid preparation of pMACS Kk
As pMACSKK is a low copy plasmid an amplification step was carried out in order to 
achieve high yields of plasmid. DH5a cells were transformed as described in Section 
2.2.2.6 with lp l of commercially available pMACS Kk. The next day 30ml of LB- 
broth supplemented with 50pg/ml of ampicillin was inoculated with a single bacterial 
colony. This culture was incubated overnight in a shaker at 37°C and left to reach 
late-log phase ( O . D . 6oo ~0.6). 500ml of LB-broth with ampicillin was subsequently 
inoculated with 25ml of the late log phase culture. This culture was incubated for 
approximately 2.5 hours at 37°C with vigorous shaking (300 cycles/min on a rotary 
shaker) until the O . D . 6oo reached ~ 0.4. At this stage 2.5ml of chloramphenicol 
(34mg/ml in ethanol) was added and the culture was left to grow overnight at 37°C in 
the shaker. The next day DNA from the overnight culture was prepared as described 
in Section 22.2.1.
2.2.2.8. Polymerase Chain Reaction (PCR)
2.2.2.8.1. Pfu method:
For each PCR reaction lOpl of the lOx Pfu buffer, lOpl of DMSO, lOpl of 50% 
glycerol, 4ul lOmM dNTPs and 0.1 pg of each primer per base where mixed in a PCR 
tube to a final volume of 98pi (made up with dH20). lp l of plasmid template 
(O.lpg/pl ) and lp l Pfu enzyme (2.5pg/pl ) were finally added to each tube. The 
reactions were overlaid with lOOpl of paraffin and heated up to 94°C for one minute. 
PCR products were obtained after 30 cycles of a one minute denaturing step at 94°C, 
one minute annealing step at 55°C and a one minute extension step at 72°C. After the
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30 cycles, the reactions were left at 72°C for 10 minutes. The whole lOOpl of the 
PCR reaction were analysed by agarose gel electrophoresis and the PCR product was 
purified using the technique described in section 2.2.2.5
2.2.2.8.2. Pre-Aliquoted Reddy Mix™ Master Mix:
To each pre-aliquoted Reddy Mix™ PCR Master Mix, lp l (lOpM) of each primer and 
50ng of plasmid template were added to a final volume of 50pl. PCR products were 
obtained after 30 cycles of a one minute denaturing step at 94°C, one minute 
annealing step at 55°C and a one minute extension step at 72°C. After the 30 cycles, 
the reactions were left at 72°C for 10 minutes. All of the PCR reaction was analysed 
by agarose gel electrophoresis and the PCR product was purified using the technique 
described in section 2.2.2.5.
2.2.2.9. Overlap extension PCR
This technique was used to join two sequences from different receptors when no 
appropriate restriction enzymes were present. The first round of PCR was set up 
using the protocol described above. Primers were designed so that the products of the 
two primary PCR reactions contained at least 20bp overlapping complementary ends; 
primers used in the secondary reaction were designed to anneal at the non 
complementary ends and to include restriction sites that allowed cloning of the PCR 
product into the appropriate backbone. A second PCR reaction was carried out using 
the products (1.5pi) of the first round as template and lOpM of each primer as before 
(Section 2.2.2.9.2.). This resulted in the primary products priming on each other and 
extending to yield a hybrid product. This hybrid product was then analysed by
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agarose gel electrophoresis, purified and digested with the appropriate enzymes and 
then cloned back into the appropriate vector (Fig. 2.1).
2.2.2.10. Site Directed Mutagenesis
Site directed mutagenesis was used to generate single point mutations in either 
CCR5HACCR5V.pKSII or D6HAD6V.pKSII. The QuickChange™ Site-Directed 
Mutagenesis Kit was used according to the manufacturer’s instructions.
2.2.11. Cloning of DNA fragments into pCR®2.1-TOPO®
Taq polymerase-amplified PCR products were cloned into pCR®2.1-TOPO® using 
the TOPO TA Cloning Kit following the manufacturer’s instructions. In brief, 4pl 
of PCR product, lp l of salt solution and lp l of linearized pCR®2.1-TOPO® were 
mixed together and incubated at room temperature for 5 minutes. Reaction mixture 
was stored on ice until used for transformation.
For each transformation reaction, 2pl of the TOPO® Cloning reaction were 
transferred into a vial of One Shot® Chemically competent E. coli, and mixed gently. 
Transformation reaction was incubated on ice for 5 minutes and subsequently heat- 
shocked for 30 seconds at 42°C without shaking. Tubes were immediately transferred 
to ice and 250pl of room temperature SOC medium were added. After incubating the 
cells in a shaker (200rpm) for 1 hour at 37°C, 50pl of each transformation were 
spread in an agar plate containing selective media (L-agar plates supplemented with 
50pg/ml of ampicillin). Plates were inverted and incubated overnight in a 37°C
Filipa L. Mendonga, 2002 Chapter 2
incubator. Colonies were isolated the following day and analysed further to check for 
successful cloning.
2.2.12. DNA sequencing
An Applied Biosystems 373A automated sequencer was used to verify the correct 
sequence of all constructs generated. First, PCR amplification of the region to be 
sequenced was carried out with primers complimentary to domains upstream and 
downstream from the region to be sequenced. In general PCR reactions contained:
0.5p,g plasmid DNA, 3.2pmmoles of primer and 4pl of Big Dye Terminator Reaction 
premix in a final volume of lOpi (made up with distilled water). 250pi thin walled 
eppendorf tubes were used for all sequencing PCR reactions. Samples were heated to 
95°C for 30 sec, 50 for 30 sec and 60°C for 4 min. This cycle was repeated 25 times. 
To each reaction 2pl of 3M Sodium Acetate (pH4.5) and 50pl of Ethanol were 
added. Reactions were incubated at room temperature for 15 minutes and then 
centrifuged for 10 minutes at top speed in a bench top centrifuge. After discarding of 
the supernatant, pellets were washed twice with lOOpi of ice cold 70% ethanol and 
again the supernatant was removed. Pellets were left to air-dry to allow evaporation 
of any residual ethanol. Members of the Beatson Institute technical services staff 
performed the sequencing gel electrophoresis. Sequencing data was analysed using 
the CHEVAL computer program.
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2.2.2.13. Vector construction:
2.2.2.13.1. hD6/mIL8RL-l chimaeric constructs
To generate Flag tagged constructs of wild type mIL8RL-l.pKSII and hD6.pKSII a 
Flag Tag was inserted by PCR after the start codon. Primer sequences are shown in 
Table2.1 with the new sequence in bold.
hD6.pKSII was amplified by D6Flag and hD6D5. The PCR product generated was 
then digested with Hindlll and Bglll and subsequently cloned into hD6.pKSII 
previously digested with the same enzymes. The new construct obtained was named 
D6FD6V.pKSII (Fig.2.2)
The IL8Flag and 831 (Table 2.1) primers were used in conjunction with mIL8RL-
l.pKSII to yield a PCR product that was digested with Hindlll and Accl. To create 
construct IL8FIL8V.pKSII (Fig.2.2), the Hindlll/AccI fragment was cloned into 
mIL8RL-l.pKSII which was previously digested with the same enzymes.
Primers D6AccI and D6Flag (Table 2.1) were used to change the Bglll site of 
hD6.pKSII into an Accl site. This fragment was then digested with Hindlll and Accl 
and cloned into mIL8RL-l.pKSII, which was previously digested with the same 
enzymes. This hybrid construct was named D6FIL8V.pKSII (Fig.2.2).
Primers IL8Flag and IL8BglII (Table 2.1), were used to mutate the Accl site of 
mIL8RL-l.pKSII into a Bglll site. This PCR fragment was digested with Hindlll and 
Bglll and then cloned into hD6.pKSII to yield the construct named IL8FD6V.pKSII 
(Fig.2.2).
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A HA Tag was cloned after the start codon of hD6.pKSII and mIL8RL-l.pKSII. To 
clone the HA tag into hD6.pKSII the primers D6HA and hD6d5 (Table 2.1) were 
used; primer IL8HA together with primer 831 (Table 2.1) were used to clone the HA 
tag into mIL8RL-l.pKSII. The HA tag was cloned into hD6.pKSII as a Hindlll/Bglll 
insert and into mIL8RL-l.pKSII as a HindlH/AccI piece. The new constructs were 
named D6HAD6V.pKSII and IL8HAIL8V.pKSII (Fig.2.2), respectively. The 
Hindlll/Bglll fragment was cloned into Hindlll/Bglll-cut D6FIL8V.pKSII to generate 
construct D6HAIL8V.pKSII (Fig.2.2). IL8HAD6V.pKSII (Fig.2.2) was obtained by 
cloning the Hindlll/AccI piece into Hindlll/AccI cut IL8FD6V.pKSII.
Once the fidelity of these constructs was checked by restriction enzyme digests and 
DNA sequencing, the plasmids were digested with Hindlll and Notl and 
subsequently cloned into the corresponding sites of the mammalian expression vector 
pcDNA.3.
2.2.2.13.2 hCCR5/hD6 chimaeric constructs- large swaps
To add HA Tag sequence on the N-terminus of hCCR5 the primers CCR5HA and 
CCR5.D1 (Table 2.2) were used in PCR. This fragment was digested with Hindlll 
and MscI and then cloned into HindlH/MscI-cut hCCR5.pKSII to generate 
CCR5HACCR5V.pKSII (Fig.2.3).
Construct CCR5HAD6V.pKSII, was obtained by cloning the 288bp Hindlll/MscI 
PCR fragment mentioned above into D6HAD6V.pKSII also digested with 
Hindlll/MscI (Fig. 2.3).
Filipa L. Mendonga, 2002 Chapter 2
Digestion of D6HAD6V.pKSII with Hindlll and MscI yield a fragment between 
nucleotides 1 and 265 of the open reading frame that corresponds to the N-terminus, 
and a a portion of the adjacent transmembrane I of the translated protein. This 
fragment was inserted into the digested CCR5HACCR5V.pKSII to generate the 
chimaeric construct D6HACCR5V.pKSII (Fig. 2.3).
D6HAD6V.pKSII, CCR5HACCR5V.pKSII, CCR5HAD6V.pKSII and 
D6HACCR5V.pKSII were then subcloned into pcDNA.3.
2.2.2.13.3 hD6/hCCR5 chimaeric constructs- extracellular domain swaps
To create the chimaera 5nt6bd.pKSII, D6HAD6V.pKSII was amplified by primers 
5nttop and hD6D4 (Reaction 1) and by primers 5ntbot and CCR5HA (Reaction 2)- 
for primer sequence see Table 2.3. The PCR products generated by reaction 1 and 2 
were further amplified together using the primers CCR5HA and hD6D4 to give a 
final PCR product. The PCR product was cloned using HindlH/Pstl into Hindlll/Pstl- 
cut D6HAD6V.pKSII to generate the hybrid construct 5nt6bd.pKSII (Fig. 2.4). This 
construct encodes the HA tag sequence right after the start codon and the first 19 
amino acids of hCCR5’s N-terminus joined on to amino acid 36 of hD6’s mature 
protein.
To make the chimaeric construct with the first extracellular loop exchanged (Fig. 
2.4), the plasmid D6HAD6V.pKSII was digested with Bglll and Smal which deleted 
a fragment between nucleotides 322 and 379 of the open reading frame. This 
fragment corresponds to the first extracellular loop of the translated protein. A 
similar fragment was obtained from hCCR5 by PCR. D6HAD6V.pKSII was
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amplified with primers (Reaction 1) Eloop5Abot and hD6U5 (Table 2.3) and with 
primers (Reaction 2) Eloop5Atop and hD6D2 (Table 2.3). In a second round of PCR, 
the PCR products obtained from Reaction 1 and 2 were amplified with the primers 
hD6U5 and hD6D2 to yield a hybrid fragment. This new fragment comprises the first 
extracellular loop of hCCR5 (nucleotides 491 to 558 of the open reading frame) 
flanked at either side by the nucleotides 207 to 322 and nucleotides 379 to 569 of 
hD6’s open reading frame. This fragment was then cloned into the TOPO TA 
Cloning Kit (Section 2.2.11). After digestion with Bglll and Smal an insert was 
obtained. This inserted was then cloned into the digested D6HAD6V.pKSII.
Amplification of D6HAD6V.pKSII with primers (Table 2.3) Eloop5Btop in 
conjunction with hD6Dl and with primers Eloop5Bbot and hD6Ul (Table 2.3) 
produced two separate PCR products. In a second round of PCR, these 2 PCR 
products were further amplified with primers hD6Ul and hD6Dl to generate a hybrid 
fragment. This hybrid fragment corresponds to the second extracellular loop of 
hCCR5 flanked by portions of hD6 at either side of the hCCR5 loop. Digestion of 
this fragment with Xmal and Xbal allowed cloning of this fragment into 
D6HAD6V.pKSII previously digested with the same enzymes. This new chimaeric 
constructs was named EloopB.pKSII (Fig. 2.4)
Cloning of the third extracellular loop of hCCR5 into the corresponding portion of 
hD6 was achieved by amplifying D6HAD6V.pKSII with primers stated below (Table
2.3 for full primer sequencing). Two separate reactions were carried out with primers 
Eloop5Ctop and hD6.3NotI (Reaction 1) and primers Eloop5Bbot and hD6Ul 
(Reaction 2). The PCR products from reactions 1 and 2 were then used as templates
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in a second round of PCR in conjunction with the hD6 internal primers hD6Ul and 
hD6Dl. The resulting PCR product was cloned into TOPO (Section 2.2.11) and then 
digested with Xmal and Notl. Digestion of D6HAD6V.pKSII with Xmal and Notl 
allowed cloning of the digested PCR product to generate construct EloopC.pKSII 
(Fig. 2.4).
Restriction enzyme digests and DNA sequencing verified fidelity of the constructs. 
All of the above constructs were then cloned into pcDNA.3 as a Hindlll/Notl 
fragments.
2.2.2.13.4. hD6/hCCR5 chimaeric constructs- intracellular mutants
iLoopl.pKSII (Fig.2.5) has the 1st intracellular loop of hD6 swapped for the 
corresponding region of hCCR5. This construct was obtained by amplification of 
D6HAD6V.pKSII with the primers iLooplA in conjunction with D6HA and 
iLooplB (Table 2.5) with conjunction with hD6D4 (Table 2.3) in 2 independent PCR 
reactions. In a second round of PCR the products from the two independent reactions 
were subsequently amplified with the primers D6HA and hD6D4. This final PCR 
product was then digested with BamHI and MscI. Digestion of D6HAD6V.pKSII 
with BamHI and MscI excises the first intracellular loop of hD6’s mature protein 
thus allowing insertion of the digested PCR product. Diagnostic digests and DNA 
sequencing checked for successful cloning. The insert iLoopl was digested from 
pKSII and subcloned into pcDNA.3 as a Hindlll/Notl fragment.
D6HAD6V.pKSII was digested with MscI and Xbal to delete a fragment that 
corresponds to the 2nd intracellular loop of hD6’s mature protein. A PCR fragment
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was generated by amplifying the products of two primary PCR reactions where the 
primers iLoop2A/hD6U5 and iLoop2B/hD6D7 (Table 2.4) independently amplified 
D6HAD6V.pKSII. The final PCR product was digested with MscI and Xbal to allow 
cloning of this digested fragment into the previously digested vector. Again, the 
hybrid construct obtained, named iLoop2.pKSII (Fig. 2.5), was analysed by 
diagnostic digests and DNA sequencing. iLoop2.pKSII was subsequently subcloned 
into pcDNA.3 as a Hindlll/Notl fragment.
The 5’ iLoop3B and 3’ hD6D7 primers were used in conjunction with the 5’ hD6U3 
and 3’ iLoop3A (see Table 2.4 for primer sequences) to generate a hybrid fragment 
comprising nucleotides corresponding to the 3rd intracellular loop of hCCR5 flanked 
by portions of hD6’s mature protein. The PCR fragment obtained was digested with 
Xmal and Xbal and then cloned into D6HAD6V.pKSII (previously digested with the 
same enzymes), to create construct iLoop3.pKSII (Fig. 2.5). Hindlll/Not I digestion 
of iLoop3.pKSII excises the insert from pKSII to allow subcloning into pcDNA.3. 
Constructs were analysed by diagnostic digests and DNA sequencing.
C-terminus swaps between hCCR5 and hD6 were obtained by using the primers 
listed in Table 4. The construct 5ct6bd.pKSII ( Fig. 2.6.) bears the C-terminus of 
hCCR5 cloned into position 946bp of hD6 (straight after the 7th TM domain).
Construct 5ct6bd.pKSII was created following the same procedure described above. 
5ctbot and CCR53BnotI (Table 2.4) were used to amplify CCR5HACCR5V.pKSII 
(Reaction 1); 5cttop in conjunction with hD6U3 (Table 2.4) amplified 
D6HAD6V.pKSII (Reaction 2). The PCR products from these 2 reactions were 
further amplified with the primers (hD6U3 and CCR53BNotI) used in the primary
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reactions to yield a hybrid PCR fragment containing the C-terminus of hCCR5 and 
flanked at the 5’ end by the 7th TM domain of hD6. The C-terminus of hD6 was 
excised from D6HAD6V.pKSII as a Xbal/Notl fragment to allow for insertion of the 
PCR product also digested with Xbal and Notl. Diagnostic digests and DNA 
sequencing were performed to confirm identity of the new construct (named 
5ct6bd.pKSII). 5ct6bd.pKSII was digested with Hindlll and Notl and the insert 
obtained was subcloned into pcDNA.3.
D6HAD6V.pKSII was amplified with primers hD6E-A5’ and hD6E-A3’ (Table 2.5 
for primer sequences) to generate construct hD6E-A.pKSII (Fig. 2.6). Construct 
hD6K-R.pKSII (Fig. 2.6) was obtained by amplification of D6HAD6V.pKSII with 
primers hD6K-R5’ and hD6K-R3’ (Table 2.5 for primer sequences).
CCR5HACCR5V.pKSII was amplified with primers 5Ketop and 5Kebottom (Table 
2.5 for primer sequences) to create construct hCCR5DKYLEIV.pKSII (Fig. 2.6).
Fidelity of the constructs hD6E-A.pKSII, hD6K-R.pKSII and 
hCCR5DKYLEIV.pKSII was checked by DNA sequencing and subsequently 
subcloned into pcDNA.3 as a Hindlll/Notl fragment
2.2.2.13.5. hCCR5/hD6 chimaeric constructs- second generation
To study the cooperative effects of hCCR5 receptor intracellular domains a second 
generation of chimaeric mutants was generated. These mutants bear a combination of 
two or more intracellular domains of hCCR5 cloned into the corresponding region of 
hD6 (Fig. 2.7).
ii
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I
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Construct iLoopl+3.pKSII has the first and the third loops of hD6 replaced by the 
corresponding region of hCCR5. This construct was obtained by cutting the first 
intracellular loop of iLoopl.pKSII with BamHI and Mscl. The digested fragment was 
subsequently cloned into iLoop3.pKSII previously digested with the same enzymes.
Digestion of hD6DRY.5.pKSII with Mscl/Xmal yields a fragment containing the 
DKYLEIV region of hD6 mutated to DRYLAIV. Constructs iLoopl.pKSII, 
iLoop3.pKSII, iLoopl+3.pKSII and 5ct6bd.pKSII were separately digested with 
Mscl/Xmal to allow cloning of the DRYLAIV fragment into the corresponding 
region of these vectors. The new constructs were named iLoopl+DRY.pKSII, 
iLoop3+DRY.pKSII, iLoopl+DRY+iLoop3.pKSII and DRY+Ct.pKSII.
Digestion of 5ct6bd.pKSII with Xbal and Notl generates a fragment containing the 
7TM and the C-terminus of this construct. This fragment was cloned into 
iLoopl+DRY+iLoop3.pKSII previously digested with the same enzymes to obtain 
construct iLoopl+DRY+iLoop3+Ct.pKSII.
All cDNAs were subcloned into the mammalian expression vector pcDNA.3 as a 
Hindlll/Notl fragment and diagnostic digests checked for the fidelity of each 
construct. Each one of these new constructs was stably transfected into HEK.293 
cells as described in Section 2.2.1.2.1.
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2.2.3. Protein Detection
2.2.3.1. SDS PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
10% SDS polyacrylamide gel was used to resolve protein samples. The resolving gel 
was made by adding the appropriate volume of 30% (w/v) acrylamide: 0.8% (w/v) 
bys-acrylamide to 0.45M Tris, 0.1% SDS (final concentration). 0.08% TEMED and 
0.1% (w/v) APS were added at the very end to catalyse polymerisation. This solution 
was poured between two glass plates, the top of the gel was covered with saturated 
butanol and the gel was left to set for 30 minutes. Once the gel was set the saturated 
butanol was poured off, washed with water and blotted dry. 10ml of a 5% stacking 
gel buffer (0.125M Tris, pH6.8, 0.1% SDS, 1.7ml 30% (w/v) acrylamide: 0.8% (w/v) 
bys-acrylamide, 0.2% APS, 0.3% TEMED; 4x stacking gel buffer: 0.5M TRIS 
(pH6.8), 0.4% SDS) was poured in top of the resolving buffer, a comb was inserted 
and the gel left to set.
Cells were trypsinised as usual and washed once with PBS. 1ml of lysis buffer (lx  
lysis buffer: 50mM Tris (pH6.8), 25mM DTT, 2% SDS) was used to resuspend the 
harvested cells and samples were boiled for 5 minutes. 60pl of each sample was 
mixed with an equal volume of 2x SDS loading buffer (2x SDS loading buffer: 
lOOmM Tris-HCL (pH6.8), 2% (v/v) p-mercaptoethanol, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol) and boiled for a further 5 minutes. 5pi of 
Rainbow™ markers was loaded into the first well; a 5pi aliquot of each sample was 
loaded into separate wells. The gel was left to run at approximately 50mA in lx  
SDS-PAGE running buffer (25mM Tris, 250mM glycine, 0.1% (w/v) SDS) until 
bromophenol blue band reached the bottom of the gel.
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2.2.3.2 Transfer of proteins from SDS-PAGE gel to nitrocellulose
Once the proteins were separated by SDS-PAGE, the glass plates were removed and 
the stacking gel was cut off and discarded. 12 pieces of 3MM filter paper and 1 piece 
of nitrocellulose membrane (Hybond cextra) were cut to size of the gel. 6 pieces of 
3MM paper were soaked in lx  Dry Blot Buffer (48mM Tris, 39mM glycine, 1.3mM 
SDS and 20% (v/v) methanol) and placed onto graphite plate of blotter. The 
nitrocellulose membrane was pre-wetted in lx  Dry Blot Buffer and placed carefully 
onto filter paper. The gel was briefly rinsed with Blot Buffer and placed carefully in 
top of the nitrocellulose membrane. Another 6 pieces of 3MM filter paper were pre­
wet in lx  Dry Blot Buffer and placed over the gel. Any air bubbles were removed by 
rolling a plastic pipette over the stack of membrane and filter paper, and the transfer 
was carried out at 180mA for 1 hour. Staining the nitrocellulose with Ponceau S 
Solution checked the efficiency of the transfer.
2.2.3.3 Western Blotting
Once gel was blotted onto a nitrocellulose membrane, the membrane was incubated 
overnight in blocking buffer (5% (w/v) dried milk in PBS-T (0.1% (v/v) Tween in 
PBS)) at 4°C with shaking. The nitrocellulose filter was washed 3x 10 min in PBS-T 
and then incubated in 10ml of a 1:500 dilution of anti-FLAG M5 or M2 antibody in 
blocking buffer for lhr at room temperature with shaking. The primary antibody 
solution was removed and the membrane was washed 3x 10 min in PBS-T. After 
this, the membrane was incubated in 25ml of a 1: 5000 dilution of anti-mouse IgG 
HRP linked antibody in blocking buffer. The secondary antibody solution was 
removed and the membrane was washed twice for 10 minutes with multiple changes
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with PBS-Tween; another 2x 10 min washes were carried out with PBS-Tween. 
Excess surface liquid was removed from the membrane and the western blot 
developed by enhanced chemiluminescence (ECL) according to manufacturer’s 
instructions.
2.2.4. Radio-iodination of PM2
PM2 was radiolabeled using Iodogen. 5[xg of PM2 (O.lmg/ml) in PBS was incubated 
with lOpg of Iodogen and 6pl of 125I in an eppendorf tube for 15 minutes on ice. 
Following this incubation on ice, unincorporated iodine was separated from the 
labelled protein by applying the reaction mixture to a disposable desalt column and 
eluting with PBS. 500pl fractions were collected and measured in a gamma counter 
to detect the peak of protein associated radioactivity, and the active fractions were 
pooled together to give 1.5ml of a 300nM 125I-PM2 solution.
2.2.5. Functional Assays
2.2.5.1. Enzyme Linked ImmunoSorbent Assay (ELISA)
All constructs were examined in triplicate. 2E5 cells/well were seeded in a 24-well 
plate one day before the assay. Cells were fixed in 4% paraformaldehyde (in PBS) for 
10 minutes on ice, washed twice in PBS and incubated with anti-FLAG antibody 
(1/1000 in PBS) for 1 hour at room temperature. Cells were then rinsed once with 
PBS and incubated for 30 minutes with anti-mouse IgG alkaline Phosphatase 
conjugated (1/10000 dilution in PBS). Cells were washed three times with PBS and 
developing solution (pNPP substrate tablet set) was added according to the
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manufacturer’s instructions. Colour development was read at 450nm using a 
microtiter plate reader.
2.2.5.2. Flow cytometry Analysis
Approximately 5E5 cells were washed with FACS buffer (0.5% Bovine Serum 
Albumin, 1% sucrose in PBS. This buffer is kept on ice at all times.) and incubated 
for 30 minutes on ice with 1/100 dilution of HA. 11 antibody or 1D4 antibody. Cells 
were then washed once on ice cold FACS buffer and subsequently resuspended in 
400ul of FACS buffer. Cells stained with 1D4 were further incubated for 30 minutes 
on ice with 1/32 dilution of anti-mouse FITC coupled antibody. At the end of this 
incubation step cells were washed once with ice cold FACS buffer and then 
resuspended in 400ul of FACS buffer. All samples were analysed in a FACS (Becton 
Dickinson).
2.2.5.3. Immunocytochemistry
Cells were seeded at lE5/well in an 8 well permanox chamber slide and left to grow 
overnight at 37°C, 5% CO2. The next day the cells were washed with FACS buffer 
and incubated for 1 hour with 1/100 High Affinity anti-HA antibody in FACS buffer 
(slides were kept on a tray of ice at all times). Cells were washed for 1 hour in FACS 
buffer with multiple changes. After this washing step cells were incubated with 1/32 
dilution of the secondary antibody (anti-rabbit FITC coupled antibody) in FACS 
buffer. Slides washed for a further 30 minutes in FACS buffer, with multiple 
changes, were subsequently mounted in 2 drops of VectaShield and sealed with nail 
varnish to prevent the slides from drying out. Cells were visualised in a Biorad MRC
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600 confocal attached to a Nikon Diaphot microscope with an oil immersion lense 
(xlO and x60 magnification). Pictures were viewed on the Confocal Assistant 
computer program.
2.2.5.4. Internalisation Assay
Cells were incubated with or without lOOnM of PM2 in complete medium for 45 
minutes at 37° C, 5% CO2. After the incubation period 1.5ml of ice cold Buffer 1 
(Buffer 1:1% BSA, 0.25% sodium azide, in PBS) was added to each tube. Cells were 
centrifuged at 1000 r.p.m. for 5 minutes at 4°C and subsequently washed twice with 
1.5ml of Buffer 1. Pelleted cells were resuspended in Buffer 1 and incubated for 30 
minutes on ice with either 1/10 dilution of anti-hCCR5 FITC-conjugated antibody or 
with 1/100 dilution of 1D4 antibody. Cells were washed twice in Buffer 1 and either 
stained with a 1/32 dilution of an anti-mouse FITC coupled antibody (for cells 
stained with 1D4); or resuspended in 400ul of Buffer 1 and fixed by adding 50ul of 
4% PFA. Excess 217 antibody was washed off twice with Buffer 1, and the cells were 
finally resuspended in a final volume of 400pl of the same buffer. Again, these cells 
were fixed by adding 50pl of 4% PFA to each tube.
Relative fluorescence of each sample was determined by the following formula:
fluorescence of sample -  fluorescence of negative control x 100
fluorescence of no-chemokine control -  fluorescence of negative control
(This method was adapted from (Mack et al., 1998))
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2.2.5.5. Receptor Binding Studies
2.2.5.5.1. Adherent Cells
CHO cells were plated at 1E5 / well in a 6 well tissue culture plate and left to grow 
overnight at 37°C, 5% CO2. The next day the cells were washed twice with 2ml of 
warm PBS and incubated with 200pl /well of binding buffer (binding buffer: 0.5% 
NaAzide, 25mM HEPES in complete SLM; pH 7.4). Various concentrations of 
unlabeled competitor chemokine, or equivalent volumes of PBS, were added to each 
well followed by 125I- labelled chemokine. After incubating the cells for 90 minutes 
at room temperature the wells were washed 3 times with ice cold PBS and then lysed 
with 0.5ml of 1% SDS. Lysates were transferred to counting vials and each counted 
for 1 minute in a Beckman Gamma S500B counter. Each point was done in triplicate, 
the average taken and converted into a percentage of binding in the absence of 
unlabelled competitor chemokine. On average, the total cpm used was between 17 
000 and 20 000 and the specific activity bound was between 3.2 and 4%.
2.2.5.5.2. Suspension assay
1E6 cells were resuspended in 35pl of binding buffer (Section 2.2.3.5.) and incubated
  19Swith or without 60nM of unlabelled chemokine. To each tube 6nM of I - labelled 
PM2 was added and cells were left to incubate for 90 minutes at room temperature. 
Non specific chemokine binding was removed by adding 50pl of wash buffer (wash 
buffer: 4% NaCl in complete media) to each tube. Cells were pelleted by 
centrifugation at 10k r.p.m. for 5 minutes. Pellets were washed once with ice cold 
and supernatant was pipetted off. Tubes were then cut in half with a hot scalpel and
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transferred to counting vials. Samples were counted and data analysed as in Section
2.2.3.6. On average, the total cpm used was between 17 000 and 20 000 and the 
specific activity bound was between 3.2 and 4%.
For I125-RANTES, and I125-MCP-4 the amounts of unlabelled and labelled 
chemokine used in the assay were 500nM and 2nM respectively. On average, the 
total cpm used was between 5 000 and 7 000 and the specific activity bound was 
between 2.9 and 4%.
2.2.5.53. Displacement curves
CHO cells stably expressing HA or Flag Tagged constructs were seeded as in Section
2.23.5. G418 resistant pools of HEK.293 expressing HA Tag constructs and 
transiently transfected COS-7 cells were prepared as described in Section 2.2.3.6.
125A full binding curve for each construct was obtained by incubating the cells with I - 
PM2 at a constant concentration of 75nM and a varying concentration, 0 to 2uM, of 
unlabeled PM2. Each point was done in triplicate, the average taken, and converted 
into a percentage of radioactivity bound in the absence of unlabeled competitor 
chemokine. IC50 was determined using EXCEL. On average, the total cpm used was 
between 17 000 and 20 000 and the specific activity bound was between 3.2 and 4%.
2.2.5.6. Signalling Assays
Untransfected and stably transfected HEK.293 were assayed for their ability to flux 
calcium upon ligand binding. Cells were resuspended in 26ml of warm SR buffer 
(SR buffer: 136mM NaCl, 4.8mM KC1, 5mM Glucose, 20mM HEPES, ImM CaCl2,
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0.05% BSA; pH 7.4), per confluent 175cm2 flask. Cells were pelleted by 
centrifugation at 1000 r.p.m. for 5 minutes and then resuspended in 6ml of SR buffer. 
To each cell suspension 12pl of FURA-2-AM (4p,g/pi) was added and cells were 
incubated for 30-40 minutes in the dark at 37°C, 5% C 02. After this incubation 
period cells were washed twice with 20ml of SR buffer and finally resuspended in 
6ml of SR buffer. The fluorescence of these samples was measured by a Perkin- 
Elmer LS50 Spectrometer at an excitation wavelength of 340nm and an emission 
wavelength of 540nm. Measurements were carried out every 100ms under continuous 
stirring at 37°C. Once the cells were loaded into the stirred cuvette they were left to 
equilibrate for 2 minutes and then basal fluorescence was measured, cells were 
diluted down to achieve a basal fluorescence of between 600-700 units intensity. 
Cells were then stimulated with 50nM PM2 (final concentration) and the intensity of 
fluorescence measured for up to 300sec.
2.2.6. The MACSelect- Transfection Cell Selection System
This system was used for the isolation of transiently transfected CHO cells. CHO 
cells were transiently co-transfected with lug of pMACS Kk and lug of DNA of 
interest following the protocol described in Section 2.2.1.1.2.
48 hours after transfection cells were washed once with PBS and 500pl of a weak 
trypsin solution (90ml PE, 5ml PBS, and 5ml trypsin) were added per 60mm 
(diameter) plate. Dishes were incubated at 37°C until cells became dissociated from 
the culture dish and from each other. Trypsinization was stopped by adding lOOpl of 
100% FCS. To each dish 40pl of MACSelect Kk Microbeads was added and rocking 
of the dish assured evenly distribution of the beads. The Microbeads were left to
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incubate on the plate for 15 minutes at room temperature. After incubation with the 
Microbeads degassed PBE ( PBS supplemented with 0.5% bovine serum albumin 
and 5mM EDTA) was added to a final volume of 2ml. Cells were resuspended 
completely to ensure cell suspension. The selection column was placed in the 
magnetic field and washed with 500pl of PBE. Cell suspension was applied to the 
column in 500pl aliquots making sure that each aliquot had been resuspended 
appropriately to avoid blocking of the column with cell clumps. Once all the negative 
cells (flow-through) had passed through the column was then washed with 500pl of 
PBE four times and subsequently removed from the separator. The column was 
placed on a suitable collection universal tube. 1ml of complete media was pipetted 
into the column. Using the plunger supplied with the column, transfected cells were 
flushed out of the column into the universal.
Staining the flow through and the sorted cells with anti-Kk antibody checked 
effectiveness of this system. In general, 5E5 cells were resuspended in lOOpl of PBE 
and lOpl of anti-Kk antibody was added to each tube. Tubes were left to incubate for 
5-10 minutes on ice in the dark. Cells were washed by adding 1.5ml of PBE and 
finally resuspended in 400pl of PBE. Samples were then examined by a FACS.
Primer Nucleotide Sequence
D6Flag
5 ’gagagagtcgacaagcttggatcctccaacatggattacaaggatgacgatgataaggccgccactgcctctccgca 3 ’ 
Ilind lll Bam lll M D Y K D D  D D K  A A T A S P Q
hD6D5 5’ aggttggagatggccagattcagc 3’
IL8Flag
5’gagagaaagcttggatcctccaacatggattacaaggatgacgatgataaggccgaggctgaatatttcatctg3’
Hindlll BamHI M D Y K D D D D K  A E  A E Y T I  W
831 5’ tcgcctgtataagataaccagca 3’
D6 AccI 5’ gagagagtcgacctcaaccatccgcctgcg 3’
AccI
IL8 Bglll 5 ’ gagagagatctccatgacggatcgggtcc 3 ’
Bgin
D6HA
5’gagagagtcgacaagcttggatcctccaacatgtacccctacgacgtgcccgactacgccgggccgggggccgccact 
AccI HindlD BamHI M Y P Y D V P D Y A G  P G  A A T
gcctctccg 3’
A S P
IL8HA 5 ’ gagagaaagcttggatcctccaacatgtacccctacgacgtgcccgactacgccgggccc
Ilindlll BamHI M Y P  Y D V P D Y A G P
ggggccgaggctgaatatttcatctg 3’
G A E  A E Y F I  W
Table 2.1. Primers used to generate hD6/mIL8RL-l chimaeric constructs. Sequence 
in bold indicates new sequence.
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Primer Nucleotide Sequence
CCR5HA
5’ gagagaaagcttggatcctccaacatgtacccctacgacgtgcccgactacgccgggccgggggattatcaa
H indlll BamHI M Y P Y D V P D Y A G  P G  D Y Q
gtgtcaagtccaatc3’ 
v s s P I
CCR5 .D1 5 ’ aacaggtcagagatggccag 3 ’
Table 2.2. Primers used to insert a HA Tag on the N-terminus of hCCR5.pKsII
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Primer Nucleotide Sequence
5nttop 5’ attatacatcggagcclctgcaglgaaggatgcagtg 3’
PstI
5ntbot 5’ accactgcatccttcpgcag|ggctccgatgtataataattg3’
PstI
hD6D4 5’ gtagggctgagcatgaacg 3’
EloopA5top
5 tgggactttggaaatacaatgtgtcaactcttgacagggctttatactattaacttttacagtggcatc3 ’
EloopA5bot
5 ’ acattgtatttccaaagtcccactgggcggcagcatagtggccccagaagggcagtgtcac3 ’
hD6U5 5’ tccttcttctcatggtcttgctccg 3’
hD6D2 5’ gacacaagcccatactatggtagc 3’
Eloop5Btop
5 ’ ctgcagctctcattttccatacagtcagtatcaattctggaagaatttccagacattaaagcagaac
ctcctagggtttctccttccac 3’
Eloop5Bbot
5 ’ atactgactgtatggaaaatgagagctgcaggtgtaatgaagaccttctttttgagatgtctgtac
aaagaccatatcaggg 3’ 
hD6Ul 5’ cgttcatgctcagccctac3’
hD6Dl 5’ ctggagtgcgtagtctagatgc 3’
EloopCtop
5 ’ tttggcctgaataattgcagtagctctaacaggttgcaccaagcactccaggtaacagagagcat
cgccttc 3’
EloopCbot 5 ’actgcaattattcaggccaaagaattcctggaaggtgttcagaaacaaggtgagattgtatgg
3’
hD6Ul 5’ tccttcttctcatggtcttgctccg 3’
hD6.3NotI 5 ’ gagagagag gcggccgcjtcaggctgatttattccccacatcc 3 ’
Notl
Table 2.3. Primers used to generate hD6/hCCR5 chimaeric constructs. Sequence in 
bold indicates hCCR5 nucleotides. Underlined sequence indicates primer overlap. 
Box indicates restriction site. Dashed box indicates Stop codon (*).
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Primer Nucleotide Sequence
iLooplA 5 ’gtcatgctcttcagccttttgcagtttatcaggatgaggagaagaaggaggttcccgct 3 ’
iLooplB 5 ’ atcctgataaactgcaaaaggctgaagagcatgacatctatctgctgaatctggccatc 3 ’
hD6D7 5’ aggtgccaggtgccatcc 3’
iLoop2A
5 ’ cctggcttttaaagcaaacacagcatggacgacagccaggtacctctgcaggctcatgcagcaaat3 ’
iLoop2B
5 ’gtcgtccatgctgtgtttgctttaaaagccaggacggtcaggtttagcctgctccttgctaccatag 3 ’
iLoop3A
5’gtgcctcttcttctcatttcgacaccgaagcagagtttttaggattccggagtagaagaagatcatggcaa
g 3 ’
iLoop3B
5’actctgcttcggtgtcgaaatgagaagaagaggcacagggctgtgaggatagcagcagccttggt
ggtgg 3’
hD6U3 5 ’ aagtattcgggaactgtgaggt 3’
CC5.U3 5’ ctggtcctgccgctgcttc 3’
5ctbottom 5’ cttttcccccatcctgtatgcctttgtcggggagaag 3’
5cttop 5’ cttctccccgacaaaggcatacaggatgggggaaaag 3’
CC53BNotI 5 ’gagagaga ggcggccgc itcaicaagcccacagatatttcctg 3 ’
Notl *
Table 2.4. Primers used to generate construct iLoopl.pKSII. Bold denotes hCCR5 
sequence. Underlined sequence shows primer overlap. Box indicates restriction site. 
Dashed box indicates Stop codon (*).
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Prim er Nucleotide Sequence
hD6E-A5’ 5’ ggacaagtacctggcgatcgttcatgct3’
hD6E-A3’ 5 ’ cctgttcatggaccgctagcaagtacga3 ’
hD6K-R5’ 5’ tgcatgagcctggacaggtacctggagatcg 3’
hD6K-R3’ 5 ’ cgatctccaggtacctgtccaggctcatgca3 ’
5KEtop 5’ tcctgacaatcgataagtacctggaggtcgtccatgctgtg 3’
5KEbottom 5’ cacagcatggacgacctccaggtacttatcgattgtcagga 3’
Table 2.5. Primers used to generate point mutations in D6HAD6V.pKSII and 
CCR5HACCR5V.pKSII. Bold indicates mutated sequences
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A.
.
B.
C. §1111
Figure 2.1. PCR strategy for generating chimaeric receptors. Black arrows 
represent internal primers to the host receptor. Black and grey arrows represent 
chimaeric primers that prime to the host receptor and have the other receptor’s 
sequence on their 5 ’end. In step A fragments of the host receptor were amplified to 
generate chimaeric fragments that overlap. In step B the same internal primers used 
in step A were used to generate a chimaeric fragment, shown in C) of a certain 
receptor.
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D6FD6V IL8FIL8V IL8FD6V D6FIL8V
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Figure 2.2. hD6/mIL-8RLl constructs. The white square represents the FLAG Tag 
and the grey one represents the HA tag epitope. Thin black lines and white rectangles 
indicate hD6 sequence, thick black lines and filled rectangles indicate mIL8-RLl.
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D 6 H A D 6 V C C R 5 H A C C R 5 V C C R 5 H A D 6 V D 6 H A C C R 5 V
H in d lll
B g lll
fl “dlUUl “"IflJ
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- 1  N o tl N otl
H in d lll
\
m
M scl V .\
H H A  T a g
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—  hC C R 5
N otl N o tl
Figure 2.3. hCCR5/hD6 chimaeric constructs. hD6 is represented by thin black
lines and white rectangles; thick black lines and black rectangles indicate hCCR5.
Grey square represents HA tag.
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5nt6bd
PstI
E L o o p A E L o o p B
H in d lll HindM I
0 H A  T ag
— hD 6
— hC C R 5
\ B g lll X m al
H in d lll
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\
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Figure 2.4. Extracellular domain chim aeric constructs. hD6 is represented by thin
black lines and white rectangles; thick black lines and black rectangles indicate
hCCR5. Grey square represents HA tag.
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H in d lll
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M scl
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Not!
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H in d lll
N otl
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— hD 6
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Figure 2.5. Intracellu lar m utants. hD6 is represented by thin black lines and white
rectangles; thick black lines and black rectangles indicate hCCR5. Grey square
represents HA tag.
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hD6DRY.5
Hindlll
h D 6: DKYLEIVHA
* 4 t
R A
Notl
hD6KtoR
Hindlll
h D 6 : DKYLEIVHA
i
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Notl
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hD6EtoA
Hindlll
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hCC R 5: DRYLAWHA
41
K E
Notl
Figure 2.6. ‘DRY’ m utants. hD6 is represented by thin black lines and white
rectangles; thick black lines and black rectangles indicate hCCR5. Grey square
represents HA tag.
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Figure 2.7. Second generation of intracellular mutants. hD6 is represented by thin 
black lines and white rectangles; thick black lines and black rectangles indicate 
hCCR5. Underlined residues represent point mutations Grey square represents HA 
tag.
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Chapter 3- Results:
3.1. Identification of hD6’s binding domain(s)
Kobilka’s pioneering work (Kobilka et al., 1988) in protein engineering set the trend 
for construction of chimaeric receptors to study the relationship between structure 
and function in 7TM receptors. Chimaeric work has been facilitated by the degree of 
identity between members of the superfamily of G protein-coupled 7 TM domain 
receptors, with the greatest similarity occurring in the transmembrane domains, and 
the greatest divergence in the N-terminal extension and the three extracellular loops 
(Schwartz, 1994). Thus, it is generally believed that swapping domains of related 
receptors permits an analysis of the effect of primary sequence determinants on 
function whilst maintaining structure.
As discussed in Section 1.5 of the Introduction, in general, binding of a chemokine to 
a chemokine receptor is a two-step process: in the first step the N-loop region of the 
chemokine interacts with the N-terminal region of the receptor and in the second step 
the N-terminus of the chemokine binds to a second site on the receptor, presumably 
located between or close to the TM helices and extracellular loops, inducing a 
conformational change of the receptor and consequent signalling.
The aim of this section of the thesis was to identify specific regions and individual 
residues within hD6 that are responsible for the high surface expression, broad ligand 
binding promiscuity, and high affinity ligand binding apparent for this receptor. 
These data will contribute towards an understanding of the biochemistry of hD6 and
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will also allow comparisons to be made to other chemokine/receptor pairs, to and 
may provide useful information in the design of effective blocking reagents.
3.1.1. Generation of mlL-8RL1/hD6 chimaeric constructs
At the outset of this project only CCR1, CCR2, CCR3, CCR4, CCR5, D6, DARC, 
CXCR1 and CXCR2 had been well characterised and assigned cognate ligands. 
Phylogenic analysis suggested that this receptor lies between the C-C and C-X-C 
receptor subfamilies, being most closely related to CCR4 and two murine IL- 
8/CXCL8 receptor-like genes, mIL-8R and mIL-8RLl (the likely murine counterparts 
of CXCR1 and CXCR2, respectively) (Nibbs et al., 1997b).
Although, hD6 and mIL-8RLl share a fairly high degree of similarity at the amino 
acid level they are unlikely to show any overlap in ligand specificity as they belong to 
two separate and distinct chemokine receptor families, the CC and the CXC 
chemokine receptor families, respectively. hD6 binds to multiple CC chemokines 
(Nibbs et al., 1997a). mIL-8RLl was isolated in 1997 (R. Nibbs, pers. comm.) and 
ligands to this receptor are yet to be identified. At the onset of this project it was 
concerning that the generation of CC/CXC chimaeric receptor constructs could 
generate constructs with defects in folding and/or expression that would be less likely 
if the chimaeras were obtained by replacing domains of a CC receptor with the 
corresponding domains of another CC receptor. Nevertheless, chimaeric constructs of 
CXCR2 and CCR1 have been successfully generated to identify domains of CXCR2 
involved in high affinity binding and receptor activation (Ahuja et al., 1996). Given 
the promiscuous ligand binding profile of hD6 it was thought that chimaeras obtained 
by replacing domains of hD6 by the corresponding regions of a CXC receptor would
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generate information about the domain(s) of hD6 that are involved both in ligand 
promiscuity and high affinity ligand binding to hD6. Thus, initially the receptor mlL- 
8RL1 was chosen for the chimaeric studies with hD6 because it is the CXC receptor 
shown to be most closely related to hD6.
Since the N-terminus of chemokine receptors has been identified as an important 
ligand binding domain involved in specificity and activity for receptors (see Section 
1.5), it was decided to first investigate the importance of this domain in hD6.
3.1.1.1. FLAG tagged chimaeras
A PCR based cloning strategy (Section 2.2.2.14.1) was used to replace the N- 
terminal extension along with the first TM domain and part of the first intracellular 
loop of hD6 by the corresponding region of mIL8RL-l. The reciprocal substitution of 
hD6 in mIL8RL-l was also generated (Fig.3.1). A FLAG epitope tag (DYKDDDD) 
was inserted between the first two amino acids of each construct to allow 
determination of surface expression of these hybrid receptors. These cDNAs were 
cloned into the pcDNA.3 vector to allow strong CMV promoter driven expression of 
the chimaeric constructs in mammalian cells.
Constructs were stably transfected into CHO cells. This cell line has been previously 
shown to be capable of high surface expression of hD6 protein and many other 
chemokine receptors (Nibbs et al., 1997a; Nibbs et al., 1997b). Resistant cells were 
selected using 1.6mg/ml G418 and single cell clones were isolated, expanded and 
subsequently tested for their ability to show displaceable binding to PM2 (Section
2.2.4.4.1). PM2 is a variant of murine MIP-la/CCL3 that does not self-aggregate
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(Graham et al., 1994), labels well with radioactive iodine, and binds to hD6 with high 
affinity (Nibbs et al., 1997a; Nibbs et al., 1997b).
Fig 3.2 shows the equilibrium binding assays carried out with CHO cells expressing 
wild type hD6 (hD6.1), D6FD6V (FLAG tagged wild type hD6) clone C, and the two 
chimaeras D6FIL8V clone 4 and IL8FD6V clone 1. Many other clones of each 
construct were tested (data not shown) but they all behaved the same way as shown 
in Fig. 3.2. D6FD6V was shown to bind five-fold less 125I-PM2 when compared to 
the wild type protein, hD6.1 and none of the chimaeras was shown to be capable of 
binding to PM2. The lack of binding to PM2 by the chimaeras D6FIL8V and 
IL8FD6V could either indicate that these constructs were not being expressed on the 
surface of the cells or that the N-terminus is essential but not sufficient to promote 
binding of ligands to hD6. In order to distinguish between these two possibilities 
detection of surface expression (Section 2.2.4.1) of these receptors was attempted by 
flow cytometry (Fig.3.3), and by ELISA (not shown). Both approaches proved 
ineffective in detecting the FLAG epitope in FLAG tagged hD6 (D6FD6V clones A, 
B, C and D in Fig. 3.3.) and in any of the chimaeric constructs (data not shown) 
despite using several commercially available antibodies. This was peculiar bearing in 
mind that D6FD6V expressing cells were capable of binding to 125I-PM2 which 
therefore indicates that the protein must be expressed on the surface for the CHO 
cells. Western blot analysis (Fig. 3.4) showed detection of the FLAG tag protein by 
the same antibodies used in the FACS and in the ELISAs (M2 and M5 anti-FLAG 
antibodies). In Fig.3.4a the anti-FLAG antibody M2 was used to detect the FLAG tag 
epitope in extracts from untransfected cells (CHO), wild type untagged hD6 (hD6.1) 
and two clones of D6FD6V (clones B and C, D6FD6V.B and D6FD6V.C in figure).
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Four different sets of bands can be seen. Band 2 has the predicted size of the hD6 
tagged protein, band 3 is thought to be a degradation product of this protein and band 
4 is a nonspecific band seen in all four lanes. Band 1 is peculiar as it is larger that the 
expected size of hD6 and the identity of this product remains uncertain although it is 
possibly weakly present in the untransfected cells. In Fig.3.4b the anti-FLAG M5 
antibody was used to detect the FLAG epitope in extracts from the same cell lines as 
used in panel A. Panel B shows three sets of bands. Band 1 is the predicted size of 
the tagged protein and band 2 is presumed to be a degradation product of the protein. 
Band 3 is thought to be a nonspecific band since it is detected in all cell lines. The 
fact that degradation products are detected by Western blotting might suggest that the 
FLAG tagged proteins are somehow being degraded or not being expressed 
appropriately. However, it is also possible that the surface FLAG epitope is somehow 
masked when the mature protein is expressed on the surface of transfected cells. It 
should be noted that the M2 antibody binds to FLAG fusion proteins so this antibody 
can recognise the FLAG epitope anywhere in a given protein whereas the M5 anti- 
FLAG antibody only recognises Met-FLAG fusion proteins. These antibodies 
therefore recognise different epitopes and this seems to be the likely explanation for 
the different patterns of bands seen in the two Western blots shown.
In order to compare binding of tagged and untagged hD6 to PM2, full displacement 
binding curves were carried out for hD6.1, D6FD6V.A, D6FD6V.B, D6FD6V.C and 
D6FD6V.D (Fig. 3.5). These data show that cells expressing FLAG tagged hD6 
(D6FD6V.A, D6FD6V.B, D6FD6V.C and D6FD6V.D in Fig. 3.5) consistently had a 
higher binding affinity than untagged wild type hD6 (hD6.1 in figure) The IC50 for 
clones A, B, C and D was estimated to be approximately 4nM, 2nM, 1.2nM and
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InM, respectively, whereas the IC50 for hD6.1 was estimated to be approximately 
6nM. These results suggest that the FLAG increases the affinity of PM2 for hD6. 
This was a surprising result as the same tag has been used on other receptors with no 
affect on binding or signalling (Wong, 1997; Monteclaro, 1996). Perez and 
colleagues have however shown (Perez et al., 1993) that the very hydrophilic FLAG 
peptide sequence interferes with ligand binding to the formyl peptide receptor. 
Consequently, it seems that the hydrophilic eight amino acid stretch in the FLAG tag 
may either alter the positioning of D6’s domains involved in binding, or directly 
enhance interaction of hD6 with PM2 in such a fashion that a higher affinity to PM2 
is achieved. The highly acidic nature of the tag and the N-terminus may suggest that 
the latter in this case. For this reason along with the lack of detectable surface FLAG 
epitope, it was concluded that the FLAG tag was not a suitable epitope to tag 
receptors in the heterologous CHO cell line.
Finally, to eliminate the chance that these observations were the result of a cell-type 
specific phenomenon, the above constructs were stably transfected into COS-7 and 
HOS cell lines (Section 2.2.1.3.1 and 2.2.1.4.1). These cell lines were also previously 
shown to be capable of successfully expressing hD6 on their surface (R. Nibbs, pers. 
comm.). Unfortunately, the FLAG epitope was not detected by flow cytometry or by 
ELISA in either of the transfected cell lines (data not shown).
3.1.1.2. HA tagged receptors
To determine whether the increasing affinity to PM2 by FLAG tagged wild type hD6 
was due to either a particular characteristic of the FLAG epitope or simply due to its 
hydrophilic nature, HA (haemagglutinin) tagged constructs were generated. This HA
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tag (YPYDWDYAGPG) has been widely used for protein tagging, in particularly 
with receptors (Rucker et al., 1996).
Initially, all the FLAG epitope of D6FD6V was replaced by an HA tag epitope 
(Section 2.2.2.13.1.) to investigate not only the ability of this epitope to be detected 
on the surface of transfected cells, but also to determine whether this new epitope 
affected binding to PM2. The new construct was stably transfected into CHO cells 
and pools of clones as well as single cell clones were isolated. A full displacement 
curve (Fig. 3.6) showed that the HA tag does not affect binding since wild type hD6 
and tagged hD6 have the same IC50 (approximately 5.5nM). Immunocytochemistry 
(Fig.3.7a) and flow cytometry (Fig.3.7b) were carried out on a pool of transfectants 
stably expressing HA tagged wild type hD6 (D6HAD6V). Surface expression of 
D6HAD6V was now successfully detected by both of these methods. The HA tag 
was therefore proven to be an appropriate epitope to be used to successfully tag hD6 
in CHO cells. So, the FLAG tag in IL8FIL8V, D6FIL8V and IL8FD6V was replaced 
for a HA tag epitope (Fig.3.8) using a PCR based strategy as before. Pools of 
transfected CHO cells and single cell clones were derived for each construct and the 
presence of surface receptor was tested by immunocytochemistry (data not shown) 
and flow cytometry (Fig. 3.9). The cells were stained with the high affinity anti-HA 
antibody and their fluorescence compared to the background fluorescence of 
untransfected CHO cells. As it can be seen in Fig. 3.9, surface expression of all of the 
HA tagged constructs was now detectable, although surface expression of 
IL8HAIL8.2, IL8HAD6V.1 and especially of D6HAIL8V.2 was not particularly 
good. An equilibrium binding assay (Fig. 3.10) was then performed to detect binding 
of the HA tagged constructs to PM2. Binding to PM2 was not detected for pools of
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transfectants expressing IL8HAIL8V, D6HAIL8V or for IL8HAD6V. 
D6HAD6V.pool bound well to PM2, although it was reduced by 40% when 
compared to the stable cell line expressing wild type untagged hD6 (hD6.1 in 
Fig.3.10).
In conclusion, the HA tag is a much better epitope than the FLAG tag for these 
proteins since it does not affect ligand binding to the wild type tagged receptor and 
allows detection of this epitope in stable cell lines expressing HA tagged constructs. 
However, surface expression of IL8HAIL8V, D6HAIL8V and IL8HAD6V was 
shown to be poor in CHO cells and moreover the continuous passaging of these 
transfected cell lines was shown to lead to loss of receptor expression. In fact, cells 
analysed by flow cytometry over an eight-day interval show a totally different 
fluorescent pattern after staining with the anti-HA antibody, Y ll  (Fig. 3.11). These 
data suggest that surface expression is lost over time. This might be for a number of 
reasons such as cell survival or promoter silencing, but highlights a problem of the 
system used.
To determine whether the low detection of chimaeras on the surface was specific to 
CHO cells, the chimaeric constructs were subsequently stably transfected into HEK- 
293, COS-7 and HOS cells but detection of the HA epitope on the chimaeras was not 
observed in any of the cell lines, although surface expression of the wild type tagged 
receptor (D6HAD6V) was always detected (data not shown).
The poor surface expression of the chimaeric constructs was a disappointment and 
may be due to a number of reasons, such as incorrect folding. It was concerning that 
the time in culture from transfection, through the generation of stable lines, was
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selecting for cells that lacked good surface expression. The data with CHO cells 
expressing D6HAD6V indicates that this may be a legitimate concern. Thus, as a 
final attempt to get good surface expression of the chimaeras, a transient transfection 
system was employed.
3.1.1.3. Transient transfections:
The HA tagged constructs D6HAD6V, IL8HAIL8V, D6HAIL8V and IL8HAD6V 
were independently transiently co-transfected into CHO cells with the commercially 
available Kk plasmid to allow selection of transfected cells. This plasmid encodes for 
the truncated mouse MHC class I molecule of H-2Kk haplotype. Transfected cells 
were incubated with the anti-Kk antibody coupled to microbeads. After incubation, 
cells were applied to a column attached to a magnetic field. Once the magnetic field 
was removed, cells bound to the column were washed off to generate a sorted 
population (Section 2.2.4). Cell sorting was carried out 48 hours after transfection 
along with determination of surface expression (Section 2.2.5.2) and binding (Section
2.2.4.4.1). Fig.3.12 shows a representative flow cytometry profile of the sorted cells 
where it can be seen that the majority (67%) of purified cells are now Kk positive. 
This approach proved very effective in generating an enriched cell population, 
however, the 20-40% recovery of the transfected cells made it technically difficult to 
produce large number of cells for full displacement binding curves.
Flow cytometry after immunofluorescent staining with anti-HA antibody showed that 
only the D6HAD6V is expressed well on the surface of these transiently transfected 
CHO cells (Fig. 3.13a). PM2 was shown to bind to cells transiently expressing 
D6HAD6V at levels similar to those registered for D6HAD6V stably transfected into
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CHO cells (Fig. 3.13b). In accordance with their lack of surface expression, 
constructs IL8HAIL8V, D6HAIL6V and IL8HAD6V did not bind to PM2 (Fig. 
3.13b). Kk plasmid expressing cells did not bind to radiolabelled PM2 at levels 
higher than untransfected cells (data not shown).
Taken together these results suggest that the HA tagged constructs IL8HAIL8V, 
D6HAIL8V and IL8HAD6V are poorly assembled on the cell surface. These 
chimaeras might be unstable and only be expressed at low levels in these cell lines, 
which could only be determined by Western blotting (not performed), but either way 
these constructs were not suitable to investigate hD6’s properties that form the aim of 
this project. The poor surface expression of the chimaeric constructs, D6HAIL8V and 
IL8HAD6V, might be due to the fact that these constructs were obtained by fusing 
domains from chemokine receptors that belong to different families. However, 
surface expression of tagged mIL-8RLl could also not be demonstrated by flow 
cytometry, immunocytochemistry or by ELISA, showing that it was not expressed on 
the surface of these heterologous cell lines despite its probable ability of being 
naturally expressed on the surface of other cells. It has been well documented that 
there is huge variability in the surface expression of different chemokine receptors in 
transfected cell lines. hD6 is known to be highly expressed on the surface of 
transfected cells to an extent that clones isolated in this laboratory were such high 
expressors that it was difficult to do displacement binding curves with these clones 
(R. Nibbs, pers. comm.). In contrast, for example, the chemokine receptor CCR3 is 
known to be difficult to express on the surface of heterologous cell lines (Dairaghi et 
al., 1997); mIL-8RLl seems to fall into the same category as CCR3.
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Whilst the first series of constructs gave little information about hD6 binding 
domains they did improve many technical aspects of the project. First, they revealed 
the unsuitability of FLAG tagged constructs and presented the FLA sequence as a 
better epitope. Second, they suggested that chimaeras between receptors for CC and 
CXC chemokine receptors are unlikely to be of use. Third, a transient transfection 
protocol was developed for rapid analysis of chimaeras. Thus, chimaeras between 
hD6 and another chemokine receptor were constructed.
3.1.2. Epitope tagged chimaeras of hCCR5 and hD6
hCCR5 is a CC chemokine receptor that shares 30-37% identity with hD6. This CC 
chemokine receptor binds to MIP-la/CCL3, MIP-1{3/CCL4 and RANTES/CCL5 
with high affinity [Combadiere et al, 1996; Raport et al, 1996) and weakly to MCP- 
2/CCL8 (Nibbs et al., 1997b). In addition, hCCR5 has been reported to bind to MCP- 
3/CCL7, MCP-4/CCL13, MCP-1/CCL2 and Eotaxin/CCLl 1 (Blanpain et al, 1999), 
however in this research group binding has only been demonstrated for MIP- 
la/CCL3, MIP-1P/CCL4, RANTES/CCL5 and MCP-2/CCL8 (R. Nibbs, 
pers.comm.). The activity of these other ligands on hCCR5 remains controversial.
hD6 also binds to MIP-la/CCL3, RANTES/CCL5, MIP-1|3/CCL4 and MCP- 
2/CCL8 although with much higher affinity than hCCR5 (Nibbs et al., 1997a). In 
addition to these ligands, hD6 also binds to MCP-1/CCL2, MCP-3/CCL7, MCP- 
4/CCL13, MCP-5 with high affinity, and to Eotaxin/CCLll and HCC-1/CCL14 with 
low affinity (Nibbs et al., 1997a). All hD6 ligands have a proline residue at position 2 
and this, at least in the context of MIP-la/CCL3, seems important for binding 
although not all p-chemokines with a proline residue at this position bind to hCCR5.
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Similarly, again in the context of MIP-la/CCL3 hCCR5 has been shown to be able 
to bind to MIP-laP/CCL3 (hM IP-la isoform that bears a Pro residue at position 
two) with higher affinity than it binds to MIP-laS/CCL3 (commercially available 
hMIP-la/CCL3, an isoform of MIP-la/CCL3 that has a Ser residue at position 2) 
(Nibbs et al., 1999). These data suggest that there may be some similar ligand 
requirements by hCCR5 and hD6. So, given that hCCR5 is not only well expressed 
on the surface of heterologous cell lines and shares sequence identity with hD6, plus 
the fact that some of the hD6 ligands do not bind to hCCR5, and that those that bind 
to both of these receptors have a higher affinity for hD6, it was decided to construct 
chimaeras of hD6 and hCCR5. These new constructs were expected to be expressed 
at higher levels on the surface of transfected heterologous cell lines and to generate 
information on the binding promiscuity and high affinity ligand binding of hD6.
hCCR5/hD6 chimaeric constructs (Fig. 3.14) were generated by overlap extension 
PCR (Section 2.2.2.15.) and they bear an HA tag at the N-terminus. Construct 
CCR5HACCR5V encodes for HA tagged wild type hCCR5. CCR5HAD6V 
represents the N-terminal portion (including the first TM domain and part of the first 
intracellular loop) of HA tagged hCCR5 cloned into the corresponding region of 
hD6. Conversely, D6HACCR5V is the reciprocal chimaera of CCR5HAD6V. These 
constructs were transiently co-transfected with the Kk plasmid into CHO cells. Once 
sorted, the cells were tested for surface receptor expression and for their capacity to 
bind PM2 (Fig. 3.15).
D6HAD6V and CCR5HACCR5V were expressed at similar levels on the surface of 
sorted CHO cells, whereas sorted cells expressing CCR5HAD6V or D6HACCR5V
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showed much lower levels of detectable surface protein (Fig. 3.15a). Displacement of 
125I-PM2 by PM2 (Fig. 3.15b) indicates that wild type HA tagged hD6 (D6HAD6V) 
is capable of PM2 binding. No displaceable binding was registered for 
CCR5HACCR5V, CCR5HAD6V or D6HACCR5V. This data was not only 
disappointing but also surprising since binding of PM2 to HA tagged wild type 
hCCR5 was not detected. hCCR5 has lower affinity for PM2 when expressed in 
CHO cells (Nibbs et al., 1999) and these results suggest that despite abundant surface 
expression of hCCR5, the assay is not sufficiently sensitive to detect robust binding 
by this receptor. Since the surface expression of the chimaeric constructs is even 
lower than the surface expression of hCCR5, to which no displaceable binding is 
observed, the absence of binding to PM2 to these constructs cannot be confidently 
attributed to the changes made.
In an attempt to increase the sensitivity of this assay the same experiment was carried 
out but this time the binding assay was performed with MIP-laP/CCL3 which has 
higher affinity than murine MIP-la/CCL3 (and to PM2) for hCCR5. Constructs were 
again transiently transfected into CHO cells and subsequently a binding assay in 
equilibrium and flow cytometry were performed this time using unsorted 
populations. In Fig. 3.16a it can be seen that surface expression is detected even 
without sorting and that in this case all constructs were expressed roughly at the same 
levels. After staining with the anti-HA antibody 33% of D6HAD6V, 24% of 
CCR5HACCR5V, 21.5% of D6HACCR5V and 25% of CCR5HAD6V expressing 
cells were positively stained for the HA epitope. The binding assay shown in Fig. 
3.16b shows that cells transfected with D6HAD6V show good displaceable binding 
of MIP-laP/CCL3. CCR5HACCR5V shows a much lower amount of binding to 125I-
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M IP-laP but this is above the background seen with untransfected CHO cells and 
can be competed off with excess unlabeled MIP-laP. The two chimaeric constructs 
showed little if any detectable binding. Although the surface expression levels of the 
two chimaeras is lower than D6HAD6V, this set of data allows to more confidently 
conclude that the region replaced by hCCR5 sequences in CCR5HAD6V is important 
for high affinity ligand binding of hD6 to MIP-laP/CCL3. This domain does not 
appear sufficient to impart hD6-like binding properties to hCCR5 in the 
D6HACCR5V chimaera. However, it proved extremely difficult to repeat these 
experiments to confirm these conclusions as consistently lower levels of chimaeric 
receptor expression compared to D6HAD6V wTere achieved, both in the transient 
CHO cell expression system and in stably transfected CHO and HOS cells (not 
shown).
The inability to demonstrate significant binding to the ligands could be explained by 
the fact that the chimaeric constructs tested comprise not only the extracellular N- 
terminus portion but also the whole of the first TM domain and half of the first 
intracellular loop of each receptor (refer to Fig.3.14 for cartoon diagram of 
constructs) which will potentially interfere with the overall structure of the receptor 
and may alter positioning of the highly conserved Cys residues that are known to be 
involved in stabilizing the conformation of these G protein-coupled receptors. This 
may explain why the chimaeras are consistently expressed at such low levels in these 
experiments, and also why they do not bind ligand. In short, one cannot be certain 
that the binding differences observed are a direct consequence of a primary 
determinant of hD6. Overall, the experiments to this point led to conclusion that 
large changes incorporated into the chimaera not only jeopardise adequate surface
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expression but also make it difficult to distinguish the effects of primary sequence on 
ligand binding, from gross conformation change brought about by the domains 
changed. It was therefore decided that more subtle changes should be introduced.
3.1.3. Small domain swaps
The first new construct to be generated was 5nt6bd. This construct was obtained by 
replacing the N-terminal portion (up to the first cysteine residue) of D6HAD6V by 
the corresponding portion of hCCR5 (Fig. 3.17a). This construct was transiently 
transfected into CHO cells (Section 2.2.1.1.2); its surface expression and its ability to 
bind to PM2 was determined 48 hours after transfection. Flow cytometry after 
immunofluorescence staining with the anti-HA HA. 11 antibody showed that 
D6HAD6V and CCR5HACCR5V have roughly the same levels of surface expression 
(37% and 30% positively stained cells, respectively) and 5nt6bd is expressed at 
slightly lower levels with 27.3% of the transfected cells staining positive for the HA 
tag. Fig. 3.17b shows that, as usual, cells transiently transfected with D6HAD6V 
bind to 125I-PM2 virtually as well as hD6.1 cells. CCR5HACCR5V binding to 125I- 
PM2 in the absence of unlabeled ligand is above background, however in the 
presence of unlabelled competitor not all the labelled ligand was competed off on this 
occasion (Fig. 3.17b). Nevertheless, Fig. 3.17b clearly shows that 5nt6bd binds well 
to 125I-PM2, and at significantly higher levels than CCR5HACCR5V implying that 
5nt6bd has a higher affinity for this ligand than CCR5HACCR5V. Also, binding of 
5nt6bd to PM2 is significantly less than that observed with D6HAD6V, although the 
chimaera was expressed at lower levels than both HA tagged wild type receptors. It 
can therefore be concluded that the N-terminus of hD6 is not essential for binding to
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PM2, and suggests that replacing it with the hCCR5 N-terminus may reduce the 
affinity of the receptor for this ligand. Moreover, the fact that the levels of surface 
expression of this new chimaera were consistently high supports the hypothesis that 
the large domain swaps previously used might affect folding of the mature protein 
and prevent PM2 binding to these chimaeras by affecting the overall structure of the 
receptor.
These were the first results that consistently showed good surface expression and 
binding by a chimaeric receptor of hCCR5 and hD6. It was therefore decided to 
embark on more detailed analysis of the role of hD6 extracellular domains by 
generating smaller domain swaps of hD6 by the corresponding domains of hCCR5. 
To this end, three other hD6/hCCR5 chimaeric constructs: ExtLoopA, ExtLoopB and 
ExtLoopC were generated. In these constructs the first, second and third extracellular 
loops, respectively, of hD6 were independently replaced by the corresponding 
regions of hCCR5 (Fig. 3.18). As before, these constructs were generated by overlap 
extension PCR (Section 2.2.2.10 and 2.2.2.15).
However, at this stage another significant technical problem was encountered with 
the transient transfection of CHO cells. Specifically, it was found that there was 
highly variable transfection efficiency of these cells that made experimentation 
difficult. Thus, attempts were made to improve this situation by selecting an 
alternative cell line. Transient transfection of constructs into COS-7 cells proved to 
have higher transfection efficiency and to be much more reproducible than the CHO 
system. For this reason, constructs were transiently transfected into COS-7 cells as 
described in Section 2.2.1.3.7 and cell surface expression for each tagged construct
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was assessed after 48 hours without sorting. Surface expression of wild type and 
mutant receptors tagged with HA at their N-termini was detected by flow cytometry 
after immunofluorescence staining with HA. 11 (Fig. 3.19). The graph in Fig. 3.19 
shows that mutants ExtLoopC and 5nt6bd have consistently higher surface 
expression than D6HAD6V. Expression of CCR5HACCR5V, ExtLoopA and 
ExtLoopB is not significantly different from expression of D6HAD6V on the surface 
of transiently transfected COS-7 cells. The fact that these constructs were expressed 
at roughly the same levels on the surface of COS-7 cells would facilitate the 
comparison of ligand binding profiles for each of these receptors. Without full 
displacement curves being carried out one cannot calculate binding affinities, 
however, if the receptors are expressed at similar levels one can get an indication of 
affinity relative to the wild type receptors.
Using the reproducible COS-7 cells expression system, the HA tag, and the small 
domain changes it was now possible to perform a detailed analysis of binding of the 
chimaeras to a selected spectrum of hD6 ligands.
3.1.4. N-terminal domain of hD6
CCR5HACCR5V, D6HAD6V and 5nt6bd were independently transiently transfected 
into COS-7 cells (Section 2.2.1.1.2). Surface expression of each receptor was 
assessed after 48 hours by flow cytometry after immunofluorescence staining with 
the anti-HA antibody HA. 11. From the flow cytometry profiles shown in Fig. 3.20a it 
can be seen that all constructs were expressed at similar levels on the surface of the 
transiently transfected COS-7 cells. These HA tagged receptor expressing cells were
19Ssubsequently tested for their ability to show displaceable binding to I-PM2 using
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an array of hD6 ligands (Fig. 3.20b). D6HAD6V, as expected, binds to 125I-PM2 and 
this binding can be effectively competed away in the presence of an excess of 
unlabelled PM2, MCP-1/CCL2, Eotaxin/CCLll, MCP-2/CCL8 or RANTES/CCL5. 
Again, no binding to 125I-PM2 was observed for CCR5HACCR5V although this 
construct was expressed at the same levels of D6HAD6V suggesting that the reduced 
affinity this receptor has for PM2 puts it below the level of detection of this assay. As 
before, construct 5nt6bd was shown to be capable of binding to PM2 and this could 
be displaced by the presence of an excess unlabeled PM2, MCP-1/CCL2, 
Eotaxin/CCLll and MCP-2/CCL8. It is likely that 5nt6bd has a higher affinity to 
PM2 than CCR5HACCR5V since they are both expressed at the same levels in these 
cells but only binding of 5nt6bd to PM2 is detected. This displacement data shows 
that 5nt6bd still retains the promiscuous binding profile characteristic of hD6 but 
intriguingly RANTES/CCL5 seems no longer able to displace 125I-PM2 from this
receptor. To further investigate this chimera, alternative labelled chemokines were
1employed. A binding assay in equilibrium was performed where 2nM of I-MCP- 
4/CCL13 were displaced by 0.5\iM of unlabeled MCP-4/CCL13. MCP-4/CCL13 
chemokine was chosen because it does not bind to hCCR5. Fig. 3.21 shows that 
5nt6bd binds to MCP-4/CCL13 at levels similar to that of D6HAD6V. More 
importantly, in an attempt to determine whether RANTES/CCL5 bound to 5nt6bd, 
another binding assay was carried out using 125I-RANTES/CCL5 (2nM) (Fig. 3.22). 
As it can be observed in the graph, replacement of the N-terminus of hD6 by the 
corresponding region of hCCR5 leads to a 40% reduction in binding to 
RANTES/CCL5 when compared to 100% of D6HAD6V but it is notable that even at 
low nanomolar concentrations of labelled RANTES/CCL5, binding to 5nt6bd is
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easily detected. CCR5HACCR5V binding to RANTES/CCL5 was not detected in 
this assay.
Taken together these data suggest that substitution of the N-terminus of hD6 with the 
corresponding domain of hCCR5 creates a receptor that has an affinity for PM2 like 
wild type hD6, and that can still bind to all ligands recognised by hD6. Thus, other 
domains of hD6 must be responsible for binding promiscuity. However, the inability 
of RANTES/CCL5 to displace radiolabelled PM2 suggests that RANTES/CCL5 and 
PM2 bind different domains of the 5nt6bd receptor, in contrast to the wild type 
receptor where these sites overlap. Binding of two different chemokines to different 
sites in the same receptor is not novel and has been reported before for DL-8/CXCL8 
and GROa/CXCLl on CXCR1/CXCR2 chimaeric receptors (Ahuja et al., 1996) and 
for MCP-1/CCL2 and MIP-la/CCL3 on chimaeric receptors (Monteclaro et al, 
1996). It is possible that inclusion of this N-terminus of hCCR5 (a receptor able to 
bind RANTES/CCL5) in this chimaera preferentially attracts RANTES/CCL5 to bind 
to this domain away from the site it usually binds to in wild type hD6 that overlaps 
with the PM2 binding site. In this way, 5nt6bd could accommodate a molecule of 
RANTES/CCL5 and another of PM2 on its surface without competition.
3.1.5. The first extracellular loop of hD6 plays a critical role in 
PM2 binding
The chimaeric construct ExtLoopA comprises wild type hD6 where the first 
extracellular loop (the extracellular domain of hD6 most strongly conserved between 
species), has been replaced by the corresponding region of hCCR5 (Fig.3.23a). This
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construct was obtained by overlap extension PCR (Sections 2.2.2.10 and 2.2.2.15), 
and includes an HA tag at the N-terminus.
The ExtLoopA HA tagged construct along with D6HAD6V and CCR5HACCR5V 
were transiently transfected into COS-7 cells and after 48 hours flow cytometry was 
performed in these cells. The flow cytometry profile (Fig. 3.23a) indicates that 
ExtLoopA has the same surface expression as D6HAD6V. Binding assays were 
performed on the transfected cells and ExtLoopA showed no detectable PM2 binding
1 9Sabove background (Fig. 3.23b). Not surprisingly, no displacement of I-PM2 was 
registered in the presence of excess unlabeled MCP-1/CCL2. These data show that 
when the first extracellular loop of hD6 is replaced by the corresponding domain of 
hCCR5, the mutant created can longer behave like hD6. However, the fact that 
binding of PM2 to CCR5HACCR5V was not detected by this assay could imply that 
binding of PM2 to ExtLoopA is not completely lost but is below the detection levels 
of this assay.
To examine if other ligands were similarly affected by alterations in the first 
extracellular loop, 125I -MCP-4/CCL13 and 125I-RANTES/CCL5 were used. As for 
PM2, binding of 125I-MCP-4 to ExtLoopA was below the detection levels of the 
assay (Fig.3.24). Similarly, binding to 125I-RANTES/CCL5 by ExtLoopA was not 
observed (Fig. 3.25). It seems, therefore that the first extracellular loop of hD6 is 
important for high affinity binding to RANTES/CCL5 and MCP-4/CCL13. One 
cannot rule out the possibility that construct ExtLoopA, like construct 
CCR5HACCR5V, has a low affinity to RANTES/CCL5 and MCP-4/CCL13 that is
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below the detection levels of this assay. Nonetheless, these data show that the first 
extracellular loop of hD6 is important for ligand binding.
3.1.6. The second extracellular loop
ExtLoopB is an HA tagged chimaeric receptor that comprises the second 
extracellular loop of hCCR5 cloned into the corresponding region of hD6 
(Fig.3.26a). This construct was generated by overlap extension PCR and 
subsequently transiently transfected into COS-7 cells. Surface expression of this 
construct was assessed by flow cytometry after immunofluorescence staining with the 
HA. 11 antibody. Fig. 3.26a shows that ExtLoopB is expressed on the surface of 
COS-7 cells at the same level as D6HAD6V. Despite the same levels of surface 
expression ExtLoopB only exhibits 50% of the binding to 125I-PM2 seen with 
D6HAD6V. Binding of 125I-PM2 to ExtLoopB could be displaced (Fig. 3.26b) by 
addition of an excess (0.5pM) of unlabelled PM2, MCP-1/CCL2, MCP-2/CCL8 or 
RANTES/CCL5, but not by Eotaxin/CCLll.
Binding of ExtLoopB to radiolabelled MCP-4/CCL13 (Fig. 3.27) and to radiolabelled 
RANTES/CCL5 (Fig. 3.28) was also shown to be reduced by over 60% when 
compared to D6HAD6V binding.
Taken together these data suggest that the second extracellular loop of hD6 is 
required for high affinity binding to PM2, MCP-4/CCL13 and RANTES/CCL5 as 
binding to these labelled ligands is reduced in the chimaera. Eotaxin/CCLll did not 
significantly displace PM2 binding. This may be because PM2 and Eotaxin/CCLll 
do not compete for the same binding site in this mutant. An alternative and probably
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more likely interpretation is that it could simply indicate that PM2 displacement by 
Eotaxin/CCLll is not detected because binding to PM2 is reduced in the first place. 
More detailed analysis would be required to distinguish between these possibilities.
3.1.7. The third extracellular loop of hD6
ExtLoopC is an HA tagged chimaeric construct that bears the third extracellular loop 
of hCCR5 in place of the corresponding loop of hD6 (Fig. 3.29a). This construct was 
again generated by overlap extension PCR and its ability to be expressed on the 
surface of transiently transfected COS-7 cells was assayed by flow cytometry using 
the HA. 11 antibody as before. As it can be seen in Fig. 3.29a, the construct 
ExtLoopC is expressed on the surface of COS-7 cells at roughly the same level of 
D6HAD6V. Binding data (Fig. 3.29b) shows that this new chimaeric mutant still 
retains its ability to bind to 125I-PM2 although at a lesser extent (approximately 70% 
less) than D6HAD6V. Data from equilibrium binding assay presented in Fig.3.29b 
shows that 125I-PM2 binding can only be displaced by an excess of unlabeled PM2 or 
MCP-2/CCL8. None of the other chemokines tested displaced binding of 125I-PM2 to 
ExtLoopC. The lack of detectable displacement could be due to the fact that the 
ability of PM2 to bind to this chimaeric receptor is reduced to an extent that small 
changes in displacement might not be detected as by this assay.
To test the ability of RANTES/CCL5 and MCP-4/CCL13 to bind to ExtLoopC two 
separate binding assays in equilibrium were performed. (Fig.3.30 and Fig.3.31). This 
chimaeric construct was shown to still be capable of binding to MCP-4/CCL13 and 
RANTES/CCL5 albeit at lower levels than D6HAD6V.
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As with ExtLoopB, it appears as though alteration of the third extracellular loop 
reduced the affinity of hD6 for ligands, but the promiscuity appears likely to be 
retained. Thus, in summary, the data suggests that the first extracellular loop is the 
main determinant of ligand binding in the hD6 molecule, with the second and third 
extracellular loops also contributing to ligand recognition. This will be further 
discussed in Chapter 4.
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Figure 3.1. Schematic diagram of FLAG tagged wild-type and chimaeric 
receptors. White rectangles and thin black lines indicate hD6 sequence. Black 
rectangles and thick black lines represent m IL-8RLl. The filled black square at the 
N-terminus of each construct represents the FLAG tag epitope. The transmembrane 
domains are represented by rectangles, and the N-terminus, the intracellular and 
extracellular loops and cytoplasmic tail are shown as solid lines. The chimaeric 
receptors were generated by PCR as described in Section 2.2.2.14.1.
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Binding of 125I-PM2 to FLAG tagged 
chimaeras
120
CHO hD6.1 D6FD6V.C IL8FD6V.1 D6FIL8V.4
Figure 3.2. Binding of l2?I-PM2 to wild type and chimaeric receptors.
125 • •Displacement of “ I-PM2 binding in the presence of unlabeled PM2 by untransfected 
CHO cells (CHO) and by CHO cells expressing the wild type hD6 receptor (hD6.1), 
the FLAG tagged wild type hD6 (D6HAD6V.C) as well as the chimaeras 
(IL8FD6V.1 and D6FIL8V.4) is shown. 1E5 cells were incubated at room 
temperature in 0.6nM " I-PM2 and 120nM unlabeled PM2 or equivalent volumes of 
PBS for 90 minutes. Cells were then washed three times with ice cold PBS and
• 125 •subsequently lysed in 0.1% SDS. The remaining “ I-PM2 in the lysate was counted 
for one minute in a gamma counter as before. Each point was carried out in triplicate, 
the average taken and then converted into a percentage of binding relative to hD6.1
125 .
binding to “ I-PM2 in the absence of competitor. Graph shows the average of three 
experiments carried out in triplicate. Error bars represent standard deviation.
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Figure 3.3. Expression of wild type FLAG tagged hD6 in CHO cells. Stably 
transfected CHO cells were examined for expression of the FLAG tag epitope by 
flow cytometry following incubation with the FLAG monoclonal antibody M2 and a 
FFTC-conjugated secondary antibody. Untagged wild type hD6 is denoted in grey; A, 
B, C and D are clones of D6FD6V and are represented by a thick black line. 
Approximately 5E5 cells were harvested, incubated on ice for 30 min. with 1/100 
dilution of the M2-anti FLAG primary antibody. Cells were subsequently washed 
with FACS buffer and further incubated with a 1/32 dilution of anti-mouse FITC- 
coupled antibody for 30 min. on ice. Cells were then washed with FACS buffer and 
resuspended in a final volume of 400pi of the same buffer. Fluorescence of each 
sample was determined by a FACS and compared to the background fluorescence of 
untagged cells (hD6.1). Profiles shown are representative of seven different 
experiments carried out in triplicate. The appropriate isotype controls were carried 
out were appropriate.
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Flow cytometry profiles of FLAG tagged
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Figure 3.4. Detection of the FLAG tag epitope by Western blotting analysis.
Whole cell extracts of untransfected CHO cells (CHO) as well as stably transfected 
CHO cells expressing FLAG tagged (D6FD6V.B and D6FD6V.C) and untagged wild 
type hD6 (hD6.1) were isolated from 1E6 cells, separated on a 10% SDS- 
polyacrylamide gel, transferred to nitrocellulose and probed with the M2 anti-FLAG 
antibody (panel A) or the M5 anti-FLAG antibody (panel B). Arrow indicates 
predicted size of hD6 tagged protein. See text for discussion of detected bands.
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FLAG tagged hD6 has higher affinity to 
PM2 than wild type hD6
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I 2SFigure 3.5. FLAG tag constructs have higher affinity to I-PM2 than wild-type
untagged hD6. Displacement of 12 I-PM2 by increasing amounts of unlabeled PM2
from CHO cells expressing wild type hD6 (hD6.1) as well as different clones of
FLAG tagged hD6: D6FD6V. A, D6FD6V.B, D6FD6V.C, D6FD6V.D. 1E5 cells
125 /  \were seeded overnight and then tested for their ability to displace I-PM2 (0.6nM)
with increasing amounts of unlabeled PM2. After a 90 min. incubation, cells were
125lysed with 0.1% SDS and the remaining I-PM2 in the lysate counted for 1 min.
Each point was done in triplicate, the average taken and converted into a percentage
of the binding observed in the absence of unlabelled competitor chemokine. The 
estimated I C 5 0  for the FLAG tagged clones is 4nM, 2nM, 1.2nM and InM , for clones 
A, B, C and D, respectively. hD6.1 I C 5 0  is estimated to be approximately 6nM.
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The HA tag epitope does not affect PM2 
binding
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Figure 3.6. HA tagged constructs have the same binding affinity to l25I-PM2 as 
wild type hD6. Stably transfected CHO cells expressing HA tagged wild type hD6 
(D6HAD6V.6 and D6HAD6V.4) have the same binding affinity to l25I-PM2 as CHO 
cells stably expressing wild type hD6 (hD6.1). 1E5 cells were seeded overnight and 
then tested for their ability to displace 12 I-PM2 (0.6nM) in the presence of increasing 
amounts of unlabeled PM2. After a 90 min. incubation at room temperature, cells 
were lysed with 0.1% SDS and the remaining 12 I-PM2 in the lysate counted for 1 
min. Each point was done in triplicate, the average taken and converted into a 
percentage of binding observed in the absence of unlabelled competitor chemokine. 
The estimated I C 5 0  for all cell lines is approximately 7nM.
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Figure 3.7. Surface expression of HA tagged wild type hD6. A. Pools of CHO 
cells stably expressing HA tagged wild type hD6 (D6HAD6V.pool) were stained 
with high affinity anti-HA antibody and subsequently with anti-mouse FITC 
secondary antibody. Untransfected CHO cells (CHO) showed little cross-reaction 
with this antibody. Cells were stained while adherent to permanox chamber slides 
and after immunostaining were visualized in a Biorad MRC 600 confocal 
microscope. Data shown is representative of three experiments carried out 
independently from each other. B. Approximately 5E5 cells were harvested and 
subsequently immunostained with the high affinity anti-HA and the FITC-coupled 
anti-mouse secondary antibody. Fluorescence of each sample was analysed by a 
FACS and compared to the background fluorescence of the untransfected cells 
(CHO, in grey). Incubation with the secondary antibody alone or with the appropriate 
isotype control showed no increase in fluorescence of the samples in comparison to 
untransfected cells. FACS profile shown is representative of four experiments 
independently performed.
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HA tagged IL-8RL1/D6 chimaeric 
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Figure 3.8. Schematic diagram of HA tagged wild-type and chimaeric receptors.
White rectangles and thin black lines indicate hD6 receptor. The mIL8Rl-l is 
represented by black rectangles and thick black lines. The white square indicate the 
HA tag epitope cloned at the N-terminus of each construct. The transmembrane 
domains are represented by rectangles, the N-terminus, the intracellular and 
extracellular loops as well as the cytoplasmic tail are shown as solid lines. Chimaeric 
receptors were generated by overlap extension PCR as described in Section 2.2.2.9.
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Flow cytometry profiles of D6/IL-8RL1 HA 
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Figure 3.9. HA tag detection by flow cytometry. Surface expression of HA tagged 
wild type hD6 (D6HAD6V.4), HA tagged wild type mIL-8RLl (IL8HAIL8V) as well 
as of the HA tagged constructs D6HAIL8V and IL8HAD6V was determined by flow 
cytometry after immunofluorescence staining with the anti-HA high affinity primary 
antibody and the anti-mouse FITC coupled secondary antibody. Fluorescence of each 
transfected cell line (black thick lines) was compared to the background fluorescence 
of untransfected cells, CHO cells (in grey). Isotype control carried out where 
appropriate. FACS profiles are representative of three experiments carried out 
separately.
160
IL-8RL1/D6 HA tagged chimaeras do not 
bind 125I-PM2
120
Figure 3.10. Binding assay in equilibrium. Stably transfected pools of CHO cells 
expressing wild type hD6 (hD6.1), HA tagged wild type hD6 (D6HAD6V.pool), HA 
tagged wild type mIL8RL-l (IL8HAIL8V.pool) or the HA tagged chimaeras 
IL8HAD6V.pool and D6HAIL8V.pool were tested for their ability to displace l25I- 
PM2 binding in the presence of unlabeled PM2. 1E5 cells were incubated at room 
temperature with 0.6nM 1_ I-PM2 and 120nM of unlabeled PM2 or equivalent 
volumes of PBS. Each point was done in triplicate, the average taken and then 
converted in a percentage relative to hD6.1 binding to 12 I-PM2 in the absence of 
unlabeled PM2 (set arbitrarily at 100%). Data shown is the average of three 
experiments carried out in triplicate.
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HA tagged hD6 expressing stable cell lines 
lose expression over time
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Figure 3.11 HA tagged hD6 stable cell lines lose expression through time. A
clonal population of CHO cells stably expressing HA tagged wild type hD6 
(D6HAD6V.4) were assessed for their surface expression by flow cytometry. 
Untransfected CHO cells (CHO, in grey) and D6HAD6V.4 (thick black line) 
expressing CHO cells were stained with the anti-HA Y l l  antibody (2pg/m l) on Day 
1 and Day 9. Fluorescence of D6HAD6V.4 expressing cells stained with anti-HA 
antibody decreases with time in culture. The appropriate isotype controls were carried 
out as appropriate.
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Enrichment of transfected cells using the 
MACS system
Figure 3.12. Detection of a Kk sorted population by flow cytometry. CHO cells 
transiently transfected with the Kk cDNA were incubated with the anti-Kk antibody 
coupled to magnetic microbeads and were subsequently sorted down a magnetic 
column (Sorted Kk). 5E5 sorted Kk and 5E5 unsorted cells (these are cells transiently 
transfected with the Kk cDNA that have not been sorted) were both stained with the 
FITC-coupled anti-Kk antibody. Fluorescence of CHO cells transiently expressing 
the Kk protein was compared to the fluorescence of unsorted CHO cells transiently 
transfected with the Kk cDNA. This graph shows a representative flow cytometry 
profile of the sorted cells. The same number of cells was analysed by flow cytometry 
for both samples, however due to sensitivity settings on the flow cytometer, less cells 
are seen for the unsorted population. Data shown are representative of five 
independent experiments.
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3.13. Surface expression and binding profiles for the sorted cell lines. A.
Transiently transfected CHO cells expressing the Kk molecule or co-expressing Kk 
and the HA tagged constructs D6HAD6V, IL8HAIL8V, D6HAIL8V and 
IL8HAD6V, were incubated with the anti-Kk microbead-coupled antibody for 15 
min. at room temperature. After incubation, cells were sorted down a magnetic 
column and Kk positive cells were subsequently stained with the anti-HA, HA. 11, 
antibody. Flow cytometry compared fluorescence of each sorted population (black 
line) to the background fluorescence given by sorted CHO cells transiently 
expressing the Kk protein (Sorted Kk, in grey), that does not cross-react with HA. 11. 
Profiles shown are representative of three independent experiments. B. Panel B 
shows a binding assay in equilibrium where the transiently transfected CHO cells co­
expressing the Kk plasmid and the HA tagged wild type hD6 (D6HAD6V), HA 
tagged wild type mIL-8RLl (IL8HAIL8V) as well as the chimaeras D6HAIL8V and 
IL8HAD6V were tested for their ability to displace 125I-PM2 with unlabeled PM2. In 
brief, 1E5 cells were incubated with 0.6nM 125I-PM2 and 120nM unlabeled PM2 or 
equivalent volumes of PBS, for 90 minutes at room temperature. Cells were
• 125subsequently washed with ice cold PBS and the remaining activity of I-PM2 was 
counted for 1 minute. Each point was done in triplicate, the average taken and then 
converted into a percentage relative to hD6.1 binding in the absence of competitor 
(set arbitrarily at 100%). Data shown as the average of three separate experiments 
carried out in triplicate. hD6.1 is a stable cell line expressing untagged wild type 
hD6. Untransfected CHO cells (CHO) showed little background binding. Error bars 
represent standard deviation.
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Surface expression and binding analysis 
of MACS sorted mlL-8RL-1/hD6 chimaeric
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hD6/hCCR5 HA tagged chimaeric 
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Figure 3.14. Schematic diagram of hD6/hCCR5 HA tagged chimaeric 
constructs. White rectangles and thin black lines indicate hD6 receptor. hCCR5 is 
represented by black rectangles and thick black lines. The white square represents the 
HA tag sequence cloned at the N-terminus of each construct. The transmembrane 
domains are represented by rectangles, and the N-terminus, the intracellular and 
extracellular loops and cytoplasmic tail are shown as solid lines. The chimaeric 
receptors were generated by PCR as described in Section 2.2.2.14.1.
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Figure 3.15. Flow cytometry and binding analysis of MACS sorted hD6/hCCR5 
HA tagged constructs. Transiently transfected CHO cells were sorted using the 
MACS system and subsequently tested for their surface expression (graph A) and for 
their ability to displace 125I-PM2 (graph B), 48 hours after transfection. A. 
Transiently transfected CHO cells expressing the Kk protein or co-transfected with 
the Kk and the HA tagged receptors cDNA were incubated with the anti-Kk antibody 
coupled to magnetic beads. After incubation cells were sorted down a magnetic 
column and Kk positive cells were purified. The sorted populations were 
subsequently stained with the anti-HA antibody, HA. 11 and surface expression was 
analysed by a FACS. Fluorescence of each transfected cell line (black line) was 
compared to the background fluorescence of CHO cells transfected with the Kk 
plasmid only (Sorted Kk, in grey). Incubation of samples with the appropriate isotype 
controls showed no increase in fluorescence in comparison to untransfected cells. B. 
Displacement of 0.6nM 125I-PM2 by 120nM unlabeled PM2 by untransfected CHO 
cells (CHO) and by CHO cells expressing the wild type hD6 (hD6.1), the HA tagged 
wild type hD6 (D6HAD6V), wild type hCCR5 (CCR5HACCR5V) as well as the 
chimaeras (D6HACCR5V and CCR5HAD6V). 1E5 cells incubated at room 
temperature in the presence of 0.5% azide for 90 minutes before washing with ice 
cold PBS. Cells were lysed in 0.1% SDS and the remaining 125I-PM2 in the lysate 
counted. Experiment was performed once in triplicate. Average of values is presented 
as a percentage of binding calculated in relation to hD6.1 in the absence of unlabelled 
competitor (set arbitrarily at 100%). Error bars represent standard deviation of a 
population.
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Figure 3.16. Displacement of 125I-MIP-lcxP by HA tagged constructs. Transiently 
transfected CHO cells were tested for their ability to express HA tagged proteins 
surface expression (graph A) and for their ability to displace 125I-MIP-laP binding 
(graph B) 48 hours after transfection. A. CHO cells transiently expressing HA tagged 
constructs were stained with the anti-HA antibody, HA. 11 and surface expression of 
each receptor was analysed by a FACS. Fluorescence of each transfected cell line 
was compared to the background fluorescence of untransfected cells, CHO (in grey). 
Isotype controls were carried out where appropriate and showed no specific staining. 
B. Displacement of 125I-MIP-laP (30nM) with unlabeled MIP-laP (lpM ) by 
untransfected CHO cells (CHO) and by CHO cells expressing the wild type hD6 
(hD6.1), the HA tagged wild type hD6 (D6HAD6V), wild type hCCR5 
(CCR5HACCR5V) as well as the chimaeras (D6HACCR5V and CCR5HAD6V) was 
assayed by a binding assay in equilibrium. 1E5 cells incubated at room temperature 
in the presence of 0.5% azide for 90 minutes and then washed three times with ice 
cold PBS. Cells were subsequently lysed in 0.1% SDS and the remaining 125I-PM2 in 
the lysate counted. Experiment was performed in triplicate, the counts averaged and 
then expressed as a percentage of binding to hD6.1 binding in the absence of 
unlabelled competitor (set arbitrarily at 100%). Error bars represent standard 
deviation of a population.
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Figure 3.17. Displacement of 125I-PM2 by 5nt6bd. A. Construct 5nt6bd is a HA 
tagged chimaeric construct of hD6 and hCCR5 where the extracellular domain of 
hD6’s N-terminus up to the first Cys residue has been replaced by the corresponding 
region of hCCR5. The white square represents the N-terminal HA tag, hD6 is 
represented by thin black lines and white rectangles whereas hCCR5 is represented 
by a thick black line. DNA sequence of hCCR5 and hD6 is shown beside the 
replaced domain. B. 2pg of D6HAD6V, CCR5HACCR5V and 5nt6bd cDNA were 
separately transiently transfected into CHO cells. 48 hours after transfection cells 
were harvested and immunostained with the anti-HA antibody, HA. 11. 37% of 
D6HAD6V, 30% of CCR5HACCR5V and 27% of 5nt6bd expressing cells stained 
positively for the HA antibody. Binding to PM2 by the transiently transfected cell 
lines expressing either D6HAD6V, 5nt6bd or CCR5HACCR5V, by the stable cell 
line expressing wild type untagged hD6, (hD6.1) and untransfected CHO cells (CHO) 
is shown. These cell lines were tested for their ability to displace 30nM of 125I-PM2 
with lpM  of unlabeled PM2. Untransfected cells are also shown (CHO). Binding 
assays were done twice in triplicate. Error bars represent standard deviation.
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Extracellular mutants
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Figure 3.18. Schematic cartoon diagram of the extracellular domain mutants.
The extracellular loops of hD6 were replaced with the corresponding domains of 
hCCR5 by overlap extension PCR. ExtLoopA represents a chimaeric construct where 
the first extracellular loop of hD6 has been replaced by the corresponding loop of 
hCCR5. ExtLoopB, bears the second extracellular loop of hCCR5 cloned into the 
corresponding domain of hD6 . ExtLoopC has the third extracellular loop of hD6 
replaced by the corresponding domain of hCCR5. All constructs were HA tagged at 
the N-terminus to facilitate detection of surface expression. HA tagged is represented 
by the white square, thin black lines and white rectangles represent hD6 whereas 
thick black lines indicate hCCR5 domains.
Surface expression of extracellular 
mutants
i l l
ExtLoopB ExtLoopC 5nt6bd
Figure 3.19. Surface expression of extracellular mutants. cDNAs encoding for the 
extracellular mutants, ExtLoopA, ExtLoopB, ExtLoopC or 5nt6bd as well as cDNA 
encoding for HA tagged wild type hD6 (D6HAD6V) and hCCR5 (CCR5HACCR5V) 
were separately transiently transfected into COS-7 cells. Cells were harvested and 
immunostained with the anti-HA antibody 48 hours after transfection. Percentage of 
positive cells was determined by comparison with untransfected cells. D6 HAD6V, 
CCR5HACCR5V, ExtLoopA and ExtLoopB are expressed at the same levels on the 
surface of COS-7 cells. ExtLoopC and 5nt6bd are consistently expressed at higher 
levels than D6 HAD6V (P<0.05). Results shown are the average of nine separate 
experiments. Error bars represent standard deviation.
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Figure 3.20. Binding of 125I-PM2 to 5nt6bd is displaced by MCP-1, eotaxin, 
MCP-2 but not by RANTES. Schematic diagram of 5nt6bd is shown. The 
extracellular N-terminus domain (up to the first Cys residue) of hCCR5 was cloned 
into the corresponding region of hD6. Grey square indicates HA tag epitope cloned at 
the N-terminus of this mutant receptor. Thin black lines and white rectangles indicate 
hD6 domains whereas hCCR5 sequence is represented by a thick black line. A. 
Untransfected (COS-7, in grey) and transiently transfected COS-7 cells expressing 
either D6HAD6V (thick black line), CCR5HACCR5V (dotted line) or 5nt6bd (dotted 
line), were stained with the FITC coupled anti-HA antibody, HA. 11, 48 hours after 
transfection. Fluorescence of each cell line was compared to fluorescence of 
untransfected cells by a FACS. HA tagged constructs 5nt6bd and CCR5HACCR5V 
were expressed on the surface of COS-7 cells at the same level of D6HAD6V. 
Incubation of samples with the isotype control showed no unspecific staining. 
Profiles shown are representative of two separate experiments. B. On the same day 
transiently transfected and untransfected COS-7 cells were tested for their ability to 
bind 125I-PM2 and whether this binding could be displaced by the presence of an 
excess unlabeled chemokine. In brief, 1E6 cells were incubated with 120nM 125I- 
PM2 and lpM  unlabeled chemokine or equivalent volumes of PBS. After 90 minutes 
of incubation at room temperature, cells were washed with wash buffer and with ice 
cold PBS. The remaining 125I-PM2 activity was counted for one minute in a gamma 
counter as before. The results shown are the average of two experiments carried out 
in triplicate. Percentage of binding is calculated in relation to hD6.1 binding of 125I- 
PM2 in the absence of competitor (set arbitrarily at 100%).
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Figure 3.21. 5nt6bd binds to MCP-4. Untransfected (COS-7) and transiently 
transfected COS-7 cells expressing either D6 HAD6V or 5nt6bd were tested for their 
ability to bind to 2nM 125I-MCP-4 and to displace it in the presence or absence of 
0.5pM  of MCP-4, 48 hours after transfection. 5nt6bd binds to MCP-4 at levels 
comparable to those registered for HA tagged wild type hD6 (D6HAD6V). The 
results shown are the average of two experiments carried out in triplicate. Percentage 
of binding is calculated in relation to binding of l2:4-PM2 to D6 HAD6V expressing 
cells in the absence of competitor (set arbitrarily at 100%).
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Figure 3.22. RANTES binds to 5nt6bd. Untransfected and transiently transfected 
COS-7 cells with D6 HAD6V, CCR5HACCR5V or 5nt6bd cDNAs were tested for
1 ^ 5their capacity to bind to “ I-RANTES (2nM) in the presence or absence of 0.5(iM of 
unlabeled RANTES, 48 hours after transfection. Binding of CCR5HACCR5V to 
RANTES is below the detection levels of this assay. 5nt6bd binds to RANTES. The 
results shown are the average of two experiments carried out in triplicate. Percentage 
of binding is calculated in relation to binding of l2:T-PM2 to D6HAD6V expressing 
cells in the absence of competitor (set arbitrarily at 100%).
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Figure 3.23. Binding of 125I-PM2 to cells expressing ExtLoopA is not detected, 
demonstrating the importance of the first extracellular loop of wild type hD6. A.
ExtLoopA bears the first extracellular loop of hCCR5 (thick black line) cloned into 
the corresponding region of hD6 (thin black lines and white rectangles) with a HA 
tag (grey square) cloned at the N-terminus. Alignment of the two sequences that 
encode for the two extracellular loops is shown. COS-7 cells were transiently 
transfected with ExtLoopA or D6HAD6V cDNAs. 48 hours after transfection, 
transfected (black and dotted lines) and untransfected (COS-7, in grey) cells were 
assayed for surface expression of the HA epitope by flow cytometry. Surface 
expression of each constructed was determined by a FACS and compared to the 
background fluorescence of untransfected cells (COS-7, in grey), as shown. Isotype 
controls were carried out as appropriate. B. Binding assay. In brief, 1E6 cells were 
incubated with 120nM 125I-PM2 and lpM  unlabeled cold competitor or equivalent 
volumes of PBS. After 90 min. incubation at room temperature, cells were washed 
with ice cold PBS and the remaining 125I-PM2 activity counted. Error bars represent 
standard deviation. Experiments were done twice in triplicate. Percentage of binding 
is calculated in comparison to D6HAD6V binding (set arbitrarily at 100% in the 
absence of competitor).
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Figure 3.24. The first extracellular loop of hD6 is necessary for binding to MCP-
4. 1E6 untransfected (COS-7) and transiently transfected COS-7 cells expressing 
D6 HAD6 V or ExtLoopA were incubated with 2nM 12 I-MCP-4 in the absence or 
presence of unlabelled MCP-4 (0.5pM). After 90 min. incubation at room 
temperature cells were washed and the remaining activity counted. Results are 
presented as the average of two experiments carried out in triplicate. Percentage of 
binding was calculated in relation to 12 I-MCP-4 binding to D6 HAD6V expressing 
COS-7 cells in the absence of competitor (set arbitrarily at 100%). Error bars indicate 
standard deviation.
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Figure 3.25. The first extracellular loop of hD6 is important for binding to 
RANTES. 1E6 transiently transfected COS-7 cells expressing D6 HAD6V, 
CCR5HACCR5V or ExtLoopA and untransfected cells (COS-7) were assayed for 
their ability to bind to 12 I-RANTES. Cells were incubated with 2nM l25I-RANTES 
and either 0.5p,M unlabeled RANTES or an equivalent volume of PBS. Graph shows 
the average of two experiments done in triplicate. Percentage of binding is calculated 
in relation to 12 I-RANTES binding to D6HAD6V in the absence of cold competitor 
(set arbitrarily at 100%). Error bars represent standard deviation.
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Figure 3.26. ExtLoopB expressing cells displace 125I-PM2 binding in the 
presence of other chemokines. A. ExtLoopB is a chimaeric construct which bears 
the second extracellular loop of hCCR5 (thick black line), cloned into the 
corresponding region of hD6 (thin black lines and white rectangles). A HA tag (grey 
square) was cloned at the N-terminus. Untransfected (COS-7) and transfected COS-7 
cells were transiently expressing D6HAD6V or ExtLoopB receptors were 
immunostained with the anti-HA antibody and fluorescence of each cell line was 
determined by a flow cytometry 48 hours after transfection. Fluorescence of each cell 
line was compared with background fluorescence of untransfected cells (COS-7 cells, 
in grey). Isotype controls were carried out as appropriate and showed no unspecific 
binding. Profile shown is representative of two separate experiments. B. D6HAD6V, 
ExtLoopB expressing COS-7 cells and untransfected COS-7 cells were incubated 
with 120nM lz5I-PM2 and lpM  of unlabelled PM2, MCP-1, eotaxin, MCP-2, 
RANTES or equivalent volumes of PBS. Binding assay was carried out as described 
before. Graph shows the average results of two experiments done in triplicate. 
Percentage of binding was calculated in relation to D6HAD6V expressing cells 
binding to 125I-PM2 in the absence of cold competitor (set arbitrarily at 100%). Error 
bars represent standard deviation.
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Figure 3.27. Displacement of l25I-MCP-4 binding from ExtLoopB expressing 
cells. Approximately 1E6 transiently transfected COS-7 cells expressing D6 HAD6V 
or ExtLoopB as well as untransfected cells (COS-7) were incubated with 2nM l25I- 
MCP-4 and 0.5pM unlabeled MCP-4 or equivalent volumes of PBS. Graph 
represents data from two experiments done in triplicate. Percentage of binding is 
calculated in relation to D 6HAD6V expressing cells binding to 12 I-MCP-4 in the 
absence of competitor (set arbitrarily at 100%). Untransfected cells showed no
125 • •binding to “  I-MCP-4. Error bars represent standard deviation.
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Figure 3.28. Displacement of l2:T-RANTES from ExtLoopB expressing cells.
Approximately 1E6 transiently transfected cells expressing D6 HAD6 V or ExtLoopB 
as well as untransfected cells (COS-7) were incubated with 2nM of l25I-RANTES 
and 0.5pM  of unlabeled RANTES or equivalent volumes of PBS. Data presented in 
this graph is the average of two experiments done in triplicate. Percentage of binding
19S • • •was calculated in relation to " I-RANTES binding to D6 HAD6V expressing cells in 
the absence of competitor, set arbitrarily at 100%. Error bars represent standard 
deviation.
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Figure 3.29. Displacement of 125I-PM2 from ExtLoopC expressing COS-7 cells.
A. Schematic diagram of chimaeric construct ExtLoopC is shown in A. The HA tag 
is represented by the grey cylinder square, transmembrane domains of hD6 are 
represented by white rectangles, hD6 sequence is represented by thin black lines, 
thick black line represents hCCR5. The sequence encoding for the third extracellular 
loop of hD6 and hCCR5 is shown. Approximately 5E5 COS-7 cells transiently 
expressing D6HAD6V or ExtLoopC were stained with the anti-HA antibody and 
subsequently analysed by a flow cytometry 48 hours after transfection. Fluorescence 
of transfected cells was compared to the background fluorescence of untransfected 
cells (COS-7). Isotype controls were carried out and showed no unspecific staining. 
Profiles shown are representative of two separate experiments. B. On the same day 
cells were incubated with 120nM 125I-PM2 and lpM  unlabeled competitor or 
equivalent volumes of PBS. Percentage of binding is calculated in relation to 125I- 
PM2 binding for D6HAD6V expressing COS-7 cells in the absence of competitor 
(set arbitrarily at 100%). Results shown are the average of two experiments done in 
triplicate. Error bars represent standard deviation.
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Figure 3.30. Displacement of ,2?I-MCP-4 binding from COS-7 cells transiently 
transfected with ExtLoopC cDNA. Approximately 1E6 untransfected (COS-7) or 
transiently transfected COS-7 cells with D6HAD6V or ExtLoopC cDNAs were 
incubated with 2nM l25I-MCP-4 and 0.5p,M unlabeled MCP-4 or equivalent volumes 
of PBS. Binding assay in equilibrium was performed as described before. Graph 
shows the average of two experiments done in triplicate; error bars represent standard
• • • I 2 Sdeviation of a population; Percentage of binding is calculated in relation to ~ I-MCP- 
4 binding for D6HAD6V expressing COS-7 cells in the absence of competitor (set 
arbitrarily at 100%). Results shown are the average of two experiments done in 
triplicate. Error bars represent standard deviation.
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Figure 3.31. Displacement of I-RANTES binding from cells expressing 
ExtLoopC. Approximately 1E6 untransfected (COS-7) and COS-7 cells transfected 
with D6 HAD6V or ExtLoopC cDNAs were tested for their ability to bind to 
RANTES 48 hours after transfection. Cells were incubated with 2nM I-RANTES 
and 0.5pM  unlabeled RANTES or equivalent volumes of PBS. Data shown in graph 
is an average of two experiments done in triplicate; error bars represent standard
• 19Sdeviation of a population; Percentage of binding was calculated in relation to * I- 
PM2 binding for D6HAD6V expressing COS-7 cells in the absence of competitor 
(set arbitrarily at 100%). Results shown are the average of two experiments done in 
triplicate. Error bars represent standard deviation.
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3.2. Recognition of chimaeric receptors by an anti- 
hD6 monoclonal antibody
During the course of this work, a mouse anti-hD6 monoclonal antibody (1D4) was 
generated that recognizes hD6 expressed on heterologous cell lines and in tissue 
sections. This work is described in (Nibbs et al., 2001). However, 1D4 could not 
successfully recognise hD6 immobilised in nylon filters using conventional Western 
blotting techniques (R. Nibbs, pers.comm.). Thus, 1D4 recognises a conformation- 
dependent epitope on hD6. It was thought that this antibody would be of use to study 
ligand binding and at the same time study its ability to interact with the chimaeric 
receptors. This will determine the position of the 1D4 epitope, and also may provide 
information concerning the overall structure of the chimaeric receptors.
HEK.293 cells stably expressing HA tagged 5nt6bd, ExtLoopA, ExtLoopB and 
ExtLoopC were stained with the anti-HA antibody HA. 11, and the anti-hD6 antibody 
1D4. The data presented in Fig.3.32 has been normalized for HA. 11 staining and 
shows that the N-terminus is the major epitope recognized by 1D4 monoclonal 
antibody. However; the second and third extracellular loop chimaeras also show 
reduced interaction with the antibody. These results suggest that the hD6 epitope 
recognised by 1D4 is within the N-terminal region and that the structure of this 
epitope is disrupted to some degree in the chimaeric constructs ExtLoopB and 
ExtLoopC. ExtLoopA binds 1D4 as efficiently as the wild type hD6 protein.
To determine whether this antibody competed with PM2 for binding to hD6, the 
same cells were stained with the 1D4 with or without PM2 and incubated for 45
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minutes. Flow cytometry (Fig. 3.33) showed that addition of PM2 still allows epitope 
recognition by the 1D4 antibody. Likewise, radiolabelled ligand binding experiments 
on wild type hD6 transfected cells by Dr. Nibbs have demonstrated that 1D4 does not 
interfere with PM2 binding. Therefore, PM2 and 1D4 bind to non-overlapping sites 
on the receptor.
These findings corroborate the binding studies with the chimaeric receptors that 
suggest that the N-terminus of hD6 is not responsible for ligand binding or 
promiscuity. Also, it can be hypothesized that the decrease in ligand binding 
observed with ExtLoopB and ExtLoopC could be due to an abnormal conformation 
assumed by these chimaeric receptors that does not allow appropriate interaction with 
the ligands, rather than a direct consequence of the primary sequence interaction with 
ligand.
In summary, the work described here has demonstrated the difficulties associated 
with chimaeric receptor studies. By mixing receptors it was hoped that receptor 
structure would be fairly well conserved so the effect of primary sequence 
determinants could be assessed. Only by swapping small regions of closely related 
receptors can it confidently be assumed that the overall gross structure of the 
resultant chimaeras has not been disrupted. In fact, the studies with the anti-hD6 
antibody suggest that even small changes may disrupt distant structure. Nonetheless, 
these data do implicate the highly conserved first extracellular domain in ligand 
binding to human D6. Discussion of the technical and scientific aspects of these 
studies is expanded in Chapter 4.
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Figure 3.32. Surface expression of stably transfected HEK.293 expressing wild 
type hD6 and chimaeric constructs. HEK.293 cells were stably transfected with 
D6 HAD6V, 5nt6bd, ExtLoopA, ExtLoopB or ExtLoopC cDNAs and immunostained 
with the anti-HA antibody HA. 11 and the anti-hD6 monoclonal antibody 1D4. 
Fluorescence of each sample was assessed by flow cytometry. Surface expression 
detected by 1D4 antibody was calculated as a percentage of HA. 11 staining. 
Appropriate isotype controls were carried out for both antibodies used and showed no 
unspecific staining. Graph shows the average of three separate experiments.
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1D4 antibody does not block PM2 binding
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Figure 3.33. Human D6-specific monoclonal antibody does not compete with 
ligand binding to hD6. HEK.293 cells stably expressing HA tagged wild-type hD6 
(D6HAD6V), and untransfected cells (HEK.293) were stained with the anti-hD6 
antibody, 1D4, in the presence or absence of PM2. Data shown are the average of 
three separate experiments.
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3.3. Signalling studies
G protein-coupled receptors mediate leukocyte activation by coupling to 
heterotrimeric G proteins. Binding of the ligand to the receptor activates G proteins 
resulting in regulation of a wide variety of second messenger systems. Selection of a 
G protein partners is likely dependent on sequence determinants within the 
intracellular domains.
In general, seven transmembrane receptors have an extended third intracellular loop 
that interacts directly with G proteins. Chemokine receptors, however, have an 
extremely short third intracellular loop so it is hypothesized that other intracellular 
portions, such as the C-terminus domain, may be critically involved in signal 
transduction via these GPCRs (Bennet et al, 2000; Oliveira et al, 1994; Scheer et al, 
1996). Also, the conserved DRYLAIVHA motif located at the interface between the 
third TM domain and the cytoplasm and the conserved aspartic acid residue found in 
the second TM domain, have been shown to be important for G protein activation 
and coupling (Bennet et al, 2000; Oliveira et al, 1994; Scheer et al, 1996).
Standard signalling assays for chemokine receptors such as calcium flux, chemotaxis, 
and microphysiometry demonstrated that hD6 cannot elicit signalling upon ligand 
binding when expressed in a variety of heterologous cells (Nibbs et al., 1997a) 
(Nibbs, R.,pers. comm.). Signalling of hCCR5 has been most commonly detected by 
calcium flux, a very sensitive technique that can register calcium fluxing in the 
presence of very low concentrations of ligand and at low levels of receptor 
occupancy. In these assays, stably transfected cells, are loaded with FURA-2AM, a
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fluorescent dye that binds to calcium ions. Upon ligand binding Ca2+ is released from 
the intracellular calcium stores and an increase in fluorescence is registered. Fig. 3.34 
shows a typical calcium flux profile obtained when cells expressing hCCR5 or hD6 
are challenged with PM2. Additionally, in heterologous cells hD6 transfectants do 
not internalise in the presence of ligand (R. Nibbs, pers. comm.) whereas hCCR5 
transfected cells have been shown to be internalised upon ligand binding (Alkhatib et 
al., 1997).
These observations suggest that hD6 most likely does not transduce an intracellular 
signal in the transfected cells tested, although one cannot rule out the possibility that 
other secondary messengers, distinct from these tested so far, are activated by ligand 
binding to exogenous D6. What these results do suggest however is that hCCR5 and 
hD6 must be structurally distinct as one couples to G proteins in transfected cells 
whilst the other does not. hD6 might not be capable of undergoing the necessary 
conformational change to allow coupling, or alternatively, hD6 might contain 
primary sequence determinants that prevent interactions with the G proteins present 
in heterologous cell lines. The divergent C-terminus, the altered DRY motif at the 
end of the third TM domain, or the absence of an aspartic acid residue in the second 
TM (all known to be important for G protein coupling in other chemokine receptors 
(Brelot et al., 2000; Gosling et al., 1997; Oliveira et al., 1994; Schraufstatter et al., 
1998)) might contribute to this. In fact, at the outset of this work it was already 
known that introducing an aspartic acid residue onto the second TM of hD6 did not 
introduce signalling to calcium flux (R. Nibbs, pers. Comm.).
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Through the generation of chimaeric constructs between hCCR5 and hD6, it was 
hoped that domains/residues would be identified that could introduce ligand-induced 
G protein coupling into hD6. This would hopefully yield some information about the 
ability of wild type hD6 to undergo ligand-induced conformational change, which has 
implications for the understanding of hD6 biochemistry and function. hD6 also 
provides a signalling-negative background that would allow the study of hCCR5 G 
protein coupling domains. Calcium fluxes and receptor internalisation assays were 
used as a functional read-out, both seen with hCCR5 but not hD6.
3.3.1. Sequence comparison of intracellular loops of hD6 and 
hCCR5
The intracellular domains of hD6 and the corresponding regions of hCCR5 share 
virtually no overlap in their primary sequence and are different in their overall charge 
and length. In the first and second intracellular loop, hD6 has more positively 
charged residues than hCCR5, whereas in the third intracellular loop hCCR5 has 
more positively charged residues than hD6. Within the second intracellular loop of 
hD6 the DKYLEIV motif is variable from the canonical DRYLAIV motif of 
chemokine receptors, with the notable exclusion, at residue 134, of a negatively 
charged Glu residue. The remaining eleven amino acids that constitute the second 
intracellular loop of hD6 are mostly positively charged whereas in hCCR5 they are 
mostly non polar. It should also be noticed that hD6 has a Pro residue at position 140 
that is also found in CCR11, to which signalling cannot be demonstrated in HEK.293 
cells (R. Nibbs pers. comm.). The C-terminus domain of hD6 is longer and encodes 
for an extra seventeen amino acids and is found to be overall negatively charged
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whereas the same region in hCCR5 is overall positive. hD6 C-terminus has more Ser 
residues than the C-terminus of hCCR5. Moreover, hCCR5 has three palmitoylated 
Cys residues recently shown to play a role in intracellular trafficking of this receptor 
(Blanplain et al., 2001) whereas hD6 only has one putative palmitoylation site. In 
comparison with the C-terminal region of hCCR5, the corresponding region of hD6 
has more Ser and Pro residues which have been shown to be involved in post 
translational modifications and bends or folds within the mature protein (Barlow & 
Thornton, 1988; Ji et al., 1998; Woolfson & Williams, 1990).
3.3.2. The second intracellular loop is necessary for 
expression of hD6 on the surface of HEK.293 cells
Four chimaeric constructs (Fig. 3.35) were initially generated by overlap extension 
PCR (Sections 2.2.2.10 and 2.2.2.17.1). Constructs iLoopl, iLoop2 and iLoop3 carry, 
respectively, the first, second and third intracellular loop of hCCR5 cloned into the 
corresponding region of hD6. 5ct6bd is a construct where the C-terminus domain of 
hD6 has been replaced by the C-terminus of hCCR5. To facilitate detection of 
surface expression of each of these chimaeric constructs a HA tag sequence was 
cloned in the N-terminus of each construct. Each one of these constructs was 
transfected into HEK.293 cells (Section 2.2.1.2.1) and, to avoid clonal differences, a 
pooled population was obtained after selection with 800pig/ml of G418.
Surface expression of wild type and chimaeric chemokine receptors was detected by 
flow cytometry after immunofluorescence staining with the anti-HA mAb, HA. 11. 
These constructs were subsequently tested for their capacity to flux calcium upon 
ligand binding. This assay was chosen to assess signalling, not only because it is
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commonly used to determine the signalling capacity of chemokine receptors, but also 
because it has been shown to be extremely sensitive in detecting signalling even 
when there is little receptor occupancy. Nibbs and colleagues have shown that low 
concentrations of PM2 are still capable of eliciting a detectable calcium flux (Nibbs 
et al., 1999).
Construct 5ct6bd was expressed at the same levels as wild type HA tagged hD6 
(D6HAD6V), whereas iLoop3 and iLoopl are expressed at lower levels. 45% of cells 
expressing iLoopl and 70% of those expressing iLoop3 stained positively for the HA 
tag epitope (Fig.3.36). Immunofluorescence staining with the same antibody detected 
the HA epitope in approximately 80% of the cells expressing D6HAD6V and 5ct6bd. 
CCR5HACCR5V was also seen to be expressed at lower levels than D6HAD6V, 
with 50% of its cells testing positively for the presence of the HA tag epitope. 
Construct iLoop2, which bears the second intracellular loop of hCCR5 cloned into 
the corresponding region of hD6, was notably completely undetectable on the surface 
of HEK.293 cells (Fig. 3.36). However, when these cells were permeabilized with 
0.01% of saponin over 50% of the cells were shown to be positive for HA tag 
(Fig.3.37). This data indicates that this chimaera does not get appropriately 
transported to the surface suggesting that its folding and therefore its trafficking to 
the membrane are likely to be compromised.
It should be noticed that the percentage of cells staining with the anti-HA antibody 
fluctuated over time in culture therefore prior to each subsequent experiment, cells 
were stained with the anti-HA antibody to determine receptor surface expression.
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To determine whether constructs iLoopl, iLoop3 and 5ct6bd retained their ability to 
bind to PM2 a binding assay was carried out (Fig. 3.38). All these hD6 mutants 
exhibited displaceable binding to 125I-PM2. 5ct6bd and iLoopl bound PM2 at levels 
comparable to D6HAD6V (Fig. 3.38). iLoop3 was shown to have its ability to bind 
to PM2 reduced by approximately 50%, even though this chimaera was expressed at 
much higher levels than the other receptors when this experiment was performed. 
The fact that iLoop3 was seen to bind the least 125I-PM2 may indicate that the affinity 
of this chimaeric receptor is reduced relative to wild type hD6.
Despite the abundant surface expression, and the ability to bind PM2, none of the 
new chimaeras were able to detectably flux calcium upon treatment with PM2 (data 
not shown). Large calcium fluxes were however detected for the F1EK.293 cell line 
stably expressing hCCR5 that were used as a positive control (Fig. 3.39). It was 
therefore concluded that simple single loop changes were insufficient to allow 
coupling of hD6 to calcium ion fluxing.
3.3.3. A single point mutation in the DKYLEIV motif of hD6 is 
sufficient to elicit signalling
Given that the iLoop2 mutant did not get expressed on the surface of HEK.293 cells, 
it was thought that by introducing smaller changes in this region one could 
investigate the effect of changing the DKYLEIV motif of hD6 whilst maintaining 
surface expression. Site directed mutagenesis was used to introduce changes in the 
DKYLEIV motif of hD6. Complete cDNA sequencing (Section 2.2.13) was 
performed and these constructs were stably transfected into HEK.293 cells (Section 
2.2.1.2.1). A stable pool of clones was obtained by selection with 800pg/ml of G418.
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Mutant hD6K-R has a point mutation changing the hD6 Lysl31 residue to an Arg 
and mutant hD6E-A has a point mutation changing the Glul34 residue to an Ala. 
Both of these constructs have an HA tag epitope cloned after the start codon. Two 
point mutations changing the hD6’s residues Lysl31 to an Arg and the Glul34 to an 
Ala generated construct hD6DRY. Cartoon diagrams of these constructs are shown in 
Fig. 3.40. The hD6DRY.5 is a cell line stably expressing the untagged hD6DRY 
mutant given by Dr. R. Nibbs.
In order to be able to compare surface expression of the HA tagged intracellular 
mutants of hD6 with the surface expression of the untagged cell line expressing 
hD6DRY.5, the anti-hD6 mAb, 1D4 was used. Flow cytometry analysis revealed that 
the mutants hD6E-A and hD6DRY.5 were expressed at roughly the same levels as 
wild type HA tagged hD6 (D6HAD6V) although the mutant hD6K-R was expressed 
on the surface of the HEK.293 cells at slightly lower levels than D6HAD6V, hD6E- 
A and hD6DRY.5 (Fig. 3.41).
To determine the ability of these constructs to bind PM2 an equilibrium binding 
assay was performed (Fig. 3.41). The hD6E-A mutant was shown to be capable of 
binding 125I-PM2 at the same levels as the wild type HA tagged receptor. hD6K-R 
and hD6DRY.5 mutants have their ability to bind to PM2 reduced by 70 and 60%, 
respectively, when compared to D6HAD6V. These results suggest that the mutations 
introduced in hD6 to generate the hD6K-R or the hD6DRY.5 constructs have 
somehow disrupted the conformation of the mature protein in such a fashion that this 
mutant has its ability to bind PM2 diminished to some extent.
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The ability of these constructs to flux calcium upon ligand binding was tested as 
before. Interestingly, constructs hD6DRY.5 and hD6E-A were shown to be able to 
elicit an increase in intracellular calcium upon stimulation with PM2 (Fig. 3.42). This 
calcium flux was much smaller than the one registered for wild type hCCR5 (Fig. 
3.42b). Mutant hD6K-R did not detectably flux calcium upon ligand binding (data 
not shown).
Previous research has demonstrated that chemokine receptors couple to Pertussis 
toxin-sensitive G-proteins (Zhao et al., 1998). As shown in Fig. 3.43, pre-treatment 
of cells stably expressing the hD6DRY.5 mutant with Pertussis toxin (Ptx) abolished 
calcium flux indicating that hD6DRY.5 can couple to Ptx-sensitive G proteins.
Taken together these results show that a single point mutation in hD6 can introduce 
the ability to generate ligand-induced signalling via pertussis toxin-sensitive G 
protein. Moreover, it seems fair to suggest that the C-terminal eleven amino acids of 
the second intracellular loop of hD6 are involved in regulating surface expression, 
possibly by maintaining correct receptor conformation. These issues will be 
discussed in greater depth in the discussion section (Chapter 4.2).
3.3.4. hCCR5 signalling mutants
Two point mutations in the highly conserved ‘DRY’ region of wild type hCCR5 were 
performed so that the role of the ‘DKYLE’ motif of hD6 could be studied in an 
hCCR5 background. hCCR5DKYLE is a mutant of wild type hCCR5 that bears two 
point mutations changing the amino acid residue A rgll5  to a Lys and the residue 
Alai 18 to a Glu. A cartoon diagram of this construct can be seen in Fig. 3.44. This
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construct was subcloned into a mammalian expression vector, pcDNA.3 and once the 
DNA sequence was verified it was stably transfected into HEK.293 cells. A pool of 
positive clones was selected with 800pg/ml G418.
Flow cytometry after immunofluorescence staining with the anti-hCCR5 antibody 
2D7 was performed to determine the surface expression of this construct (Fig. 3.45). 
hCCR5DKYLE was shown to have a much higher surface expression than 
CCR5HACCR5V. It is interesting to note that two point mutations in the second 
intracellular loop of hCCR5 are sufficient to increase the surface expression of 
hCCR5 by more than 30%.
A binding assay was performed to determine whether the ability to bind to PM2 had 
been affected. HEK.293 cells stably expressing CCR5HACCR5V were shown to still 
be able to bind PM2 although hCCR5DKYLE expressing cells bound approximately 
20% less PM2 (Fig. 3.45).
A calcium flux assay was performed to test the signalling capacity of these constructs 
upon ligand binding. CCR5HACCR5V-expressing cells produced robust calcium 
fluxes as previously shown (Fig. 3.34 and 3.39). Although hCCR5DKYLEIV was 
shown not only to be expressed at high levels on the surface of HEK.293 cells but 
also to be capable of PM2 binding, this mutant was not capable of fluxing calcium 
upon ligand binding (Fig. 3.46). This data shows that, in agreement with previous 
studies (Gosling et al., 1997), the conserved ‘DRY’ domain of hCCR5 is essential for 
G protein activation.
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3.3.5. Second generation of chimaeric receptors
To determine whether the weak signalling detected for the hD6DRY.5 and hD6E-A 
cell lines could be increased by a cooperative effect from other domains of hCCR5, a 
second generation of intracellular chimaeric constructs was obtained in which two or 
more intracellular domains of hCCR5 were cloned into the corresponding region of 
hD6. Five new constructs were generated (Section 2.2.2.18) and cartoon diagrams of 
these constructs are shown in Fig.3.47. Construct iLoopl+3 bears the first and third 
intracellular loops of hCCR5 cloned into the corresponding region of hD6. 
iLoopl+DRY+iLoop3 is the same as iLoopl+3 and has the DKYLEIV motif in the 
second intracellular loop mutated to DRYLAIV. iLoopl+DRY and iLoop3+DRY are 
mutants of iLoopl and iLoop3, respectively, where the DKYLEIV motif has been 
mutated to DRYLAIV. Cloning of the hCCR5 receptor C-terminus into 
iLoopl+DRY+iLoop3 generates construct iLoopl+DRY+iLoop3+Ct. These 
constructs were subcloned into the mammalian expression vector pcDNA.3, stably 
transfected into HEK.293 cells (Section 2.2.1.2.1) and a pool of positive clones were 
selected using 800jxg/ml G418.
The surface expression of each construct was assessed by flow cytometry after 
staining with the 1D4 antibody and the HA. 11 antibody (Fig. 3.48). D6HAD6V was 
shown to have the highest surface expression (88% of the cells stained positive) and 
iLl+DRY, DRY+Ct and CCRHACCR5V have approximately 50% of detectable 
receptors on the surface of HEK.293 cells. Constructs, iLl+3, iL3+DRY, 
iLl+DRY+iL3 and iLl+DRY+iL3+Ct have the lowest percentage of stained cells: 
21%, 13%, 14% and 30% respectively (Fig. 3.48). Saponin treatment of cells 
expressing these constructs allowed intracellular staining with the same antibody and
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revealed that these constructs were abundantly expressed intracellularly (Fig. 3.49) 
suggesting that these constructs were not efficiently transported to the cell 
membrane.
Equilibrium binding assays were performed (Fig. 3.48) that showed that D6HAD6V- 
expressing cells bound radiolabelled PM2, whilst cells expressing CCR5HACCR5V, 
or the chimaeric constructs iLoopl+DRY, iLoopl+DRY+iLoop3 and DRY+Ct all 
showed displaceable binding to PM2 with variable efficiency. No binding was 
detectable to iLoopl+3 or the mutant in which all the intracellular loops were altered 
(iLoopl+DRY+ iLoop3+Ct). It seems likely that this lack of detectable binding was 
due to a combination of low receptor surface expression and a decrease in ligand 
binding affinity, although this has not been rigorously tested. iLoop3+DRY was 
peculiar as binding was detected to radiolabelled PM2, but this was not displaced by 
unlabelled PM2. Currently, there is no explanation for this phenomenon but it is 
possible that this particular pool of transfected cells has upregulated molecules that 
enhance non-specific binding to PM2. This observation does however, demonstrate 
the importance of examining displaceable binding, rather than just radiolabelled 
ligand binding.
All these cell lines were next tested in the calcium flux assays in comparison to cells 
transfected with hD6DRY or hCCR5. As expected, hCCR5 transfected cells gave a 
large robust flux, whereas those expressing hD6DRY gave a small flux. However, 
none of the new chimaeric receptors were able to elicit detectable calcium fluxes 
(data not shown).
205
It can be concluded from these results that the introduction of additional domains 
from hCCR5 into a background of hD6 already carrying a mutant DRYLA motif, 
does not bring about a dramatic increase in ability to elicit calcium fluxes. In fact, 
these multiple mutants are often compromised in their ability to correctly assemble at 
the surface of the cell. However, if hCCR5-like signalling activity had been 
introduced into these chimaeras, we would have expected to detect calcium fluxes 
even with low surface expression because of the sensitivity of the assay. The absence 
of signalling by those receptors that are abundantly expressed (iLoopl+DRY, 
DRY+Ct), although detectable signalling is observed with DRY mutants alone, 
cannot be confidently attributed as a loss of signalling in itself, but rather as a 
consequence of the small size of the flux combined with the low surface expression.
3.4. Internalization Studies
As an alternative way of assessing signalling by the intracellular domain chimaeras it 
was decided to examine receptor internalisation. This was thought to perhaps reveal 
activation of alternative signalling pathways by ligand binding, independent of 
calcium fluxes.
The surface expression of wild type HA tagged hD6 (D6HAD6V) and its 
intracellular mutants stably transfected into HEK.293 cells was measured by flow 
cytometry using the hD6-specific mAb 1D4 (Section 2.2.4.3). Wild type hCCR5 and 
hCCR5 mutants surface expression was determined by using the anti-hCCR5 mAb, 
2D7. As it can be seen in Fig. 3.50, wild type HA tagged hD6 (D6HAD6V) was not 
internalised after 45 minutes incubation with lOOnM of PM2. Wild type hCCR5
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(hCCR5 in Fig. 3.50) surface expression in contrast, decreased by 35% after 45 
minutes incubation with lOOnM of PM2 in agreement with previous studies in the 
same cell line (Ling et al., 1999). Surprisingly, PM2 treatment for 45 minutes caused 
approximately 28-56% reduction in cell fluorescence in cells expressing iLoopl, 
iLoop3, 5ct6bd, hD6E-A, iLoopl+DRY, DRY+Ct, and no reduction in cells 
expressing hD6K-R (Fig 3.50). The only mutant that showed no reduction, and in 
fact, possibly an increase in surface expression was mutant hD6K-R.
Fig. 3.51 shows that treatment of HEK.293 stably expressing wild type (hCCR5 in 
Fig.) and HA tagged hCCR5 (CCR5HACCR5V in Fig.) with PM2 for 45 minutes 
induced a 50% reduction in cell surface expression in both of these cell lines. 
However, surface expression of the hCCR5 intracellular mutant, hCCR5DKYLE, 
was reduced by 23% after treatment with PM2 for 45 minutes. Thus, although 
changing the DRYLA domain of hCCR5 to DKYLE abolishes the ability of hCCR5 
to couple to calcium fluxes, it reduces, but does not completely prevent, 
internalisation of this mutant receptor.
These data are somewhat surprising as they suggest that all the mutants, except 
hD6K-R, are able to signal into HEK.293 cells to mediate internalisation in response 
to PM2. The inability to detect ligand-induced calcium ion fluxes from some of these 
mutated receptors, in particular iLoopl, iLoop3, 5ct6bd and hCCR5DKYLE where 
abundant surface receptor is detectable, suggests that receptor internalisation is not 
dependent on coupling to calcium ion fluxes. An alternative mechanism is more 
likely. This will be discussed in greater detail in chapter 4.2.
\
207
In summary, the results detailed here show that a single point mutation in hD6 can 
introduce the ability to couple to pertussis toxin-sensitive G proteins in HEK.293 
cells and stimulate calcium ion fluxes. This change, E to A neutralises a charged 
residue in the conserved DRYLAIV motif of hD6. Introducing DKYLE into hCCR5 
completely blocks coupling to calcium ion fluxes. These data reinforce the 
importance of the DRYLAIV motif on G protein partner selection. The receptor 
internalisation data suggest that many domains of hCCR5 are involved in receptor 
internalisation, and that this is probably not dependent on coupling to calcium ion 
fluxes. The implications and interpretation of the results are discussed below.
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Ligand induced calcium flux undetectable 
in hD6 expressing HEK.293 cells
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Figure 3.34. Calcium flux detection in HEK.293 cells expressing hCCR5 and 
hD6 cDNAs. Pools of HEK.293 cells were stably transfected with hCCR5 and hD6 
cDNA. Pools of G418-resistant clones were loaded with Fura-2AM and assayed at 
37°C in a continuously stirred cuvette in a Perkin-Elmer LS50 Spectrometer (340nm 
(X ex ); 500nm (X em) ) ,  with fluorescence emission recorded every 100ms for 300s. PM2 
was added to a final concentration to a final concentration of 50nM at the time 
indicated by the black arrow. The figure shows that after addition of PM2 an increase 
in fluorescence is registered in hCCR5 expressing HEK.293. This increase in 
fluorescence reflects detection of intracellular calcium No change in basal 
fluorescence is seen for hD6 expressing cells upon addition of PM2. The graph 
shown is representative of the calcium flux profile observed in many occasions (n 
>20). Int, intensity; s, seconds.
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Schematic diagram of intracellular 
chimaeric constructs
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Figure 3.35. Schematic diagram of chimaeric constructs. Intracellular loops of 
hD6 were individually replaced by the corresponding domains of hCCR5. Constructs 
were generated by overlap extension PCR. Grey square indicates HA tag (grey 
square) at the N-terminus. hD6 domains are represented by thin black lines and white 
rectangles. Thick black lines represent hCCR5 sequence. The amino acid sequence of 
the domains is indicated using the single letter amino acid code.
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The second intracellular loop of hD6 is
important for surface expression
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Figure 3.36. Surface expression of wild type and chimaeric receptors. HEK.293 
cells were stably transfected with D6HAD6V, iL oopl, iLoop2, iLoop3, 5ct6bd and 
CCR5HACCR5V cDNAs and examined for expression of the HA tagged constructs 
by flow cytometry, following incubation with the FITC-coupled HA tag monoclonal 
antibody HA. 11. Fluorescence of each sample was determined as a percentage of 
positively stained cells over background fluorescence registered for untransfected 
HEK.293. The results shown are representative of the surface expression for the 
various tagged constructs.
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Chimaeric construct iLoop2 is expressed 
intracellularly
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Figure 3.37. Expression of iLoop2 expressing HEK.293 cells. HEK.293 cells 
stably expressing iLoop2 were stained with HA. 11 antibody in the presence (+) or 
absence (-) of saponin (0.01% v/v in PBS). Results shown are representative of the 
data observed in three independent experiments. Percentage of positively stained 
cells is determined in relation to untransfected HEK.293 cells also stained with the 
anti-HA antibody in the presence or absence of saponin.
212
125 I-PM2 binding to intracellular chimaeric 
constructs
Surface
Expression (%): 47.57 45.07 69.07 51.34 52.3
150
120
90
O
Z 60m
30
■ PBS 
□ PM2
HEK.293 D6HAD6V iLoopl iLoop3 5ct6bd CCR5HACCR5V
Figure 3.38. Displacement of 125I-PM2 from cells expressing HA tagged wild 
type and chimaeric receptors. Approximately 1E6 HEK.293 cells stably expressing 
wild type hD6 (D6HAD6V), wild type hCCR5 (CCR5HACCR5V), iLoopl, iLoop3 
and 5ct6bd were incubated with 6nM of 125I-PM2 and 60nM of unlabeled PM2 or 
equivalent volumes of PBS. After 90 min incubation at room temperature, cells were 
washed with wash buffer and ice cold PBS. Remaining " I-PM2 activity was 
counted for 1 min in a Beckman Gamma S500B counter. The data presented is an 
average of two independent experiments carried out in triplicate. Percentage of 
binding was calculated in relation to binding registered for D6HAD6V in the absence 
of competitor (set arbitrarily at 100%). Error bars represent standard deviation. The 
percentage of cells expressing surface receptor was determined relative to 
untransfected HEK.293 cells using the anti-HA antibody as indicated above the 
graph.
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Signalling by hCCR5 in response to PM2
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Figure 3.39. Detection of intracellular calcium in HEK.293 cells stably 
transfected with hCCR5 cDNA. A pool of G418-resistant HEK.293 cells 
expressing hCCR5 were loaded with Fura-2AM and assayed at 37°C in a 
continuously stirred cuvette in a Perkin-Elmer LS50 Spectrometer (340nm (Xex); 
500nm (7.em))> with fluorescence emission recorded every 100ms for 300s as 
described in Section 2.2.5.6. PM2, or an equivalent volume of PBS, was added to a 
final concentration of 50nM at the time indicated by the black arrow. Int, intensity; s, 
seconds. Data shown is representative of the results observed in three independent 
experiments.
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Schematic diagrams of iLoop2 mutants
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Figure 3.40. Point mutations in the second intracellular loop of hD6. hD6DRY.5 
bears two point mutations that change the DKYLEI sequence of hD6 to DRYLAI as 
found in hCCR5. This plasmid was generated by PCR and constructed by Dr. R. 
Nibbs. Mutants hD6E-A and hD6K-R were generated by site directed mutagenesis to 
mutate residues Glu 134 to an Ala and Lysl31 to an Arg, respectively. Grey square 
indicates HA tagged construct. Thick black lines represent area where the mutation 
has been introduced. Arrow points to the new residue.
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Binding of 125I-PM2 to mutants of hD6
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Figure 3.41. Surface expression and binding to ,25I-PM2 by m utant receptors of 
hD6. Pools of G418-resistant HEK.293 cells expressing HA tagged wild type hD6 
(D6HAD6V), hD6DRY.5, hD6K-R and hD6E-A were assayed for their surface 
expression and ability to bind to 12 I-PM2. Cells were stained with the anti-hD6 
specific antibody, 1D4, and surface expression determined as a percentage of positive 
cells in comparison to untransfected HEK.293. Transfected cells were incubated with 
l2^I-PM2 (6nM) and unlabeled PM2 (60nM) or equivalent volumes of PBS. Binding 
was calculated as an average of two experiments done in triplicate. Percentage of
• 125binding was calculated relative to " I-PM2 binding to D6HAD6V in the absence of 
competitor (set arbitrarily at 100%).
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Figure 3.42. Detection of intracellular [Ca2+] in HEK.293 cells stably expressing 
hCCR5 and the mutants hD6E-A and hD6DRY.5. Pools of G418-resistant 
HEK.293 cells transfected with hCCR5, hD6E-A or hD6DRY.5 cDNA, were loaded 
with Fura-2AM and assayed at 37°C in a continuously stirred cuvette in a Perkin- 
Elmer LS50 Spectrometer (340nm (Xex); 500nm (7wm)), with fluorescence emission 
recorded every 100ms for 150s. PM2 was added to a final concentration of 50nM at 
the time indicated by the black arrow. Data shown is representative of the 
observations from three independent experiments. Int, intensity; s, seconds.
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Figure 3.43. Detection of intracellular [Ca2+] in HEK.293 cells stably transfected 
with hD6DRY.5 cDNA. HEK.293 stably expressing hD6DRY.5 were treated O/N 
with (+Ptx) or without lpg/m l of Pertussis toxin the day before the calcium flux 
assay was performed. Untreated and treated cells were loaded with Fura-2AM and 
assayed at 37°C in a continuously stirred cuvette as described before. 50nM PM2 was 
added at the time indicated by a black arrow and fluorescence recorded every 100 ms 
for 300s. Int, intensity; s, seconds. Data shown is representative of the results 
observed in three independent experiments.
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hCCR5 signalling mutants
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Figure 3.44. Schematic diagram of the hCCR5DKYLE mutant. Mutant 
hCCR5DKYLE bears two point mutations in the second intracellular loop of hCCR5. 
Mutated residues are underlined and arrow points to new residue(s). This mutant was 
generated by site directed mutagenesis.
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Figure 3.45. Surface expression and 125I-PM2 binding by wild type hCCR5, and 
hCCR5DKYLE in stably transfected HEK.293. A pool of G418-resistant 
HEK.293 cells expressing CCR5HACCR5V or hCCR5DKYLE were examined for 
surface expression by flow cytometry following incubation with the anti-hCCR5 
antibody, 2D7. Fluorescence of each sample was compared to the background 
fluorescence given by untransfected cells and then expressed as a percentage. 
Untransfected and transfected HEK.293 expressing HA tagged wild type hCCR5 
(CCR5HACCR5V) and hCCR5DKYLE, were incubated with 6nM 125I-PM2 and 
60nM PM2 or equivalent volumes of PBS. Data shown is the average of two 
experiments carried out in triplicate. Percentage of binding is calculated in relation to 
125I-PM2 binding registered for CCR5HACCR5V expressing cells in the absence of a 
competitor (set arbitrarily at 100%).
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Figure 3.46. HEK.293 cells stably expressing hCCR5DKYLE do not generate a 
rise in intracellular [Ca2+] upon stimulation with PM2. A pool of G418-resistant 
HEK.293 cells stably transfected with hCCR5DKYLE cDNA, were loaded with 
Fura-2AM and assayed at 37°C in a continuously stirred cuvette cuvette in a Perkin- 
Elmer LS50 Spectrometer (340nm (^ex); 500nm (^era)), with fluorescence emission 
recorded every 100ms for 300s. PM2 was added to a final concentration of 50nM at 
the time indicated by the black arrow. HEK.293 cells stably expressing the signalling 
competent chemokine receptor hCCR5 were also tested and were seen to be capable 
of signalling (data not shown). Data shown is representative of three independent 
experiments. Int, fluorescence intensity; s, seconds.
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Second generation of intracellular mutants
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Figure 3.47. Schematic diagram of the second generation of hD6 intracellular 
mutants. Grey squares indicate HA tag at the N-terminus. Thin black lines indicate 
hD6 sequence. White rectangles indicate hD6 TM domains. Thick black lines 
indicate hCCR5 sequence. Arrows indicate point mutations. All cDNAs were stably 
transfected into HEK.293 cells. A pool of clones was obtained by selection with 
800pg/ml G418.
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Figure 3.48. Surface expression and 125I-PM2 binding by HEK.293 cells stably 
expressing HA tagged hD6 (D6HAD6V), wild type hCCR5 (CCR5HACCR5V) 
and second generation of hD6 intracellular mutants. Surface expression of HA 
tagged constructs was assayed by flow cytometry after staining with the FITC- 
coupled anti-HA antibody, HA. 11. Surface expression is shown as a percentage of 
positively stained cells in comparison to the background fluorescence of 
untransfected cells. Transfected cells were incubated with 6nM 125I-PM2 and 60nM 
PM2 or equivalent volumes of PBS. Untransfected cells were also tested in the 
binding assay and showed no significant binding to 125I-PM2 (not shown). 125I-PM2 
binding was calculated as a percentage of binding in relation to the values registered 
for 125I-PM2 binding to D6HAD6V in the absence of PM2 (set arbitrarily as 100%). 
Data shown is the average of two experiments done in triplicate.
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Figure 3.49. Detection of the HA tag in HEK.293 cells expressing second 
generation of hD6 intracellular mutants. HEK.293 cells stably expressing 
iLoopl+3, iLoop3+DRY, iLoopl+3+DRY  or iLoopl+DRY+iLoop3+Ct were 
examined for expression of the HA epitope by flow cytometry. Cells were stained 
with the anti-HA antibody, H A .ll , in the presence (+) or absence (-) of saponin. 
Surface expression is shown as a percentage of positively stained cells in comparison 
with background fluorescence of untransfected cells. Data shown is representative of 
the results observed in three independent experiments. Isotype controls were carried 
out as appropriate.
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Figure 3.50. Internalization studies with HEK.293 cells expressing wild type 
hCCR5 (hCCR5), HA tagged hD6 (D6HAD6V) and the intracellular mutants of
hD6. Cells were stained with the anti-hD6 antibody or with the anti-hCCR5 antibody 
(for hCCR5 expressing cells) before and after treatment with lOOnM PM2 for 45 
minutes at 37°C; appropriate control at 4°C was carried out and no internalisation 
was detected.. Surface expression of the receptors was assessed by flow cytometry 
and percentage of internalisation was determined according to the formula stated in 
Section 2.2.5.4. Data shown is the average of two independent experiments carried 
out in triplicate. Samples were incubated with the appropriate isotype controls and 
showed no unspecific staining.
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Surface expression of hCCR5 intracellular 
mutants after treatment with PM2
CCR5HACCR5V hCCR5DKYLE hCCR5
■  0 min 
□  45 min
Figure 3.51. Surface expression of HEK.293 cells stably expressing wild type 
hCCR5 (hCCR5), HA tagged hCCR5 (CCR5HACCR5V) and the hCCR5 
intracellular mutants and hCCR5DKYLE cDNAs after treatment with PM2.
Cells were stained with the anti-hCCR5 antibody before (0 min) and after treatment 
with lOOnM PM2 for 45 minutes at 37°C (45 min in graph). As a negative control, 
samples were also incubated in parallel at 4°C and no internalisation was detected 
(data not shown). Surface expression of the receptors was assessed by flow cytometry 
and percentage of internalisation was determined according to the formula described 
in Section 2.2.5.4. Data shown is the average of two independent experiments 
performed in triplicate. Isotype controls were carried out where appropriate (data not 
shown).
231
Chapter 4- Discussion
4.1. Identification of hD6 domains involved in ligand 
binding using chimaeric receptors
Generation of chimaeric constructs has been used extensively in structure-function 
studies of 7 TM G protein-coupled receptors. In most cases these chimaeras have 
been used to identify domains involved in ligand binding and receptor activation. 
This approach has also been shown to be useful in pinpointing segments of 
pharmacological importance. The high degree of homology between members of the 
G protein coupled-receptors has facilitated the construction of chimaeric receptors.
In order to identify the extracellular domains of hD6 responsible for its high surface 
expression and binding promiscuity, chimaeric receptors of hD6 and other 
chemokine receptors were generated. It was hoped that in these chimaeric proteins 
the gross structure of the receptor would be maintained allowing the role of primary 
sequence determinants in ligand binding to be assessed. However, as is clear from the 
results section, considerable technical problems involving the expression and 
detection of chimaeric receptors were encountered. This eventually led to the 
selection of small domain changes between hD6 and hCCR5 as the preferred method 
of analysis, using transient COS-7 cell transfection in combination with an HA 
epitope tag for detection of surface expression.
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4.1.1. Optimising chimaeric receptor assays: construction, 
conformation and data interpretation
Epitope tag selection. The inclusion of an epitope tag on the N-terminus of 
expressed receptor was essential to permit consistent detection and quantitation of 
surface expression. Initially, a FLAG sequence (DYKDDDD) was used as this has 
been successfully employed in other similar studies (Gayle et al., 1993; Monteclaro 
& Charo, 1997; Pease et al., 1998). Binding of PM2 was consistently detected in 
several different cell lines transfected with tagged hD6 but using flow cytometry or 
ELISA, and two different anti-FLAG antibodies, it was not possible to detect the 
FLAG tag on the surface of these cells, despite it being readily detected by Western 
blotting. Without an adequate system to detect surface receptor, negative results in 
the binding assay were impossible to interpret. Moreover, there was an indication that 
the FLAG tag enhanced hD6 binding affinity for PM2. In fact, although some 
workers have used FLAG tags before with no effect on ligand binding, Perez and 
colleagues have shown that the FLAG epitope appears to increase spontaneous 
dissociation of the ligand from the FLAG tagged formyl peptide receptor when 
compared to the wild type receptor (Perez et al., 1993). In this study the authors 
suggest that the hydrophilic sequence of the FLAG might alter the positioning of the 
first extracellular domain causing a reduction in time of receptor occupancy. It is 
possible that the FLAG tag might subtly modify the position of hD6’s domains 
involved in binding in a way that a higher affinity to PM2 is achieved. Alternatively, 
the highly acidic character of both the FLAG tag and the N-terminus of hD6 might 
increase charge in the N-terminus and possibly enhance hydrostatic interactions with 
the ligand.
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These observations are not likely to be due to some cell-type specific phenomena 
since expression of these constructs in COS-7 and HOS cell lines, also shown to 
successfully express hD6 on their surface, did not result in successful detection of the 
FLAG epitope (data not shown).
The FLAG tag from D6FD6V was replaced by an HA tag (YPYDVPDYAGPG), a 
tag also widely used for tagging proteins specially receptors (Rucker et al., 1996, 
Verrall et al, 1997). Full displacement curves showed that HA tagged wild type hD6 
stably expressing CHO cells (D6HAD6V) have the same affinity for PM2 as 
untagged wild type hD6 expressing CHO cells (hD6.1). Importantly, detection of the 
HA tag epitope was proven to be possible by immunocytochemistry and flow 
cytometry. For these reasons, it was concluded that this tag was much more useful 
and was therefore used in all subsequent experiments.
Expression systems for analysing chimaeric receptors. Since the HA epitope tag 
allowed successful detection of receptor on the cell surface, it was then possible to 
confidently examine tagged mIL-8RLl and the chimaeric constructs IL8HAD6V and 
D6HAIL8V. However, flow cytometry profiles using the anti-HA antibody showed 
that expression of IL8HAIL8V, IL8HAD6V and especially that of D6HAIL8V was 
not good. Cells expressing D6HAD6V were, on the other hand, strongly positive for 
expression of this receptor on the surface of the transfected cells. Binding assays 
showed that no binding to 125I-PM2 was detected for the chimaeric constructs or for 
wild type HA tagged mIL-8RLl, although binding to tagged and untagged wild type 
hD6 was successfully detected. This of course is not surprising when only HA-tagged 
hD6 was found to be expressed on the surface of these cells. The HA tagged
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constructs were stably transfected into HEK.293, COS-7 and HOS cells but as with 
the CHO cells only HA tagged wild type hD6 was ever detectable. The poor surface 
expression of the chimaeric constructs was disappointing and concerning. Even more 
concerning was the fact that continuous passaging of transfected cell lines lead to 
loss of receptor expression through time. Problems with stable cell lines losing 
chemokine receptor expression as a result from long maintenance of cells in culture 
has been reported before (Power & Meyer, 2000) and has been a common problem in 
this research group. It seemed possible that time in culture from transfection to 
analysis may be responsible for the absence of surface expression seen in cell lines 
stably transfected with IL8HAIL8V, D6HAIL8V and IL8HAD6V.
A transient transfection system was developed to attempt to circumvent this problem. 
The HA tagged constructs were transiently co-transfected into CHO cells with the Kk 
plasmid used here to produce a marker protein on transfected cells for sorting. This 
approach was shown to be effective in generating an enriched population of 
transfected cells but the 20-40% recovery of transfected cells made it technically 
difficult to generate large numbers of cells for full displacement binding curves. 
Unfortunately, as with the stable transfectants, only D6HAD6V was shown to be 
expressed on the surface of sorted CHO cells.
Nonetheless, this system did represent a rapid method for screening constructs for the 
production of surface expressed protein. However, frustratingly, it was found that 
transfection efficiency could be highly variable in these transient assays, most likely 
dependent on plasmid or transfection reagent batch, or the confluence of the cells. 
Finally, transient transfection of COS-7 cells was seen to be much more reproducible.
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This cell line was therefore used as the optimal rapid expression system for future 
analyses.
Chimaeric receptor partners and the size of the swap. At the outset of this thesis 
only CCRs 1 to 5, DARC and D6 had been identified within the (3-chemokine 
receptor family. At this time, it was thought that all these receptors bound ligands 
that also bound to D6 (later it was shown that CCR4 is the receptor for MDC/CCL22 
(Imai et al., 1998) and TARC/CCL17 (Imai et al., 1997) rather than MIP-la/CCL3, 
MIP-ip/CCL4 and RANTES/CCL5 as it was first thought (Power et al., 1995)). Thus 
it was felt that choosing these receptors as partners for D6 could prevent the 
identification of domains of D6 involved in ligand binding as a result of 
complementation. As a result, mIL-8RLl was chosen.
The poor surface expression of the chimaeric constructs could possibly be attributed 
to the fact that these constructs were obtained by fusing the domains from chemokine 
receptors that belong to different families. However, surface expression of wild type 
mIL-8RLl could not be demonstrated by flow cytometry, immunocytochemistry or 
by ELISA despite presumably being naturally presented on the surface of cells in 
which it is present endogenously. Variability between surface expressions of 
chemokine receptors in transfected cell lines has been reported before (Power & 
Meyer, 2000). For example, the chemokine receptor CCR3 is known to be very 
difficult to express on the surface of heterologous cell lines (Dairaghi et al., 1997) 
whereas hD6 is easily highly expressed on the surface of all of the cell lines tested so 
far (R. Nibbs, pers. comm.). The reasons for this remain unknown. It is possible that 
some receptors require accessory proteins, or post translational modifications for
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optimal surface expression that are only available in certain cell types (Farzan et al., 
1999, McLatchie et al, 1998, Blanpain et al, 1999). Nonetheless, it can be concluded 
that mIL-8RLl is of little use as a partner for hD6 in chimaeric receptor studies.
Wild type receptors hD6 and hCCR5 bearing a HA tag at their N-terminus were 
expressed at similar levels on the surface of transiently transfected CHO cells. The 
first chimaeric receptors, CCR5HAD6V and D6HACCR5V, generally revealed much 
less surface expression. As before, binding of 125I-PM2 to D6HAD6V expressing 
CHO cells was detectable but none of the other HA tagged constructs showed 
displaceable binding to 125I-PM2. The fact that hCCR5 stably expressing CHO cells 
have been shown to bind to 125I-PM2 in routine binding assays in this research group 
((Nibbs et al., 1999) and R. Nibbs, pers.comm.), suggests that the transient 
expression assay is not sensitive enough to detect robust binding by this receptor 
despite its high surface expression.
The experiments with radioiodinated M IP-laP binding did provide some potential 
insight into the binding activity of the chimaeras. Unfortunately, there was great 
difficulty in replicating this observation due to the consistently low surface 
expression of the chimaeras compared to the wild type tagged proteins not just in 
CHO cells but in other cell types too. This in itself suggested that the chimaeras were 
not folding correctly and led to the belief that the changes introduced into these 
chimaeras may have caused gross conformational changes in receptor structure. 
Other researchers have used large domain swaps to generate chimaeric constructs 
between not only chemokine receptors but also between other members of the GPCR 
family without disrupting the overall structure of the mutant receptor (Doranz et al,
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1999; Quehenberger et al, 1997; Kobilka, 1988; Wu et al, 1997; Samson et al, 1997). 
However, the absence of binding by the hD6/hCCR5 chimaeras may not be due to the 
effects of the primary sequence of the N-terminal tail on ligand recognition, but 
rather due to a global disruption in receptor structure. It is possible that hD6 
possesses specific sequence determinants that are important for the overall structure 
of the mature protein, which has been disturbed when the chimaeric constructs were 
generated. In this type of chimaeric receptor studies it is important that the overall 
structure remains constant so that the role of primary sequence determinants can be 
assessed. Disruption of the global structure of a chimaeric construct has been 
previously reported by Maggio and colleagues that showed that mixing of domains 
can indeed generate non-functional proteins (Maggio et al., 1993a; Maggio et al., 
1993b) So, in order to provide more robust data about ligand recognition sites in 
hD6, more subtle swaps were employed.
Altogether the studies discussed above were of great value for improving many 
technical aspects of this project. They demonstrate the advantage of the HA tag over 
the FLAG tag epitope, they suggest that chimaeric constructs between members of 
two different families of chemokine receptors may be uninformative and lastly they 
allowed for the development of a transient system for rapid analysis of chimaeric 
constructs. Indeed, all the small single domain swaps that were made, with the 
exception of iLoop2, were extremely well expressed on the cell surface. However, 
the data from the experiments with the anti-hD6 antibody, suggest that in fact even 
small domain swaps may affect the overall structure of the mature chimaeric protein.
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4.1.2. Extracellular ligand binding domains of hD6
Four hD6/hCCR5 chimaeras were generated where the N-terminus, or the first, 
second or third extracellular loops of hD6 were replaced by the corresponding 
domains of hCCR5 to obtain constructs 5nt6bd ExtLoopA, ExtLoopB and ExtLoopC 
respectively (Fig. 3.18).
COS-7 cells expressing 5nt6bd behaved similarly to those expressing wild type hD6, 
except for their ability to interact with RANTES/CCL5. Although 125I- 
RANTES/CCL5 bound this receptor (with slightly less efficiency than it bound wild 
type hD6) unlabelled RANTES was completely unable to displace 125I-PM2 from this 
chimaera when present in a 250-fold molar excess. One possible explanation for this 
observation is that inclusion of the N-terminus of hCCR5 to generate 5nt6bd creates 
a chimaeric receptor that preferentially attracts RANTES/CCL5 to bind to this 
domain away from the site it usually binds to in wild type hD6. Binding of different 
chemokines to separate domains of a given receptor has also been demonstrated for 
IL-8/CXCL8 and GROa/CXCLl on CXCR1/CXCR2 chimaeric receptors and for 
MCP-1/CCL2 and MIP-la/CCL3 on CCR1/CCR2 chimaeric constructs (Ahuja et al., 
1996; Monteclaro & Charo, 1997).
These data suggest that the N-terminal of hD6, after the cysteine residue is not 
essential for high affinity PM2 binding, or promiscuous |3-chemokine binding. 
Evidence corroborating this comes from the work with the anti-hD6 monoclonal 
antibody. This antibody recognises the N-terminus of D6 (evidenced by its inability 
to bind to 5nt6bd), yet does not compete with PM2 in binding to wild type D6. As 
mentioned before the importance of the N-terminus in receptor specificity has been
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well demonstrated for many chemokine receptors (LaRosa et al., 1992; Monteclaro & 
Charo, 1996, Doranz et al, 1999; Mizoue et al, 1999; Zhao-hai et al, 1995; Hebert et 
al, 1993; Pease et al., 1998, Monteclaro, 1997).
It remains possible that the N-terminus of hCCR5 is compensating for this region of 
hD6 in 5nt6bd. The presence of acidic residues and sulphated tyrosines, creating an 
overall large negative charge in this region, may be sufficient to mediate weak 
interaction with positively charged areas on the chemokine, with selectivity and 
affinity then determined by other domains. N-terminal truncations of hD6 would be 
useful in identifying the indispensable function of this region. Indeed, early studies 
on chimaeric receptors suggested that the N-terminus of hCCR5 was of little 
importance in ligand binding but this was shown not to be the case when N-terminal 
truncations of this receptor were studied (Blanpain et al., 1999). I have discussed 
earlier that the results with the large domain swaps could be interpreted as a crucial 
role for the N-terminus in hD6 ligand binding. If this is correct, these studies suggest 
that the small domain between the cysteine residue and the first TM domain plays a 
role in ligand binding. Examining this domain could prove informative in the future.
Binding of ExtLoopA expressing cells to PM2, MCP-4/CCL13 or RANTES/CCL5 
was not detected. This data indicates that the first extracellular loop of hD6, the 
hD6’s extracellular domain most conserved between species, is important for hD6 
binding profile. However, because binding of 125I-PM2 and 125I-RANTES/CCL5 was 
not detected for CCR5HACCR5V expressing cells, it is not possible to determine 
whether ExtLoopA has reduced affinity to these ligands like hCCR5 or whether this 
construct has totally lost its ability to bind to these ligands. Nevertheless, these data
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clearly indicate that ExtLoopA no longer behaves like wild type hD6. The epitope for 
the anti-hD6 antibody is not disrupted in this chimaera giving some indication that 
this receptor is folded like wild type hD6. It would be interesting to see if cloning of 
the first extracellular loop into the corresponding region of hCCR5 would be 
sufficient to introduce hD6’s promiscuous binding profile and affinity into hCCR5.
Swapping the second or third extracellular loop with the equivalent part of hCCR5 
(the amino acid sequence of which is very different) produced receptors that appeared 
to have reduced affinity for PM2, MCP-4/CCL13 and RANTES/CCL5, yet retained 
their ligand promiscuity. However, the studies with the hD6 antibody show that the 
epitope for this antibody may be disturbed to some extent by these changes. This is 
indicative that the reduction in ligand binding may be caused by the changes 
disrupting the overall structures of the receptor. Thus, it is felt that one cannot 
definitely conclude that loops B and C interact directly with the ligand. Instead, they 
may play a role in maintaining the structure of the ligand binding domain. Finally, as 
discussed for the 5nt6bd chimaera, we cannot exclude that sequence determinants in 
loops B and C of hD6 important in binding to ligand are compensated for in the loops 
of hCCR5. However, it is of note that the sequences of these loops are quite different.
The second extracellular loop has been shown to be the major determinant of ligand 
specificity for hCCR5 (Samson et al., 1997). Samson et al have shown that this 
domain is involved in high affinity binding to MIP-la/CCL3, MIP-1|3/CCL4 and 
RANTES/CCL5 and in activation of hCCR5. Cloning of hCCR5’s second 
extracellular loop into the corresponding domain of CCR2 is sufficient to confer high 
affinity binding by the chimaeric receptor to the hCCR5 ligands. However the data
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presented above shows that cloning of hCCR5’s second extracellular loop of hCCR5 
into the corresponding region of hD6 is not sufficient to reduce levels of PM2 
binding to an extent that they are no longer detectable as seen for hCCR5. Also, this 
receptor, ExtLoopB, still binds to non-hCCR5 ligands. Thus, the fact that ExtLoopB 
does not behave like wild type hCCR5 suggests that in the context of this construct 
the ligand binding domain of hD6 is dominant over the hCCR5 ligand binding 
domain.
4.1.3. Conclusions and future work
Considerable energy has been put into optimising the experiments to generate robust 
data. However, the methods finally used to generate information about the ligand 
binding domains of hD6 do have their limitations. First, the use of the transient COS 
(or CHO) cell expression, while allowing rapid screening of constructs, restricts the 
number of cells available for study preventing the generation of full displacement 
curves. Without this, changes in receptor affinity can only be implied by examining 
receptor surface expression in comparison to single point binding assays. Future 
work should provide more detailed assessment of binding affinity of all ligands by 
using stable transfection protocols. In fact, preliminary data suggests that the small 
domain swaps are adequately expressed on stably transfected HEK.293 cells. Second, 
small changes may miss important binding sites deeper within the receptors. 
However, it is felt that experiments targeting these residues would be difficult to 
interpret, as it is expected that such changes may disrupt the overall structure of the 
chimaera.
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The data collected from the hCCR5/hD6 small domain swaps studies shows that the 
N-terminus, the second and the third extracellular loops of hD6 are not essential for 
hD6’s promiscuous binding profile whereas the first extracellular domain of hD6 
seems to play a central role in ligand binding. The fact that the constructs ExtLoopB 
and ExtLoopC bind less ligand than the wild type protein could be due to an 
abnormal conformation of the receptors that does not allow the ligand to properly 
interact with the receptors. Thus, perhaps not surprisingly the ability to bind ligand 
may be dependent on cooperative interactions between extracellular domains that 
contribute to forming binding determinants (Wang et al., 1999). The importance of 
the first extracellular loop of hD6 for ligand binding is compatible with the high 
divergence between hCCR5 and hD6 in this region: out of the 19 amino acids that 
constitute this domain only five are the same in the two receptors. hD6 has three Ser 
residues in this domain that may be important for appropriate interaction with the 
ligand. Three serine residues are present in the second extracellular loop of hCCR5 
and this loop has been shown to play a central role in high affinity binding (Samson 
et al., 1997). Moreover, the third extracellular loop of hCCR3 that has been shown to 
be essential for ligand specificity (Monteclaro & Charo, 1996) has four Ser residues 
in this region. Recent studies have shown that O-glycosylation of hCCR5 at Ser 6 or 
7 is required for high affinity binding of MIP-la/CCL3 and MIP-1|3/CCL4 (Bannert 
et al., 2001). hD6 mutants bearing smaller mutations in the first extracellular loop 
would most certainly help identification of important residues involved in ligand 
binding within this domain. Point mutations of the uncharged polar Ser residues to 
neutral Ala residues would clarify the role of these residues in terms of ligand 
binding. Cloning of hD6’s first extracellular loop into the corresponding region of
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hCCR5 would also be useful to study the role of this domain in the context of 
hCCR5.
Given that construct 5nt6bd only bears the hCCR5 N-terminal sequence up to the 
first Cys residues cloned into the corresponding region of hD6 it is possible that the 
remaining 10 amino acids that constitute the N-terminal domain of this receptor 
might in fact be important for ligand biding and promiscuity. Therefore, it would be 
useful to generate an extended version of 5nt6bd where the whole of the extracellular 
domain of hD6 was replaced by the corresponding region of hCCR5. In fact, it has 
been shown for CXCR4 that the distal N-terminus of this receptor (the first 27 amino 
acids up to the conserved Cys) was neither necessary nor sufficient for SDF- 
1/CXCL12 binding but the carboxy terminal to the conserved Cys residue of the N- 
terminus near first TM domain is indeed required for SDF-1/CXCL12 binding 
(Doranz et al., 1999). However, as proposed above the N-terminus of hCCR5 or 
indeed the extracellular loops B and C may functionally replace that of hD6. 
Therefore, truncations or more subtle targeted mutations may be a more productive 
and informative approach.
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4.2. Signalling studies
Construction of chimaeric receptors has been shown to be useful to determine 
domains of the host receptor that are involved in ligand binding, receptor activation 
and signalling (Schwartz, 1994). It was decided that by constructing chimaeras of 
hD6 and hCCR5 it would be possible to investigate the function of intracellular 
domains. Initially, it was thought that by replacing the intracellular domains of hD6 
by the corresponding domains of hCCR5 one could determine the roles of these 
domains in signalling through hCCR5. Moreover, it was thought that these constructs 
would also provide some information about the biochemistry and function of hD6. 
HEK.293 cells were used, as these have been show to provide a cell background that 
gives robust signalling to calcium ion fluxes through exogenous hCCR5, but no 
detectable signals when cells expressing hD6 were challenged with ligand. 
Furthermore, hCCR5 has been shown to be readily internalised into these cells upon 
ligand binding (R. Nibbs pers. Comm, and (Ling et al., 1999)) whereas hD6 is not (R. 
Nibbs pers. comm.).
4.2.1. The second intracellular loop: cell surface expression 
and signalling
Four chimaeric constructs were generated where the intracellular loops of hD6 were 
independently replaced by the corresponding domains of hCCR5. All constructs, 
except for iLoop2, produced proteins that were detected on the surface of HEK.293 
cells. iLoop2 protein was only detected after permeabilisation of the transfected cells
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with saponin. It should be noticed that this construct, iLoop2, is the only chimaera 
made using single small domain swaps, either intracellular or extracellular, which is 
not detectable on the cell surface. Given that hD6DRY protein, which has essentially 
the first nine amino acids of this loop from hCCR5 cloned into hD6 is trafficked as 
efficiently as wild-type hD6 to the cell surface it seems fair to suggest that the 
carboxyl-terminal portion of the second intracellular loop of iLoop2 is responsible 
for the lack of cell surface expression.
This observation suggests that iLoop2 has some kind of structural problem that 
affects folding of the mature protein to an extent that trafficking to the cell surface is 
affected. It is possible that the precise positioning of the TM domains is affected 
when the second intracellular loop of hD6 is replaced by the corresponding loop of 
hCCR5. Alternatively, as demonstrated for other GPCRs (Arai & Charo, 1996), 
interaction of accessory proteins with the second intracellular loop of hD6 might be 
necessary for cell surface expression of hD6. It should be noted that hD6 carries a 
conserved proline residue in the middle of this loop (Pro 140) that is only seen in two 
other receptors CCR10 (Pro 147) (Jarmin et al., 2000) and CCR11 (Pro 125) 
(Schweickart et al., 2000). Interestingly, CCR11 like hD6 is not capable of eliciting a 
calcium flux upon ligand binding when expressed on HEK.293 cells (R. Nibbs, Pers. 
Comm.). It is possible that this Pro residue may introduce a kink into the loop leading 
to alteration of the relative positions of the third and/or fourth TM domains. 
Alternatively, the high positive charge on this loop (four basic residues in hD6 and 
only two in hCCR5) might play a role in surface expression of the wild type protein. 
Further mutagenesis of this region would address these issues.
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Although good surface expression and binding to PM2 was observed for iLoopl, 
iLoop3 and 5ct6bd none of these chimaeric constructs were shown to be capable of 
eliciting a calcium flux upon ligand binding. These data were curious given that 
previous reports have shown that the C-terminus and the third intracellular loop of a 
given chemokine receptor are important for coupling to G proteins and indicate that 
in the context of hD6 these domains of hCCR5 are not sufficient to independently 
allow coupling of the mutant receptors to the same G proteins that couple to hCCR5. 
For example, replacement of the third intracellular loop of CXCR1 by the 
corresponding domain of CCR2b is sufficient to make this new mutant receptor 
couple to G a l6 proteins known to couple to wild type CCR2b (Arai & Charo, 1996). 
Conversely, replacement of the same loop in CCR2b for the corresponding region of 
CXCR1 generates a mutant receptor that has lost its ability to couple to Gaq but 
retained its ability, albeit impaired, to couple to G a l6 (Arai & Charo, 1996). 
Moreover, studies with C-terminal truncations of hCCR5 have shown that this region 
of hCCR5 is important for the ability of this receptor to initiate signalling (Gosling et 
al., 1997).
To further investigate the role of the second intracellular loop in the context of hD6 
and at the same time study the effects caused by introducing changes in the 
DKYLEIV motif, smaller changes were introduced in this region. Two constructs 
were generated: hD6K-R, where the residue Lysl31 was mutated to an Arg, and 
hD6E-A, where the Glul34 residue was mutated to an Ala (mutant hD6E-A). Mutant 
hD6DRY.5 bears two point mutations that change Lysl31 to an Arg and Glul34 to 
an Ala. Flow cytometry and radiolabelled ligand binding analysis revealed that 
HEK.293 cells transfected with these mutant cDNAs expressed abundant surface
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protein, and that this protein bound ligand. It was noticed that the K to R change 
might possibly reduce ligand binding, however, without full displacement binding 
curves one cannot be certain of this observation.
Of these three constructs only hD6E-A and hD6DRY.5 were shown to be able to 
elicit a calcium flux and become internalised in the presence of ligand. hD6E-A and 
hD6DRY.5 flux much less calcium than hCCR5 indicating that the response 
generated by the mutant receptors is much weaker than that registered for wild type 
hCCR5. Nevertheless, these studies show that a single point mutation in hD6 
(E134A) introduces weak ligand-induced coupling to calcium ion fluxes. Moreover, 
the ability of hD6DRY.5 to signal was shown to be inhibited by Pertussis toxin. This 
indicates that this construct couples to Ptx-sensitive G proteins (most probably Gcii) 
in order to flux calcium upon ligand binding. Additionally, when the DRYLAIV 
motif was changed to DKYLEIV, hCCR5 could no longer couple to calcium ion 
fluxes upon ligand binding and was not internalised as efficiently as the wild type 
receptor. Although, single point mutations were not generated, it is likely that the A 
to E change in the hCCR5DKYLE construct is principally responsible for lack of 
signalling. This evidence highlights, as shown before (Gosling et al., 1997), the 
importance of the DRYLAIV motif of hCCR5 in signalling and its sensitivity to 
mutation.
A second generation of hD6’s intracellular mutants was generated in order to 
investigate the cooperative role of hCCR5 intracellular domains in the context of 
hD6; however, none of them produced detectable calcium ion fluxes upon ligand 
binding. In fact, the data from these mutants indicates that swapping of multiple
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domains between receptors generates constructs that are often compromised in their 
ability to assemble correctly on the surface of the transfected cells. Thus, the lack of 
detectable calcium flux after stimulation of the transfected cells expressing 
combinations of the ‘DRY’ motif and one or more domains of hCCR5 cannot be 
confidently attributed to a loss of signalling by the mutant receptor but is probably a 
reflection of its poor surface expression. Given that signalling is detectable in hCCR5 
transfectants, even at very low receptor occupancy, it seems fair to conclude that the 
additional domains of hCCR5 introduced along with the DRY mutation do not cause 
a dramatic enhancement of signalling.
4.2.2. Chimaeric receptor internalisation assays: evidence of 
alternative signalling pathways?
The studies discussed above generated mutants of hD6 to which a calcium ion flux is 
detectable (hD6E-A, hD6DRY.5) and a mutant of hCCR5 (hCCR5DKYLE) to which 
calcium ion flux is not detectable. As expected, these mutants behave differently 
from their wild type receptors counterparts when internalisation assays were 
performed. However, it was notable that hCCR5DKYLE was still internalised to 
some extent. What was even more surprising was that the hD6 mutants in which a 
single intracellular domain had been changed were also shown to be readily 
internalised after incubation with the ligand. Moreover, these mutants of hD6, were 
seen to be more efficiently removed from the cell surface than the signalling 
competent hD6 mutants, hD6E-A and hD6DRY.5. Furthermore, internalisation of 
hD6DRY.5 was increased by the addition of the first intracellular loop or the C- 
terminus from wild type hCCR5.
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These intriguing and unexpected data suggest that ligand-induced signals must be 
coming from the chimaeric receptors in order to mediate internalisation. These 
signals appear to be independent from G-proteins regulated calcium ion fluxes 
although it is not possible to rule out the possibility that chimaeras like iLoopl might 
be capable of inducing a calcium flux that is below the levels of detection of the 
assay. It is also possible that the chimaeric receptors might have acquired the ability 
of constitutively internalising ligand and recycling to the surface, and that the 
reduction in cell surface receptor upon stimulation with the ligand is actually due to 
the ligand preventing receptor recycling to the surface. Nevertheless, the data does 
show that any single intracellular domain of hCCR5 is sufficient to completely 
change the trafficking of hD6.
4.2.3. Conclusion and future work
In conclusion, the intracellular mutants of hD6 demonstrate the importance of the 
second intracellular loop for surface expression of this receptor and show that a 
single point mutation in this loop that changes the glutamine residue at position 134 
to an alanine is sufficient to elicit calcium flux by this mutant receptor in the 
presence of ligand. Also, these studies emphasize again the importance of the DRY 
motif found in the second intracellular loop of hCCR5. Moreover, these studies show 
that any changes in the intracellular domains of hD6, except for the conservative 
mutation that changes the lysine residue at position 131 to an arginine, are sufficient 
to mediate ligand-induced downregulation of hD6 expression from the surface of the 
transfected cells. Furthermore, these studies provide evidence that suggests that
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internalisation and calcium flux in response to ligand binding can be independent 
from each other.
These studies have generated a collection of data that deserves further investigation. 
Detailed analysis of the C-terminal part of the second intracellular loop should help 
to identify residues important in receptor conformation involved in surface 
presentation of hD6. These studies should be concentrated on making smaller 
mutations in this region (particularly altering the Pro residue at position 140 as well 
as neutralisation of basic residues) followed by surface expression assays.
Other studies should be carried out to identify signals coming from the chimaeric 
receptors, iLoopl, iLoop3 and 5ct6bd, which are responsible for ligand-induced 
internalisation. It is possible that these three chimaeric constructs are capable of 
inducing heterotrimeric G-protein complexes distinct from those measured by 
calcium flux assays. Internalisation of GPCRs requires phosphorylation of the 
receptor by serine-threonine kinases, like GRKs or PKC (Lefkowitz, 1998), and these 
might be activated upon ligand binding to these chimaeras. In fact, these chimaeric 
constructs are probably a much cleaner background to identify signals involved in 
receptor internalisation without the interference from other signals.
However, there is an alternative interpretaion of the results, which was raised earlier, 
and which requires further investigation. It is possible that the chimaeric receptors 
have actually become constitutively active. It is feasible that the reason why the 
ligand-induced calcium ion flux is so small in cells expressing hD6E-A or 
hD6DRY.5, is that these receptors already have a high basal signalling level and that 
only very small increases in this are possible. Likewise, the observed ligand-induced
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internalisation of chimaeric receptor may actually be an indication that these 
receptors are constitutively active, and are therefore internalised in the absence of 
ligand and subsequently recycled back to the surface. It is possible that ligand 
treatment might in fact prevent recycling to the surface rather than be responsible for 
internalisation. This matter could be investigated in a transient transfection assay 
where the accumulation of intracellular second messengers, such as inositol 
phosphate would be measured. These types of studies have been used to show 
constitutive signalling by several viral chemokine receptors and mutated human 
receptors (Allen et al., 1991; Arvanitakis et al., 1997; Burger et al., 1999; Casarosa et 
al., 2001; Samama et al., 1993; Scheer, 1996).
Another important question that remains unanswered is whether wild type hD6 is 
capable of eliciting signals upon ligand binding. The results collected so far show 
that small changes in the intracellular domains of hD6 create signalling-competent 
receptors, as shown by calcium flux assays. It is possible that the changes introduced 
in order to generate the chimaeric constructs are sufficient to alter D6 structure in 
such a fashion that this receptor acquires the ability to undergo the conformational 
change(s) necessary for ligand-induced signalling. Perhaps a more likely explanation 
is that wild type hD6 is already capable of undergoing ligand-induced conformational 
change, and that the chimaeras allow this event to be detected by coupling to calcium 
ion fluxes and of internalisation. Nonetheless, identification of second messengers 
coupled to ligand-bound hD6 awaits further studies. This could be achieved by 
carrying out experiments where additional G proteins were introduced into HEK.293 
cells previously transfected with hD6. Alternatively, analysis of cells that naturally 
express hD6 might be more useful. Recently published work describing the culture of
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lymphatic endothelial cells from human dermis may prove extremely interesting in 
improving our understanding of D6 signalling and function (Makinen et al., 2001, 
Kriehuber, 2001).
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Chapter 5- Concluding remarks
The studies described in this thesis highlight the importance of careful design and 
interpretation of work involving chimaeric chemokine receptors. Chimaeric 
constructs bearing domains of a CXC chemokine receptor and a CC chemokine 
receptor are unlikely to be appropriately transported to the cell surface of 
heterologous cell lines and therefore unlikely to be of use in the study of chemokine 
receptors. Moreover, in my hands, large domain swaps between members of the same 
CC chemokine receptor family are likely to also have conformational problems and 
for this reason have a poor surface expression. Small domain changes are less likely 
to dramatically alter the overall conformation of the receptor, allowing the 
investigation of primary sequence determinants on receptor function. Whilst these 
initial experiments proved disappointing and frustrating, they allowed for the 
optimisation of chimaeric receptor studies that should influence future interpretation 
of these kind of experiments.
The chimaeric receptors have demonstrated the importance of the receptor’s first 
extracellular loop for ligand binding. The hD6 intracellular mutants have shown that 
the second intracellular loop is important for surface expression of this receptor and 
that a single point mutation within this loop is sufficient to elicit calcium flux upon 
ligand binding. The internalisation assays carried out for the many intracellular 
mutants indicate that receptor trafficking is altered by manipulating any of the 
intracellular domains. The hCCR5DKYLE mutant has once again emphasized the 
importance of the DRY motif for signalling transduction.
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All in all these studies show that although chemokine receptors are thought to share 
the same structure and conformation, many domains and residues play fundamental 
roles in conformation, ligand binding, receptor trafficking and signalling of a given 
receptor. It is important to bear in mind at the time of constructing chimaeric proteins 
that any effect seen with a certain mutant may not be a direct reflection of the 
function of the primary sequence mutated, but could instead be a phenotype that 
reflects a new overall conformational adapted by the new construct in which many 
distant domains may be affected.
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